

Annual Report 2007

OOA



Address

Oncology Graduate School Amsterdam OOA
VU medisch centrum
Kamer CCA 3.36
De Boelelaan 1117
1081 HV Amsterdam

phone : 020-4444054
e-mail : e.ruhe@vumc.nl
website : www.ooa-graduateschool.nl

Contents

Preface		5
1	Board and organization	9
2	General report	13
3	Educational activities	19
4	PhD research program	25
5	Awards	43
Annex 1	Faculty and staff	47
Annex 2	International visitors	59
Annex 3	PhD theses completed	63
Annex 4	Scientific publications	69



preface

Preface

The mission of the Oncology Graduate School Amsterdam (Onderzoekschool Oncologie Amsterdam - OOA) is to educate graduate students in basic and clinical cancer research, and to ensure proper supervision and mentoring of graduate students in the Amsterdam region. OOA's graduate students are scientist-in-training who receive additional theoretical and practical education on various subjects related to cancer.

OOA is a joint venture of the Netherlands Cancer Institute (Nederlands Kanker Instituut - NKI) and the medical faculties VU Medical Center (VUmc) and Amsterdam Medical Center (AMC) of the Free University Amsterdam (Vrije Universiteit - VU) and the University of Amsterdam (Universiteit van Amsterdam- UvA), respectively. These organizations strive for excellence in research and education in oncology, the realization of which is promoted by their participation in OOA.

The OOA research program ranges from basic molecular biology to clinical bedside research. It includes, for instance, fundamental studies on cellular signal transduction and the control of gene expression, but also clinical trials of new immunotherapeutic approaches and the development

of new tools to evaluate the quality of life in cancer patients. OOA organizes a range of educational activities, including specialized training courses, meet-the-expert sessions and an annual graduate student retreat.

This report describes the activities and scientific output of OOA in 2007. It includes detailed listings of our educational activities, such as training programs, and an overview of the scientific output, including listings of PhD theses completed and scientific papers published throughout the year 2007.

Executive Directors,

Prof.dr. G.A. Meijer (VU)
Prof.dr. T.K. Sixma. (NKI)
Prof.dr. J.P. Medema (UvA)

board and organization

1

1. Board and organization

Board

Prof.dr. A. Berns, chairman
Prof.dr. S. Rodenhuis
Prof.dr. H.M. Pinedo
Prof.dr. P. Postmus
Prof.dr. C.E.E. Konings
Prof.dr. D.J. Richel

Executive directors

Prof.dr. G.A. Meijer, chairman
Prof.dr. T.K. Sixma
Prof.dr. J.P. Medema

Founding institutes

Free University Amsterdam (VU)/ VU Medical Center (VUmc)
Administrative center
Contact / secretariat: dr. P. Keblusek/ dr. E.M. Ruhé-Hoogervorst
De Boelelaan 1117
1081 HV Amsterdam
phone : 020-4444054
fax : 020-4442964
email : p.keblusek@vumc.nl/ e.ruhe@vumc.nl

University of Amsterdam (UvA)/ Academic Medical Center (AMC)
Contact / secretariat: dr. Y. Donselaar
Meibergdreef 15
1105 AZ Amsterdam
phone : 020-5668502
fax : 020-5669165
email : y.e.donselaar@amc.uva.nl

Netherlands Cancer Institute. (NKI)
Contact / secretariat: Ms. M. van der Velde
Plesmanlaan 121
1066 CX Amsterdam
phone : 020-5122015
fax : 020-5122029
email : m.vd.velde@nki.nl

Faculty and staff

The complete list of founding institutes' faculty and staff involved in educational activities and research projects conducted by OOA is provide in Annex 1.

general report

2

2. General report

Educational activities

The core activity of OOA is training PhD students in conducting cancer research. For this purpose, OOA has developed a high-quality curriculum. In 2007, OOA organized various graduate training courses and also the Annual Graduate Student Retreat.

All courses were evaluated by means of standard evaluation procedures. In this way, OOA carefully monitors the quality of its courses. Based on the outcome of these evaluations, the training programs are being improved continuously.

A detailed description of all training courses offered in 2007 is provided in chapter 3 of this Annual Report.

Research program

Research projects at OOA's institutes can be clustered under two main themes. The theme 'Experimental biology' covers 'Oncogenesis' and 'Tumor cell biology' as the main lines of research. The second main theme is 'Experimental clinical research' and covers 'Diagnosis of cancer' and 'Prevention and therapy of cancer'. Chapter 4 provides listings of all individual PhD projects conducted within these main themes. More detailed descriptions of these research programs and their output are provided in the annual reports of the founding institutes.

Theme 1: Experimental biology

The development of cancer is frequently associated with aberrations in cell signaling and signal transduction pathways. Transformation of a normal cell into a fully malignant cell requires multiple (sequential) genetic alterations affecting key genes controlling essential cellular pathways involved in cell division, proliferation, and apoptosis. Studying the genes and proteins involved in these pathways should result in a better understanding of the processes of tumorigenesis and tumor progression and should contribute to the development of novel diagnostic tools and better treatment strategies.

By applying innovative research tools, novel components of the major cancer-relevant pathways may be discovered. Tools applied in research projects include high-throughput methods for genetic, epigenetic, transcriptomic and proteomic analyses. Examples are gain-of-function

genetic screens with retroviral cDNA expression libraries, and loss-of-function genetic screens with RNA interference libraries. In addition, advanced mouse models have been developed for the genetic dissection of cancer.

At the cellular level, processes like cell-cell communication, cell-cell adhesion, cell migration and proliferation are being studied. Metastasis, the spread of tumor cells to distant sites in the body, is the main cause of cancer lethality. The mechanisms of metastasis of lymphomas and carcinomas are being investigated in the research projects.

The 'viral oncogenesis projects' focus the role of human papilloma viruses (HPVs) and Epstein-Barr virus (EBV) in the development of human cancers, like anogenital cancers (i.e. cervical cancer), head and neck cancer and lymphomas. Virus-induced oncogenesis is investigated using both in vitro models and clinically well-defined patient tumor samples. Viral and host markers are being tested in screening and clinical trials for their capability to assess the risk associated with the development of cancer. These markers have increased sensitivity and specificity compared to currently used methods.

Theme 2: Experimental clinical research

This theme focuses on the identification of new methods for the diagnosis, prognosis and individualized treatment of cancer. Early detection of cancer greatly increases the chance of a favorable outcome.

The emerging and rapidly growing fields of molecular imaging and genomics provide new opportunities to study the unique biology of a specific malignant disease in an individual patient. Combining an integrated research approach with clinical data collection and evaluation allows for the development of highly valuable indicators for the diagnosis and prediction of disease outcome in the individual patient. In our research, modern state-of-the-art CT and MRI machines enable imaging of anatomical details with high precision. In addition, imaging techniques like SPECT, PET, PET-CT and MRI, provide non-invasive methods to obtain unique molecular and biological information at the tissue level in vivo. For the purpose of molecular imaging studies, novel reporter probes are being developed and evaluated in (pre)clinical studies. In addition, by using the (advanced) mouse models available at the OOA institutes, new

clinical strategies for molecular imaging are being developed.

High-throughput tools are being applied to measure genetic variation and improve the criteria for disease classification. These tools include expression micro-arrays and CGH arrays for human and mouse studies. Quantitative mass spectrometry is being applied in the search for proteins capable of distinguishing between diseased and disease-free states with high sensitivity and specificity. The newly identified proteins may be used as specific cancer markers for routine non-invasive tests.

Cancer therapy is another important focus within this theme. This program includes research lines focused on targeted therapy, both by medical and radiotherapeutic means. Patient-tailored therapy should ensure that the benefits of a treatment are optimized and that patients who are unlikely to benefit, are spared the side-effects of treatment. The research projects include preclinical evaluation and clinical application of the new generation of molecular targeted therapies and anti-angiogenic agents against novel cellular targets in the tumor and its environment. The pharmacological optimization of conventional cytotoxic drugs is another line of research that is being studied.

The theme "Experimental clinical research" also focuses on passage of the blood-brain barrier by drugs. Inadequate passage of the blood-brain barrier is generally considered a major cause of the lack of efficacy of systemic chemotherapy against intracranial malignancies.

Yet another research line is focused on immune therapy. New immunotherapeutic approaches for the treatment of malignant disorders are being investigated. The impact of vaccination in the adjuvant and primary treatment settings is being explored.

Projects focused on radiotherapy and surgery is directed at the clinical implementation and optimization of 4-dimensional, image-guided approaches to improve local disease control by radiation treatment and to reduce toxicity to normal tissue.

In the gene therapy area, clinical trials are evaluating gene therapy in malignancy with the current focus on optimal targeting of tumors and improving viral vector efficacy.

PhD projects and students

Overall, 312 PhD projects were actively elaborated throughout 2007. A total number of 37 students obtained their PhD degree in 2007. The names of the PhD students at the three OOA institutes and the projects in which they participated are listed in chapter 4. Of all PhD projects, 18% was funded by the participating institutes themselves (primary funding; 'eerste geldstroom'); 20% was financed by public funds (secondary funding; 'tweede geldstroom') and 42% by private (including cancer

charity) and industrial funds (tertiary/quaternary funding; 'derde / vierde geldstroom').

International visitors

Training of PhD students can be stimulated and enhanced by having scientific interactions between students and foreign experts operating in the field of the students' research projects. OOA is part of a large international network of cancer researchers and, therefore, international guests from other research institutes visit OOA's institutes frequently to interact with OOA students and staff.

Throughout 2007, we welcomed 83 international experts in various settings (Annex 2).

Awards

Several PhD students and staff of the OOA institutes won prestigious awards and honors - scientific or otherwise - in 2007. Chapter 5 provides a listing of these awards and honors.

Scientific publications

Scientific output of OOA's research efforts takes shape mainly as scientific papers published in the literature and PhD theses produced by PhD students at the end of their training. A total of 25 students completed and defended their PhD thesis and obtained their PhD degree in 2007. Annex 3 provides the complete list of PhD students who obtained their degree in 2007 with details of their theses and graduation.

We are content with the scientific output of the three institutes participating in OOA. It was a productive year with important new findings and scientific publications that received wide recognition and were published in top scientific journals. Highlights were amongst others the results of an European study published in the New England Journal of Medicine by B. Slotman et al. showing that prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival of patients with extensive small-cell lung cancer.

The identification of a new gene, the FANCN-gene involved in childhood and familial breast cancer was published in Nature Genetics by the research group of H. Joenje.

Another important finding was published by the research group of C. Meijer. They showed that the implementation of HPV DNA testing in cervical screening leads to earlier detection of CIN3+ lesions as compared with the conventional cytological testing. Earlier detection of such lesions could permit an extension of the screening interval. These results were published in the Lancet in 2007.

The group of van Leeuwen and Caron presented a large study on survivors of childhood cancer and reported a 75% incidence of health problems in this population. These studies have suggested to change the follow-up of cancer survivors and were presented at a JAMA press conference in New York as well as published in the prestigious JAMA in 2007.

The group of Reuven Agami used a novel genetic screening approach to select micro RNAs (miRNAs) that target any gene of interest. This revealed that miR-221 promotes cancerous growth of glioblastomas by restricting the expression of the tumor suppressor p27. They also identified miR-372 and miR-373 as miRNAs that stimulate cellular migration, invasion and metastasis of breast tumors and uncovered the the function of Dead End (DND1), a gene essential for germcell survival and protection from germ-cell cancer.

Wilbert Zwart and Rob Michalides discovered a novel mechanism of resistance to anti-estrogens. They found that Protein kinase A-mediated phosphorylation of the Estrogen Receptor (ER) alters the orientation of ER towards its cofactor in a transcription factor complex in such a way that transcription now does occur in the presence of the anti-estrogen tamoxifen.

Sophia Bruggeman in the group of Van Lohuizen (Division of Molecular Genetics) demonstrated that the Polycomb gene Bmi1 is not only important for regulating normal neural stem cells but also controls tumorigenicity and cell migration of high-grade glioma, a cancer harboring cancer stem cells.

The Division of Radiotherapy reported on the 10-year results of the randomized Boost Versus No Boost trial. A higher radiation dose (boost) led to a significant improvement of local control in all age groups and an excellent survival of 82%.

Linn and collaborators have analyzed the RASTER study, in which the 70-gene expression prognosis-prediction profile in breast cancer (Agendia Mammaprint (R)) was applied in community hospitals in the Netherlands. The novel test was clearly practice-changing..

A total of 1061 publications have been published (with participation) by researchers from the three institutes combined. Of these, 40 papers were published jointly by researchers from different participating institutes in OOA. Annex 4 provides the complete list of scientific publications in 2007.

Facilities

At the NKI, the complete renovation and conversion of the old hospital into state-of-the-art laboratories is nearly completed and the vast majority of the research groups will relocate to the renovated facilities. In addition, a number of research groups have been reassigned to existing or new divisions to match better with the work performed.

At the AMC, the TRC lentiviral shRNA library has been introduced allowing for knockdown of the complete mouse and human genome. This library is

maintained by the group of R. Versteeg, participant in the OOA and available for all oncology groups within the AMC.



educational activities

3

3. Educational activities

In line with its mission, i.e. providing graduate students education in oncology research, OOA organizes several advanced courses in the field of oncology annually. The educational program is drawn up by the Board of Directors based upon evaluations of previous courses, contemporary developments in cancer research, and educational needs expressed by PhD students as well as initiatives from the OOA faculty. OOA offers courses focused on a wide variety of topics.

As a follow-up to the recommendations by the site visit committee in 2002, the number of clinically oriented courses has been increased since.

In 2007, 7 courses and 3 Meet-the-Expert sessions were organized. Courses are usually restricted to about 15-20 graduate students to ensure optimal interaction between students and faculty. Courses are advertised on the OOA website and announced by e-mail to the PhD students.

Courses included lectures given by (inter)national experts, demonstrations and practical training. In addition, the Annual Graduate Student Retreat was organized again in 2007.

Besides the specialized oncological courses mentioned below, the graduate students followed several general courses such as courses on biostatistics and epidemiology, on laboratory animal technology and on writing and (poster)presentations techniques in scientific English. These courses were organized by the AMC, VUmc and NKI.

Trends in Tumorimmunology

Organization: Prof. dr. R Scheper
Dr. T. de Gruijl
Prof. dr. T. Schumacher
Prof. dr. J Haanen
Date: 5 - 7 March
Location: VUmc

This 3-day course will highlight the newest insights in cancer immunotherapy. During three days the focus will be on recruitment and amplification of DC/T cell functions (discussed by dr T. Harding (CellGenesys), prof.dr. T. Schumacher (NKI), dr. J. de Vries (NCMLS) and dr. T. de Gruijl (VUmc)), development of novel antibody-based tumor-targeting strategies (discussed by Dr. G. van Dongen (Vumc), Dr H. Hoogenboom (Ablynx), prof. dr. J. vd Winkel (GenMab) and dr W. Helfrich (RUG)), and ways to circumvent mechanisms of immunotolerance (discussed by dr F.vd Eertwegh (VUmc), dr. T. de Gruijl (VUmc), prof. dr. J. Haanen (NKI), prof. dr. Y. van Kooyk (VUmc) and dr. R. Offringa (LUMC)).

A total of 14 students participated in the course. The overall evaluation rate was 7.9 (scale 1-10).

The Microscopic, Macroscopic and Pathologic Anatomy of the Mouse

Organization: Prof. dr. R van Noorden
Prof. dr. W Lamersl
Date: 20 - 23 March
Location: AMC

Most biomedical PhD students perform animal experiments at some stage of their research career, but most students have never received practical instructions with respect to the anatomy, histology and pathological anatomy of experimental animals. For this reason, experimental animals are usually not subjected to a thorough and systematic inspection to assess whether, besides the local (expected) effects in the organ(s) under study, other organs are affected as well.

This annual course aims at providing insight(s) into the anatomy and histology of the mouse, presently the most frequently used animal species in cancer research. In addition, the course focused on the recognition of pathological changes in the mouse. During the course each student dissected either a male or a female mouse, to become acquainted with the topographic anatomy of this species. The microscopy part of the course focused on studying the architecture of normal and pathologically altered mouse tissues. During the practical part, recognition of cell and tissue types, and changes in architecture of tissues as a result of pathological processes, were studied microscopically.

In addition to standard staining techniques, functional staining techniques were demonstrated. This year the practical part of the microscopical anatomy has been done with computerized sections and computer assisted magnifications.

Of the total number of 27 participants, 14 were PhD students of the OOA, 3 postdocs, 1 assistant professor, 2 biotechnicians and 7 master oncology students. The overall evaluation rate was 7.9 (scale 1-10).

Meet the Expert with Prof. dr. D. Neri

Organization: Prof. dr. G van Dongen
Time: 10 September
Location: VUmc

This session was focussed on an in depth discussion with prof. dr. D. Neri including questions and answers on the topic of the Keynote Lecture of September 10: "Vascular tumor targeting: About targets, ligands and

applications". Prof. Neri's view on how to develop a successful line of research and scientific career was also discussed. The session was meant to give the students more insight into the personal motivation of the expert and his view on the development of the particular line of research. Articles were handed out and presented by the PhD students to trigger the discussion.

Research activities of prof. dr. D. Nerio include the development of antibody-based therapeutic agents, the identification of vascular markers of pathology and the construction and use of DNA-encoded chemical libraries.

Three of the products developed are currently being investigated in Clinical Trials. Dario Neri is a co-founder of Philogen (www.philogen.com) and Philochem (www.philochem.com).

A total of 5 students participated in the course. The overall evaluation rate was 8.8 (scale 1-10).

Annual Graduate Student Retreat

Organization: Prof.dr. T. Sixma
M. Van der Velde
S. Boonen
Time: 3 - 5 October
Location: Texel

A highlight of the educational program is the Annual Graduate Student Retreat. This three-day retreat focuses entirely on research conducted by the graduate students themselves. At the retreat, students not only present their work as a poster in the first year of their participation and as an oral presentation in subsequent years, they are also in charge of chairing sessions, discussions. In recent years, students participated in peer review of presentations given by others in order to award the prize for the best poster and best presentation. In this manner, the retreat trains important skills in presentation and interaction but it also provides an overview of research conducted within OOA at an early stage of the student's career, contributing significantly to the interaction between different groups.

A total of 91 students participated this retreat. The overall evaluation rate was 4.3 (scale 1-5).

Microsatellite instability in colorectal cancer and Meet the Expert with Prof. dr. A. Duval and R. Secura

Organization: Dr. B. Carvalho
Time: 11 - 12 October
Location: VUmc

Genetic instability is a hallmark of cancer. As in other solid tumours, gastrointestinal tumours follow two main genetic instability pathways, namely chromosomal instability (CIN) and microsatellite instability (MSI). In this course we wanted to make an overview of what is known on MSI in gastric and

colorectal cancer. For this purpose we assembled several experts in the area, who covered the subject in both hereditary and sporadic forms of colorectal cancer as well as in gastric cancer.

The program started with Prof. Hein te Riele (NKI, Amsterdam, NL) who talked about his experience in trying to understand the mechanisms of MSI in hereditary colon cancer by the use of functional studies in embryonic stem cells. Next, Prof. Françoise Praz (INSERM, Paris, FR) talked about the regulation of mutated mRNA in MSI sporadic colorectal cancer by the regulatory mechanism Nonsense Mediated Decay (NMD). Also, in colorectal cancer, Prof. Richard Hamelin (INSERM, Paris, FR) approached the technical aspects of analysis of hMLH1 promoter hypermethylation in MSI tumours. In gastric cancer, Prof. Raquel Seruca (IPATIMUP, Porto, PT) discussed the MSI at the nuclear level as well as in mitochondria. Finally, Dr. Carla Oliveira (IPATIMUP, Porto, PT) talked about oncogenic point mutations occurring in MSI gastric cancer.

The next day, students had the opportunity to thoroughly discuss two articles from literature with the experts:

Beghelli S, de Manzoni G, Barbi S, Tomezzoli A, Roviello F, Di Gregorio C, Vindigni C, Bortesi L, Parisi A, Saragoni L, Scarpa A, Moore PS. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. *Surgery*. 2006 Mar;139(3):347-56.

You KT, Li LS, Kim NG, Kang HJ, Koh KH, Chwae YJ, Kim KM, Kim YK, Park SM, Jang SK, Kim H. Selective Translational Repression of Truncated Proteins from Frameshift Mutation-Derived mRNAs in Tumors. *PLoS Biol*. 2007 May;5(5):e109.

A total of 9 students participated this course. The overall evaluation rate was 7.9 (scale 1-10).

Meet the Expert with Prof. dr. R.J. O'Reilly

Organization: Dr. J. Janssen
Time: 18 October
Location: VUmc

This session was focussed on an in depth discussion with prof. dr. R. O'Reilly including questions and answers on the topic of the Keynote Lecture: "Allogeneic hematopoietic cell transplants as a platform for cellular immunotherapies". The session was meant to give the students more insight into the personal motivation of the expert and his view on the development of the particular line of research. Prof. dr. R. O'Reilly performs his research at the Sloan-Kettering Cancer Institute New York, NY, USA. He is Chair of the Department of Pediatrics, Chief Pediatric Bone Marrow Transplant Service, and Chair in Pediatric Oncology His clinical expertise is Pediatric Oncology; Allogeneic and Autologous Bone Marrow and Peripheral Blood Stem Cell Transplantation; Congenital and Acquired Diseases of Hematopoiesis and Immunity

A total of 5 students participated this course. The overall evaluation rate was 7.3 (scale 1-10).

Predicting the outcome of Cancer Treatment

Organization: Dr. A. Begg
Time: 22 - 26 October
Location: NKI

Accurate prediction of outcome to current cancer therapies, and to new therapies now being developed, would represent an important step forward. It would allow the doctor to choose the most effective treatment for each individual. It would also allow ineffective (and potentially toxic) treatments to be avoided. The development of a variety of powerful techniques having the ability to monitor large numbers of genes or proteins concurrently opens the possibility to pinpoint which pathways are deregulated in individual tumors. This can in turn indicate how a tumor will respond to a particular treatment. It can also indicate which pathways would provide the most effective target for therapy. In addition, more and more drugs are being discovered or designed which target particular molecular pathways. The combination of better prediction with increased choice of pathway-specific drugs is therefore the future for more individualized, effective therapy. This course covered the current status and future potential of accurate outcome prediction. It focused on who will benefit from particular treatments and summarized current knowledge of causes of failure after radiotherapy, chemotherapy (including "molecular targeted" drugs) and their combination. In addition to covering the biology of treatment resistance, the performance of several current genome wide assays used for predicting response were discussed. The present and future technical and clinical status of these assays were also be discussed. This one-week interactive course consisted of lectures from invited experts with subsequent discussions between the participants and these experts.

A total of 16 students participated this course. The overall evaluation rate was 8.4 (scale 1-10).

Technology transfer: How to protect and utilise your scientific discovery

Organization: Dr. H. Kaptein
Dr. A Speksnijder
Prof. dr. TK Sixma
Time: 19 November
Location: NKI

The Technology Transfer course was organized in collaboration with the Cancer Genomics Centre (CGC). The CGC is a joint center of the NKI, Erasmus MC, Hubrecht Laboratory Utrecht and the UMC Utrecht. A major aspect of research nowadays is the link of scientific results and the society (communication and valorisation). Appliance of patents, spin off companies and collaboration with existing companies are major issues. This course is focussed on these aspects, and

will make young investigators more aware of valorisation.

A total of 23 students participated this course. The overall evaluation rate was 4.1 (scale 1-5).

Molecular biology and its diagnostic implications for clinicians

Organization: Dr. D. Heidemans
Dr. E. Thunnissen
Prof. dr. P. Snijders
Time: 20 December
Location: VUmc

Advances in molecular biology have enhanced our understanding of the primary defects and basic molecular mechanisms responsible for the pathogenesis of cancer. In addition, it made available new techniques for cancer diagnosis and/or therapy selection. In this course, we will discuss a variety of molecular diagnostic assays with focus on understanding the construction and elements on which they are built. This course aimed to gain knowledge on present and coming methods for molecular diagnostics and its clinical implications through lectures by experts in the field. The course was especially suitable and focussed on clinical fellows and medical PhD students. After introductory lectures on molecular biology and the techniques used in molecular diagnostics, a series of lectures highlighted a specific molecular assay and its use in the clinical setting.

A student who met the objectives of the course will be able to:

- Describe techniques used in molecular diagnostics such as PCR, real time PCR, sequencing, micro-arrays, separation technologies, hybridization techniques, etc.
- Summarize current and future technologies for molecular diagnostics of cancer
- Explain the molecular basis why a certain molecular diagnostic assay can be used to solve a clinical problem
- Identify weaknesses and limitations of techniques used in molecular diagnostics
- Describe how molecular diagnostics is enhancing diagnosis and treatment of cancer
- Select suitable molecular tool depending on methodology and biomedical problem

A total of 23 students participated this course. The overall evaluation rate was 7.6 (scale 1-10).

PhD research program

4

4. PhD research program

This chapter describes the PhD projects conducted within the two main themes of the OOA research programs, with the names of the PhD students involved and their supervisor(s). Graduate students who obtained their PhD degree in 2007 are marked by means of an asterisk added to their name.

Funding

- 1 Financed by OOA institute (“eerste geldstroom”)
- 2 Financed by public funds (“tweede geldstroom”)
- 3-4 Financed by private funds (“derde / vierde geldstroom”)

Theme 1 Experimental Biology

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Cell Biology (NKI)				
J.I. van den Bout	The role of $\alpha 3 \beta 1$ integrin in the development and pathophysiology of the glomerulus	Sonnenberg	2000	3
S. Ellenbroek	Tiam1/Rac signaling and wnt/beta-catenin-induced tumorigenicity	Collard	2004	3
Q. le Duc	The role of actomyosin contraction in the down-regulation of E-cadherin mediated cell adhesion	De Rooij	2007	3
A. Hajdo-Milasinovic	Ras en Rho signaling networks and epithelial-mesenchymal transition	Collard	2001	3
E. Frijns	Controlling hemidesmosome dynamics by phosphorylation of residues on the integrin beta4	Sonnenberg	2007	4
S. Huveneers	Cooperation between the SRC oncogene and integrin $\alpha v \beta 3$ in oncogenic transformations of epithelial cells	Danen	2003	3
M. Ketema	Analysis of the function of a novel nuclear envelope protein, nesprin 3 in anchoring the nucleus to the intermediate filament system	Sonnenberg	2005	2
C. Margadant	Generation of a mouse model for EBS-MD	Sonnenberg	2006	4
J. Meijer	Role of the chemokine SDF-1 and its receptor CXCR4 in carcinoma and melanoma metastasis	Roos	2003	3
S. Mertens	Initiation and progression of lymphomas and skin carcinogenesis in Tiam1 mutant mice	Collard	2001	3
T. Rygiel	Function based screening for genes involved in invasion of epithelial tumor cells	Collard	2002	3
N. Sachs	Function of integrin-CD151 complexes in tumor cell invasion and metastasis	Sonnenberg	2004	3
D. Visser	TRPM7: a novel regulator of cytoskeletal tension: implications for cancer progression, invasion and metastasis	Moolenaar	2007	3
Cellular Biochemistry (NKI)				
H. Albers	Modulation of antitoxin activity by small molecules	Ovaa	2007	2

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
C. Berkers	Chemistry-based functional proteomics, new tools for cancer biology	Oova	2004	1
F. Frederiks	The role of histone methylation in the regulation of gene expression	van Leeuwen	2004	4
R. Hoppes	MHC synthesis	Ovaa	2007	2
A. Houben	Autotaxin, a secreted lyso PLD: role in tumor progression	Moolenaar	2006	3
A. Los*	Role of diacylglycerol kinases in cell cycle progression and cytoskeletal organisation	van Blitterswijk/ Moolenaar	2000	3
L. van Meeteren*	LPA receptors: signaling, migration and proliferation	Moolenaar	2001	3
B. Ponsioen	LPA receptor signaling	Moolenaar	2003	3
K. Verzijlbergen	The role of histone methylation in gene silencing and transcriptional memory	van Leeuwen	2005	2
L. van Zeijl	Cell-cell connexin signalling: suppression of cell transformation	Moolenaar	2000	3

Immunology (NKI)

S. Ariotti	Introvital imaging of epidermal immune phenomena in virus infections and DNA tattooing	Schumacher	2007	1
A.H. Bakker	Analysis and manipulation of tumor specific T cell immunity	Schumacher	2002	2
A.D. Bins*	Melanoma-specific T cell immunity in advanced-stage melanoma patients	Borst	2001	1
M. Coccoris	Dissecting virus-specific cytotoxic T cell immunity	Kruisbeek	2000	2
C. Gerlach	Cellular barcoding and dissection of T cell differentiation	Schumacher	2005	1
M. Heideman	Role of translesion DNA synthesis in Immunity and Cancer Development	Borst	2005	2
J. van Heijst	Tracing lineage relationships by cellular barcoding	Schumacher	2004	3
A. Jorritsma	Analysis of vaccine-induced melanoma specific T-cell immunity: a combined human + mouse study	Haanen	2002	3
A.M. Keller	Cellular and molecular basis of effector and memory T cell responses	Borst	2002	1
P. Krijger	The role of post replication repair in lymphoma development and somatic hypermutation	Jacobs	2006	2
P. Langerak	Complementation tagging and lymphocyte development	Borst	2003	4
C. Maas	Apoptosis signalling of BH3-only protein Bid, mechanisms of action and modes	Borst	2004	3
K. Oosterhuis	Treatment of HPV positive penile and cervical cancer by introduction of NPV7 special TCI	Schumacher	2006	2
V. Peperzak	The role of CD27/CD70-regulated cell survival in shaping effector and memory T cell responses	Borst	2004	2
E. Veraar	TNF ligands in cancer: CD70	Borst	2006	4
I. Verbrugge	Tumor therapy with ionizing radiation and death ligand Trail efficacy and key mol. determinants	Borst/ Verheij	2004	3
M. Witte	Induction of T-cell immunity through adoptive transfer of T cell receptors	Borst	2003	2

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Molecular Biology (NKI)				
M. Aarts	High-throughput gene modification by single-stranded DNA oligonucleotides	Te Riele	2004	4
S. Bakker	Significance of the Fanconi Anemia caretaker pathway in development and treatment of cancer	Te Riele	2007	2
J. van Bommel	Multi-gene chromatin domains	Te Riele	2007	2
R. Drost	Therapy responses of BRCA-mutated tumors and role of PALB2 in mammary tumorigenesis	Jonkers	2005	3
B. Evers	Mammary tumorigenesis in conditional tumor suppressor gene knockout mice	Berns	2003	2
P.-A. Genest*	Function of a new modified base in DNA, β -D-glucosyl-hydroxymethyluracil (J) and its interaction with proteins	Borst	2001	2
T. van Harn	Role of the G2 restriction point in tumor development and behaviour	Te Riele	2007	2
H. Holstege	The role of BRCA1 and BRCA2 loss-of-function in breast cancer	Berns	2002	3
T. Vormer	The identification of oncogenic events collaborating with loss of function of the retinoblastoma gene family in tumor development and progression	Te Riele	2003	3
C. Klijn	Dissection of the role of E-cadherin loss-of-function in breast cancer development and metastasis	Jonkers	2007	2
M. Vollebergh	Predicting therapy responses in breast and lung cancer	Rodenhuis	2007	3
E. Wielders	Subtle gene modification to study the role of the mismatch repair complex Msh2/Msh5 in mutation avoid	Te Riele	2004	3
R. van Leuken	Roles of human Cyclin-dependent kinase subunits HsCks1 and HsCks2 in mitotic progress	Bernards	2003	3
Z.-J. Yu	Function of a new modified base in DNA, β -D-glucosyl-hydroxymethyluracil (J) and its interaction with proteins	Borst	2001	2
W. van Zon	Control of Mitosis by regulated protein destruction	Wolthuis	2004	1
S. Zanders	Mechanisms of chemotherapy resistance of spontaneous mammary tumors in genetically-engineered mouse models	Te Riele	2007	2
Molecular Carcinogenesis (NKI)				
M. Epping	Molecular basis of anti-cancer activity of HDAC inhibitors	Bernards	2002	4
A. Fabius	Molecular barcode screens to identify genetic interactions with protein kinases in mammalian cells	Beijersbergen	2004	3
A.C. Faesen	3D repertoire	Sixma	2005	2
E. Geutjes	The role of deubiquitinating enzymes in apoptotic signalling pathways	Bernards	2006	2
P. Knipscheer*	Crystal structure determination of the components of an E2/E3 ligase ubiquitination system involved in cell cycle control	Sixma	1999	2
R. Kortlever	Senescence rescue screens	Bernards	2002	1
H.J. Kuiken	HCD/HT using RNAi technology	Bernards	2005	4
J. Mullenders	High throughput functional screens for stable loss-of-function phenotypes	Bernards	2003	3

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
F. Mattioli	Structural and functional analysis of a novel E3 ubiquitin ligase consisting of the pcp's BMI1 and ING1B	Sixma	2006	3
J. Nijwening	Development & application of shRNA in cell based screening technologies	Bernards	2005	4
K. Repanas*	Function structure studies of components of the lines retroposition machinery	Perrakis	2001	2
A. Reumer	LI & Alu elements: Structural and functional analysis of human non-LTR retrotransposons	Sixma	2005	2
J.J. Smit	Ubiquitin conjugation	Sixma	2007	4
M. Vargas	Structural analysis of the mechanism of ubiquitin conjugation	Sixma	2004	2

Molecular Genetics (NKI)

A. Alendar	Identificaiton of the PIM regulatory network by micro array analysis and high through put retroviral tagging	Berns	2002	3
E. Boutsma	Functional analysis of BMI-ring finger interacting proteins and application of microarray technology to identify BMI-1 response genes	Bernards	2000	3
U. Braunschweig	Genome-wide analysis of chromatin structure	van Lohuizen	2005	2
S. Bruggeman	Characterisation of oncogenic potential and mechanism of gene repression of TBX2	van Lohuizen	2003	3
T.Geiger	Oncogenic function of human DRIL1	Berns	2003	3
J. Kaplon	The relationship between cell metabolism, sencescence and cancer	Peeper	2007	2
T. Kuilman	Novel functional genomic screens to identify pathways that protect mouse & human cells against oncogenic transformation by mutant RAS	Berns	2003	2
C. Michaloglou	Senescence-like replicative arrest in melanocytic naevi: a melanoma-suppressive mechanism?	Peeper	2003	1
E.H.M. van Montfort	Development of a mouse model to study the genetic basis of malignant mesothelioma	Berns	2000	3
M. Peuscher	Novel factors involved in chromosome protection by telomeres	Berns	2007	3
M. Smit	The role of the neurotrophic tyrosine kinase receptor	Berns	2005	3
P. Taghavi	Functional analysis of MBI1-ring finger interacting proteins and application of microarray technology to identify BMI1-responsive genes	van Lohuizen	2000	3
V. Theodorou*	Cloning of novel mammary tumor progression and metastasis genes	Hilkens	2001	2
J. van der Torre	Novel factors involved in chromosome end protection by telomeres	Berns	2006	3
Y. van der Velden	The role of Ikb1 in tissue morphogenesis and cancer zebrafish	Haramis	2006	2
J. Vissers	Regulation of histone H2A monoubiquitination by Ring 1b/Bmi1 and USP3 in DNA damage respons	van Lohuizen	2006	4
L. Vredeveld	The role and mechanism of escape from Ras induced senescence in oncogenesis	Peeper	2002	3

Tumor Biology (NKI)

J. Drost	Identification and characterization of human tumor suppressor genes in the p53 pathway	Agami	2005	3
J. van Duijse	Genome wide screens for DNA-damage check point in human cells	Agami	2005	4
A. Duursma	Activated proteolysis in response to DNA damage	Agami	2001	1
D. Engelsma	Synthetic transport signals to predict and regulate nucleocytoplasmic transport	Fornerod	2002	1
J. Hendriksen	Role of the nuclear pore complex in β -type catenin nuclear signalling	Fornerod	2001	2
T. van den Hoorn	Defining the MHC class II microdomain to understand immune responses	Neefjes	2004	3
D. Houben	Pathways of antigen presentation by CD1 a,b and c	Peters	2006	2
M. Jongsmma	Manipulating the MHC class II system to control immune responses in auto immunity	Neefjes	2007	2
B. Kalverda	The role of RamBP3 in beta cetenin dependent nuclear signaling and oncogenesis	Fornerod	2004	3
R. van der Kant	Manipulating the MHC class II system to control immune responses in auto immunity	Neefjes	2007	2
M. Kedde	Studying tumorigenesi using RNAi	Neefjes	2003	3
M. van Kouwenhove	Role of miRNA genes in etiology of germ cell tumors and derived malignant tumors	Agami	2007	2
R. Nagel	Genome wide search for DNA damage checkpoint functions in humans	Neefjes	2005	4
J. Neijssen	Peptidases and improving the MHC class I response	Neefjes	2002	2/1
B. Pang	Manipulation of phagosomal pathways	Neefjes	2006	2
P. Paul	Drugs for therapy	Neefjes	2006	2
J. Pierson	EG immunoprion immunological and structural studies of prion diversities	Peters	2006	4
N. Rocha	Structure elucidation of cord7 and complexe	Neefjes	2001	1
C. le Sage	Activated proteolysis, a novel rapid respnse to DNA damage	Agami	2002	2
I. Salomon	Microban	Neefjes	2005	4
Y. Souwer	The role of HLA-DO and HLA-DM in effective MHC class II mediated immune activation	van Ham/ Neefjes	2001	2
A. Zwaagstra	Identification of novel mammary tumor progressions genes	Hilkens	2005	3
W. Zwart	Molecular basis of resistance to anti-estrogens	Michalides	2003	1

Clinical Genetics (VUmc)

N. Ameziane	Role of Fanconi anemia genes in familial and sporadic breast cancer	Joenje/Pals	2004	2
S. Bakker	The Achillesheel of tumours with the Fanconi anemia phenotype	Joenje/te Riele	2005	1
C.J. Dommering	Retinoblastoom en erfelijkheid	Meijers	2006	1

P. van der Lelij	The role of sister chromatid cohesion in the maintenance of genetic stability	Joenje / de Winter	2006	1
------------------	---	--------------------	------	---

Medical Oncology (VUmc)

B.G. Molenkamp	Immunomodulation of the melanoma sentinel lymph node	de Gruijl	2004	3
J.J. Lindenberg	Adenovirus-based and CD40-targeted in vivo tumor vaccination	de Gruijl	2006	2

Molecular Cellbiology and Immunology (VUmc)

E.M. van Beek	SIRP-alpha-CD47 interactions in viral and tumor immunity	van den Berg	2003	1
G. van der Bij	Role of macrophages in peritoneal and liver metastasis	van Egmond / Beelen	2003	1

Obstetrics and Gynaecology (VUmc)

B. Hermsen	Risk assessment and preventive measures in women at high risk of developing breast and ovarian cancer	von Mensdorff-Pouilly / Kenemans	2002	4
M.E. Nowee	Oncogenic factors in ovarian and tubal carcinoma	Verheijen	2002	4

Oral and Maxillofacial Surgery and Pathology (VUmc)

J.F. Bremmer	Diagnosis and therapy of genetically altered mucosal lesions in the oral cavity and oropharynx	van der Waal / Brakenhoff	2002	1
P.K.E. Börjesson	Detection and therapy of head and neck cancer with radiolabeled anti-CD44v6 monoclonal antibodies	van Dongen / de Bree	2000	1
A.P. Graveland	Molecular diagnosis of head and neck squamous cell carcinoma (HNSCC)	Brakenhoff	2005	3
S.R. de Kemp	Functional characterization of stem cells and signal transduction pathways in head and neck squamous cell carcinoma	Braakhuis / Brakenhoff	2007	1
M. Moreno	Study of MUC1 as a target for the immunotherapy of patients with breast and ovarian carcinomas	Von Mensdorff-Pouilly / Scheper	2004	1
S. Smeets	Multi-step head and neck carcinogenesis	Brakenhoff	2003	1
B.M. Schaaij-Visser	A quantitative proteome progression model for squamous cell cancer	Brakenhoff	2004	4
H.J.T. van Zeeburg	Innovative therapies of precancerous lesions in the oral cavity and oropharynx	Brakenhoff	2004	1

Pathology (VUmc)

M. Bierkens	Genetic profiling of CIN 3 lesions diagnosed in the subsequent screening round following screening by HPV testing and cytology	Snijders / Steenbergen	2007	1
L.J.W. Bosch	Methylation for Early Coloractal Cancer Detection	Meijer	2005	4
N.W.J. Bulkman	HPV-BOB	Snijders / Meijer	2001	2
S.A.G.M. Cillessen	Functional analysis of apoptosis signaling pathways in B-cell lymphomas	Oudejans / Meijer	2003	3
J. van Galen	Polycomb expression in normal human lymphocyte development	Meijer / Oudejans	2002	4

A. Hardebol	Functional characterization of chromosome 20q amplified genes suitable for CRC screening	Meijer	2005	4
F.E. Henken	Defining the essential molecular pathways involved in cervical carcinogenesis	Snijders	2005	1
A.T. Hesselink	HPV quantification in cervical smears: consequences for screening and management of women with equivocal cervical smears	Snijders / Meijer	2002	1
E.K. Hoebe	Role of soluble BARP1 oncoprotein in Epstein-Barr virus driven carcinogenesis and its functional inhibition by antibodies	Middeldorp	2007	3
P.A.J. Krijnen	Epstein-Barr virus LMP1,2 specific immunoreactivity and immunotherapy in Hodgkin's Disease	Middeldorp	2005	3
R.M. Overmeer	TSLC1 silencing, a marker for risk assessment of cervical cancer	Meijer	2005	3
E. Reinen	Genetic profiling for risk assessment of preneoplastic endobronchial lesions	Snijders / Smit	2007	3
D. Rijkaart	Stratifying high-risk HPV positive women for risk of CIN 3 and cervical carcinoma by HPV transcript analysis	Snijders / Meijer	2006	3
A. Turksma	Towards adjuvant immunotherapy for squamous cell carcinoma	Hooijberg / Meijer / Leemans	2007	3
R. van de Ven	ABC Transporters in dendritic cell function	Scheffer / de Gruijl	2003	3
J. de Wilde	Cervical carcinogenesis: unraveling of the multistep pathways using well-defined clinical material and in vitro cell culture model systems	Snijders / Steenbergen	2002	1
M. de Wit	Molecular imaging of colorectal cancer	Meijer / Fijneman	2006	4
Urology (Vumc)				
A. Mol	New experimental markers for early detection of high-risk prostate cancer	Van Moorselaar / Geldoff	2006	3
Cell Biology & Histology (AMC-UvA)				
J.M.E.D.Gillis	When protein degradation fails	Reits/ van Noorden	2005	2
H.A.G. Krol	Role of peptidases in polyglutamine disorders	Reits/ van Noorden	2004	1
P. Krawczyk	Double strands DNA breaks and their repair	Aten/ van Noorden	2003	3
Center for Experimental Molecular Medicine (AMC-UvA)				
S.A. Bleumink	Morphostasis of the adult gastrointestinal tract	Peppelenbosch/ van Deventer	2002	1
T. Borovski	Chromosomal aberrations and cancer stem cells	Medema	2006	3
H. Braat	Innovative feedingintervention in patients with chronic inflammation	van Deventer	1999	3
S.H. Diks	Tissue factor-dependent signalling	van Deventer	1999	2
F.F. van Doormaal	The association between hemostasis and cancer	Buller/ Richel	2006	1
K. Kemper	The role of cancer stem cells in tumorigenesis and metastasis in colon cancer	Medema	2006	1

L. Kodach*	Early detection of colorectal cancer using proteomic technology	van Deventer	2003	3
A.M. Rygiel	Follow-up study of a cohort of Barrett's oesophagus patients by brush cytology and fish	van Deventer	2003	2
J.B. Tuynman	A phase II study on the effects of celecoxib on several pharmacodynamic endpoints, including activity of the Wnt/b-catenin pathway, apoptosis, proliferation, and angiogenesis in sporadic colorectal polyps and colorectal cancer in human	Richel/ van Deventer	2002	3
I. Vermeulen	Wnt signalling and cancer stem cells	Medema	2006	2
G.Hardenberg	The role of APRIL and its receptors in tumour growth and immune regulation	Medema	2003	3
F.B. Mullauer	Inventory of the anti-cancer efficacy of the plant-derived compound Betulinic acid and the clarification of the mechanisms underlying its induction of tumor-specific apoptosis	Medema	2005	3
Clinical chemistry (AMC-UvA)				
O.G. Besancon	Preclinical screening of drug combinations for neuroblastoma	Kuilenburg	2008	3
Gastroenterology & Hepatology (AMC-UvA)				
N. van Til*	Development of a method for hepatocyt transplantation and repopulation	Oude Elferink	2001	1
F. Milano*	Developing novel strategies for treating oesophageal cancer: dendritic cells immunotherapy	Krishnadath	2003	3
Human Genetics (AMC-UvA)				
A.C.J. Ammerlaan	Genetic profiling of gliomas and their recurrences for improvement of diagnosis and prognosis	Hulsebos / Versteeg	2002	3
J. Bunt	The role of OTX2 in medulloblastoma	Versteeg/ Kool	2005	1
H.J. Gierman	The human genome: understanding functional nuclear organisation from landmarks in the human transcriptome	Versteeg	2003	1
T. van Groningen	The role of Notch signalling in Neuroblastoma	Versteeg	2008	2
A. Koppen	Gene silencing by Myc-oncogenes	Versteeg	2001	3
I.M. Revet	The role of the MEIS homeobox genes in neuroblastoma pathogenesis	Versteeg	2003	3
Pathology (AMC-UvA)				
D. Gorter	Functional and molecular analysis of HGF/Met signaling in germinal center B cells and B cell neoplasia	Pals	2000	3
R. Groen*	Heparan sulfate proteoglycans and HGF activator in HGF/MeT-signaling and lymphomagenesis	Pals/ Spaargaren	2003	2
R.M. Reijmers*	The role of heparan sulphate proteoglycans in B cells and multiple myeloma	Pals/ Spaargaren	2003	2

Theme 2: Experimental Clinical Research

<i>Name</i>	<i>Title of the project</i>	<i>Supervisor(s)</i>	<i>Start</i>	<i>Funding</i>
Clinical Oncology (NKI)				
S. Mook	Prognostic profiling in breast cancer	Van 't Veer	2006	2
Experimental therapy (NKI)				
J. Hannemann	Micro array analysis of breast cancer as a diagnostic tool to guide optimal treatment	van de Vijver	2002	3
A.E. van Herwaarden*	Generation and validation of cytochrome 450 3A k-o and transgenic mice as tools for improved DDR	Schinkel	2001	3
H. Horlings	Genetic classification of breast cancer	van de Vijver	2006	2
M. Joerger*	Pharmacogenetics in solid tumor patients	Schellens/Beijnen	2003	3
M. de Jong	Prediction of local control after radiotherapy in head and neck cancer	Begg	2007	3
S. Joosse	Specific chromosomal imbalance in breast carcinomas as a marker for breast cancer susceptibility	Nederlof	2007	3
M. Kok	Molecular prediction of therapy outcome in breast cancer	Van 't Veer	2004	4
J. Lagas	Impact of the multidrug transporters p-glycoprot., MRP2 and BCRP on the behaviour of anti-cancer drugs	Schinkel	2004	4
S. Neijenhuis	Determinants of radiosensitivity	Begg	2003	3
R. Oostendorp	Preclinical and clinical pharmacology of oral drugs	Schellens/Beijnen	2004	4
D. Peric-Hupkes	Chromatin Profiling of Human gene silencing complexes	van Lohuizen	2004	3
J. Prama	Gene expression profiling to predict outcome after chemoradiation in head and neck cancer	Begg	2005	3
E. van der Steeg	The impact of OATP drug carriers on in vivo pharmacology toxicology & physiology	Beijnen	2004	4
S. Veltkamp	Clinical Pharmacology of oral gemcitabine and other (oral) anti-cancer agents	Schellens/Beijnen	2003	4
C. Vermeulen	Determinants of radiosensitivity	Begg	2002	3
M. Vlaming	Compound Mrp2 (Abcc2) and other drug transporter knockout mice to study determinants ...	Schinkel	2003	3
M. Vogel	Functional Genomics of Gene Regulation by heterochromatin proteins	van Steensel	2002	3
A. Vrieling	The IGF system in breast and colorectal carcinogenesis: dietary intervention and mol. studies	van Leeuwen	2002	3
R. van Waterschoot	Generation and validation of cytochrome P450 3A knockout and transgenic mice as tools for...	Beijnen	2005	2
E. de Wit*	Bioinformatics of transcription regulation	van Steensel	2003	1

Medical Oncology (NKI)

D. Boss	Clinical pharmacology of anticancer drugs	Schellens	2005	4
J. Bueno de Mesquita	Predictive and prognostic factors in breast cancer	Linn/v.d. Vijver	2003	4
M. Deenen	Clinical pharmacology and pharmacogenetics of fluoropyrimidine anti-cancer agents	Schellens/Beijnen	2006	4
E. de Jongh	Effectivity anti-cancer therapy	Schellens	2007	4
R. Keizer	Population pharmacokinetics and pharmacodynamics of investigational anti-cancer agents	Schellens/Beijnen	2006	4
R. Koornstra	Predicting hormonal treatment sensitivity in breast cancer	Linn	2007	4

Pharmacy and Pharmacology (NKI)

E. Brouwers	Bioanalyse van metalen (i.h.b. Platina) in biologische matrices m.b.v. ICP-MS	Beijnen	2003	4
C. Ekhart	Genotyping as tool for dose individualization in high-dose chemotherapy	Huitema	2006	3
J. Engwegen	Clinical proteomics	Beijnen	2003	4
M.C. Gast	Proteomics in Oncology	Beijnen	2003	4
M. Klous	Pharmaceutical development of diacetylmorphine formulations	Beijnen	2001	4
S. Koolen	Oral administration of anti-cancer agents	Schellens/ Beijnen	2006	4
S. van der Schoot	Pharmaceutical development of anti cancer agents	Beijnen	2002	1
L. Tran	High-dose 121I-labelled rituximab in the treatment of non-Hodgkin lymphomas	Beijnen	2006	4
A. Zandvliet	Population pharmacokinetics & pharmacodynamics of investigational anticancer drugs	Beijnen	2003	4

Psychosocial Research and Epidemiology (NKI)

S. v.d. Belt-Dusebout	Risk of second malignancy and cardiovascular disease after treatment for testicular cancer	van Leeuwen	2003	3
K. Douma	Long-term psychosocial impact of genetic testing among familial adenomatous polyposis families	Aaronson	2004	3
M. Hooning	Long term risk of second cancers following treatment of Hodgkin's disease, testicular cancer and breast cancer	van Leeuwen	2000	3
C. Lammens	LFS-VHI-study -> Psychosocial aspects of genetic testing in families at high risk of multiple tumors	Aaronson	2005	3
V. Retèl	Constructive technology assessment in an early stage of clinical implementation of microarray testing for node-negative breast cancer patients	van Harten	2006	4
A. van Rosmalen	The role of early life-style factors in the etiology of breast cancer	Rookus	2001	4
C. Schilder	Assessment of neuropsych. sequelae of tamoxifen & exemestane in postmenopausal women with EBC	van Dam/Schagen	2003	4
J. Verloop	Physical activity and breast cancer risk	Van Leeuwen	1997	3

Radiotherapy (NKI)

G. Borst	Optimization of conformal radiation therapy of non-small cell lung cancer by advanced 3-D planning	Lebesque	2003	3
L. McDermottt*	Dose verification and dose optimization of radiotherapy using portal imaging	Mijnheer/ van Herk	2001	1
M. Smitsmans	On-line tomographic guidance for RT of the prostate	Bartelink	2003	4
S. Vink*	Improvement of tumor response by combined modality treatment: a translational approach	Verheij	2001	3
J. Wolthaus	Optimization of conformal RT of nonsmall cell lung cancer by advanced 3-D planning	Bartelink	2003	3

Gastroenterology (VUmc)

F.A. Oort	Colorectal polyps and cancer in Amsterdam	Mulder / Craanen	2007	4
J.S. Terhaar sive Droste	Colorectal polyps and cancer in Amsterdam	Craanen	2005	3
J.M.W. van de Water	Predicting T-cell lymphoma development in refractory coeliac disease patients by profiling of apoptosis pathways in intestinal T-lymphocytes	Mulder / Meijer	2007	1

Obstetrics and Gynaecology (Vumc)

E.M. Davelaar	Serum tumour markers in cervical carcinoma	Verstraeten	2004	2
M. Verbruggen	Clinical and molecular aspects of borderline ovarian tumours	Dorsman	2002	1

Hematology (VUmc)

C. Hess	The nature of minimal residual disease in acute myeloid leukemia	Schuurhuis / Ossenkoppele	2002	3
M. Terwijn	Detection of residual leukemic stem cells during minimal residual disease in AML	Schuurhuis / Ossenkoppele	2006	3
W. van den Ancker	Optimizing strategies in dendritic cell vaccination in myeloid leukaemia	v.d. Loosdrecht / Ossenkoppele	2006	1
M. van Luijn	Regulation of MHC class-II in acute myeloid leukemia and its impact on immunoserveillance	v.d Loosdrecht / Ossenkoppele	2006	3
A. van Rhenen	The nature of primitive clonogenic aml cells and the role in emergence of minimal residual disease in AML	Schuurhuis / Ossenkoppele	2002	4
M.J. Wondergem	Can transformation of indolent lymphoma be detected at an early stage by PET scanning?	Huijgens / Hoekstra	2006	1
J. Zijlstra-Baalbergen	Response monitoring in non-Hodgkin's lymphoma using Positron Emmission Tomography	Huijgens / Lammertsma	2003	1

Medical Oncology (VUmc)

A. Adema	Development of novel strategies to optimize cytotoxic and targeted therapy	Peters	2003	4
M.N.A. Bijman	Docetaxel: its role in the inhibition of angiogenesis and the mechanism for induction of apoptosis	Boven / Hoekman	2001	3
I. Bijnsdorp	Enhancement of trifluorothymidine cytotoxicity by	Peters	2005	3

	docetaxel				
A. Checinska*	The role of caspases in the sensitivity of lung cancer cells to chemotherapy	Kruyt / Rodriguez	2002 / 2007	3	
H. van Cruijssen	Clinical trials with receptor tyrosine kinase inhibitors in patients with advanced cancer	Hoekman	2004	3	
M.I. Gallegos Ruiz	Mutational and functional analysis of the EGFR pathway in NSCLC patients: correlation with prognosis and response to small molecule EGFR inhibitors	Giaccone	2005	3	
E. Giovannetti	Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients	Peters	2007	4	
C. Lemos	Folate supplementation in chemotherapy: increase of efficacy versus induction of drug resistance	Peters	2005	3	
J. Sigmond	Interaction of gemcitabine with novel molecular targets	Peters	2002	4	
J. Voortman	Efficacy and mechanism of combination therapy with proteasome inhibitor PS-341 (Velcade(tm)) in NSCLC	Kruyt / Giaccone	2003	4	
L. Vroling	Circulating endothelial cells as markers for anti-angiogenic therapy	Broxterman	2005	3	
Medical Psychology (VUmc)					
J. van Dijk	Psychosocial functioning and quality of life of retinoblastoma survivors and parents in the Netherlands	Imhof	2004	3	
Neurology (VUmc)					
I. Bosma	Health-related quality of life and neurocognitive functioning of long-term surviving high-grade glioma patients / Synchronized brain activity and neurocognitive function in brain tumor patients: a MEG study / Efficacy and toxicity of cerebral glioma treatment	Klein / Stam / Postma	2004	4	
L. Douw	Changes in functional connectivity after tumor resection in brain tumor patients: a magnetoencephalography study	Stam / Reijneveld	2007	4	
S. Toering	Correlation between SV2A expression in tumour tissue and efficacy of levetiracetam in glioma patients with epilepsy	Reijneveld / Heimans / Klein	2007	3/4	
Neurosurgery (VUmc)					
S. Idema	Improving oncolytic viral therapy for glioma	Dirven / Lamfers	2003	4	
Nuclear Medicine (VUmc)					
W. Direcks	Experimental and clinical studies using positron emission tomography (PET) for monitoring response to chemotherapy in (locally) advanced breast cancer	Molthoff / v.d. Wall	2003	3	
J. Emmering	Towards a rational use of PET in breast cancer patients	Teule	2003	1	
A.J. de Langen	Evaluating therapeutic impact of induction therapy for locally advanced NSCLC with molecular imaging	Hoekstra	2005	1	
A.A.M. van der Veldt	PET imaging of [11C]docetaxel kinetics: part I, the role of bioavailability of [11C]docetaxel in predicting	Hendrikse	2007	3	

response in breast cancer

Otolaryngology / Head and Neck Surgery (VUmc)

J. Brouwer	Investigation into cost-effectiveness of diagnostic algorithms of patients with head and neck cancer to prevent unnecessary treatments	Leemans	2000	1
C.D.L. van Gogh	Voice therapy for patients with voice problems after treatment for early glottic cancer / Voice after laryngectomy by means of a sound-producing tracheoesophageal shunt valve	Mahieu	2002	2
A.M. Lo Galbo	Hypothyroidism after treatment for laryngeal cancer	Leemans	2005	1
G.B. Flach	The sentinel node procedure in head and neck cancer: clinical value and potential technical improvements / Aspiration cytology and sentinel node biopsy in the detection of occult lymph node metastases of early oral and oropharyngeal cancer	De Bree / Van Dongen	2007	3
I.M. Oskam	Health related quality of life in head and neck cancer patients	Leemans	2004	1
L.R. Perk	Molecular imaging with PET using long-lived positron emitters	van Dongen	2003	2
L. van der Putten	FDG-PET for avoidance of futile direct laryngoscopies under general anesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapy	Leemans	2005	3
A. Senft	Screening for distant metastases and second primary tumors with FDG-PET (the school study)	Leemans	2002	2
B.M. Tijink	Antibody-based therapy with emphasis on head and neck cancer	Van Dongen / de Bree / Leemans	2003	3

Pathology (VUmc)

T. Buffart	Predicting lymph node status in gastric cancer by DNA-based genomic profiling for stratifying surgical therapy	vd Velde / Meijer	2004	3
E.A. Greijer	Early pathogenesis and intervention in Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease (PTLD) in stem cell (SCT) and solid organ transplant (SOT) recipients	Middeldorp	2005	3
J.C. Haan	Prediction of response to drug therapy in advanced colorectal cancer based on DNA copy number profiles of primary tumors	Meijer / Ylstra	2007	3
A. Hardebol	CRC screening by faeces DNA based testing using chromosome 20q genes	G.A. Meijer	2005	4
I. van Houdt	Involvement of resistance to apoptotic cell death in the response to immunotherapy	Kummer / van den Eertwegh	2003	1
J. Molling	Anti-tumor effector functions of skewed natural killer T cells	Scheper / von Blomberg	2002	3
S. Santegoets	Dendritic and T cell functions in patients with metastatic hormone-refractory prostate cancer treated with Prostate GVAX cancer immunotherapy and Ipilimumab	de Gruijl	2002	3
Q.J.M. Voorham	Increasing sensitivity for detection of high risk flat adenomas in population screening for colorectal cancer	G.A. Meijer	2006	3
S.M. Wilting	Distinction of early, intermediate and late cervical intraepithelial neoplasia grade III (CIN III) lesions by	Snijders / Steenbergen	2003	3

micro-array analysis

Pediatrics (VUmc)

C. Bachas	Characterization of relapsed acute myeloid leukemia	Cloos/ Schuurhuis	2007	1
K.I. Braam	Silicone gel sheet to improve cosmetic outcome of the scar after removal of an implantable central venous access device (ICVAD) in childhood cancer survivors	Van Dulmen-den Broeder/Kaspers	2007	4
N. Franke	Drug resistance in childhood leukemia	Cloos / Kaspers	2006	4
B.F. Goemans*	Cellular resistance to conventional and targeted anticancer agents in relation to molecular biological features in childhood relapsed and refractory acute myeloid leukemia	Kaspers / Zwaan	2002 / 2007	4
I. Hubeek	Tyrosine phosphatases as new targets in childhood cancer	Cloos	2005	3
W.A. Kors	Retinoblastoma	Cloos	2005	1
M. Luttjeboer	Ex vivo radiosensitivity and modification by anticancer agents in pediatric brain tumors	Kaspers / Sminia	2002	4
S.E. Mir	Therapeutic potential of histone deacetylase inhibitors in the treatment of Medulloblastomas: from anticancer drugs to neuroprotective agents / Role HDACs in childhood brain tumors	Kaspers / Cloos	2007	2
S. Mostert	Compliance with chemotherapy in childhood acute lymphoblastic leukemia in a developing country	Veerman	2003	4
J. Vink	Glucocorticoid-induced apoptosis and glucocorticoid resistance in lymphoid malignancies and autoimmune diseases	Kaspers	2001	3/4
D.G. van Vuurden	Targeted therapy in pediatric brain tumors	Kaspers	2005	1

Pulmonology (Vumc)

R. van den Berg	The use of molecular biomarkers in early lung cancer	Snijders / Smit	2003	2
-----------------	--	-----------------	------	---

Radiology (VUmc)

P. de Graaf	Clinical and experimental high resolution ocular MR Imaging: towards improved detection of retinoblastoma tumor extent	Castelijns	2006	3
R. Ljumanovic	Prognostic value of MRI-determined lymph node parameters in development of distant metastases in head and neck carcinoma	Castelijns	2003	3
J.H. Weijs	Optimization of US selection criteria of lymph nodes (size, laterality, aspect and behaviour) to perform USgFNAC in follow-up of patients's oral cavity or oropharyngeal carcinoma	Castelijns	2005	2

Radiotherapy (VUmc)

K.A. van Nifterik	Malignant glioma genetics and related chemoradiosensitivity as guidance for individualized therapy	Sminia / Hulsebos	2002	1/3
-------------------	--	-------------------	------	-----

Surgery (VUmc)

R.P.M. Brosens	Tumor profiling for prediction of clinical outcome in	Cuesta / G.A.	2006	3
----------------	---	---------------	------	---

	colorectal cancer patients	Meijer		
H. Fabry	Strategy and results in early breast cancer	Meijer	2003	1
G. Melis	Quantifications of the generation of arginine in the kidney during liver surgery	Van Leeuwen	2001	2
M.P.C. Siroen	ADMA clearing after liverresection for metastatic cancer	Van Leeuwen/ van der Sijp	2002	2
M. Westerterp	The role of FDG PET in eosophageal cancer staging and monitoring the response to neoadjuvant therapy	Molthoff	2005	2
Gastro-enterology & Hepatology (AMC-UvA)				
M.A. van Geer	Development of infectivity enhanced conditionally replicating adenovirus vetors for gene therapy of pancreatic cancer	Oude Elferink	2002	3
Hematology (AMC - UvA)				
D. Hallaert	Novel therapeutic approaches to attack the microenvironment in Chronic Lymphocytic Leukemia	Van Oers/ Eldering	2004	3
M. Jak	Immunotherapy for B-CLL in human CD20 transgenic mice	Van Oers/ van Lier	2007	4
Medical Oncology (AMC-UvA)				
S.J. de Kort	Ethical aspects of palliative cancer chemotherapy	Willems/ Richel	2003	3
Pathology (UvA/AMC)				
W.W.J. de Leng	Carcinogenese in het Peutz-Jehgers syndroom	Offerhaus	2002	3
Pediatric Oncology (AMC-UvA)				
E.J. Aukema	Late consequences and needs of young survivors of a brain tumor and their parents	Last/Schouten/ Grootenhuis	2006	1
J.J. Molenaar	Delineating the biological and clinical importance of CyclinD1 in neuroblastoma	Caron	2000	1
R.Cuperus	Modulation of Fenecitinide induced apoptosis in Neuroblastoma cells	Caron	2004	3
E.C. van Dalen*	Anthracycline-induced cardiotoxicity in childhood cancer	Caron	2002	3
V. Engelen	QLIC-ON quality of life in childhood oncology	Versteeg/ van Nes	2005	3
E. Sieswerda	new drug development, clinical trials and late effects	Caron/ Kremer	2007	3
J. Stutterheim	MRD monitoring at children with neuroblastoma	Caron/ Tytgat	2006	3
Radiotherapy (UvA/AMC)				
J. Bergs*	Aberrations in premature condensed chromosomes(PCC) as a predictive assay for the response of human cervical carcinomas after radiotherapy combined with hyperthermia	Haveman/ Konings	2002	1
H.P. Kok*	Development of an new dual modality heating technique form treatment of cancer at the esophagus and other intracavitary locations	Crezee/Konings	2002	3

A.L.J. Uitterhoeve*	Results of radiotherapy alone or in combination with chemotherapy in non small cell lung cancer	Gonzalez	1998	1
---------------------	---	----------	------	---

Surgery (AMC/UvA)

R. Bakx*	Pouch versus STE-anastomoses bij rectum-carcinoom	Van Lanschot	2001	3
----------	---	--------------	------	---

M.C. Janssen	Locale ablatie van levertumoren: het effect van radiofrequente thermoablatie, interstitiele lasercoagulatie en cryoablatie op de acute fase immuunreactie en stollingsactivatie in de rat	Van Gulik	2001	3
--------------	---	-----------	------	---

Urology (AMC-UvA)

P. Beemster	Cryosurgery of small renal tumors	De la Rosette/ Laguna/ Wijkstra	2005	1
-------------	-----------------------------------	------------------------------------	------	---

awards

5

5. Awards

This chapter lists awards and honors won by staff and students involved in OOA throughout 2007. The lists are in alphabetical order of the recipients' last name.

Faculty and staff members of the OOA fulfilled numerous functions in national and international organizations, on scientific boards of scientific journals, as members of study sections, and as organizers or co-organizers of scientific meetings, workshops and congresses.

Scientific awards and honors

R. Bernards (NKI) became member of the Netherlands Academy of Sciences.

R. Agami (NKI) received the prestigious Steiner Price

P. Borst (NKI) received the distinguished Service Award sponsored by a number of US institutions and presented at the Miami Nature Winter symposium

R. Bernards (NKI) received the ESMO Lifetime Achievement Award in Translational Research in Breast Cancer

L. van 't Veer (NKI) was the recipient of the BCRF Estee Lauder Pink Ribbon research award.

A. Berns (NKI) was awarded a Charles B. Smith visiting professorship at MSKCC.

R. Agami was elected as EMBO member.

S. Bruggeman won the AVL prize 2007 for young, promising NKI-scientists for her work on cancer stem cells

J.W.A.M. Celie and J. van den Born (Vumc) were the 3rd prize award winners of the Methods in Renal Research essay contest 2007.

J.P. de Winter and J.C. Dorsman (Vumc) received the FA Research Fund Discovery award for the identification of FANCI in Chicago.

J.C. Dorsman (Vumc) received the Deutsche FA HilfeAward for cloning of FANCI in Gersfeld, Germany.

G.J.M. Herder (Vumc) won the Vera Bonte award.

H. Joenje (Vumc) received the Spanish Fanconi anemia Research Senior Scientist Award for life-time contribution to Fanconi Anemia research and

commitment with FA patients and their families in Santander (Spain) and the Distinguished Service Award in Chicago (USA).

B. Molenkamp, T.D. de Gruijl, P.A.M. van Leeuwen and R.J. Scheper (Vumc) won the poster award Melanoma Sentinel Lymph Node Immunology at the Dendritic Cell Conference, Bamberg (Germany)

C.B.M. Oudejans (Vumc) received the Science Award Dutch Society for Clinical Chemistry in Seoul (South Korea).

B.J. Slotman (VUmc) received the Heine Hanse Lectureship at the Internat Association for the Study of Lung Cancer Seoul (South Korea).

A.A. van de Loosdrecht (Vumc) won the MDS Foundation, Young Investigators Award: Multicolour Flow Cytometry in Myelodysplastic Syndromes (US Dollar 40,000) in Atlanta (USA).

M. van Dijk (Vumc) received the Charlie Loke Award in Kingston (Canada).

S.J. van Vliet (Vumc) received the Chris Meijer Prijs at the CCA/V-ICI annual plenary meeting

L. vd Stadt (Vumc) won the "Arthron Reumatologie Aanmoedigingsprijs 2007" for literature thesis entitled: "The proteasome: A novel experimental target for rheumatoid arthritis treatment" in Amsterdam.

Q. Waisfisz (Vumc) won the FA Research Fund Discovery award for the identification of FANCI in Chicago (USA).

General awards and honors

H. Bartelink received the Royal Honor of Knight in the Order of the Dutch Lion.

B. Kroon received the Royal honor of Knight in the order of Oranje Nassa



faculty and staff

annex

1

Annex 1.

Faculty and staff of OOA

Faculty

Prof.dr. N.K. Aaronson (Theme 2)
Department of Psychosocial Research and
Epidemiology
Netherlands Cancer Institute

Dr. R. Agami (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Dr. J.A. Aten (Theme 1)
Department of Cell Biology and Histology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.M.M. Bartelink (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof.dr. A. Begg (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. R. Beijersbergen (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. R. Bernards (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. A.J.M. Berns (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. J.H. Beijnen (Theme 2)
Division of Pharmacology
Netherlands Cancer Institute

Prof.dr. J.G. Borst (Theme 1)
Department of Immunology
Netherlands Cancer Institute

Prof.dr. P. Borst (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. R.H. Brakenhoff (Theme 1 and 2)
Department of Otolaryngology-Head & Neck Surgery
VU University Medical Center

Prof.dr. H. N. Caron (Theme 1 and 2)
Pediatric Oncology

Academic Medical Centre / Universiteit van
Amsterdam

Dr. J.G.N.M. Collard (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Dr. J. Crezee (Theme 2)
Department of Department of Radiation Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.A.M.S. van Dongen (Theme 1 and 2)
Department of Otolaryngology-Head & Neck Surgery
VU University Medical Center

Dr. E.F. Eldering (Theme 1)
Department of Experimental Immunology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. D. Geerts (Theme 1)
Department of Human Genetics
Academic Medical Centre / Universiteit van
Amsterdam

Dr. W.R. Gerritsen (Theme 2)
Department of Medical Oncology
VU University Medical Center

Prof.dr. D.J. Gouma (Theme 2)
Department of Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G. Giaccone (Theme 2)
Department of Medical Oncology
VU University Medical Center

Dr M. A. Grootenhuys (Theme 2)
Department of Pediatrics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. T.M. van Gulik (Theme 2)
Department of Experimental Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof. Dr. A. Hagenbeek (Theme 1 and 2)
Department of Hematology

Academic Medical Centre / Universiteit van Amsterdam

Dr. J. Haanen (Theme 1 and 2)
Department of Immunology
Netherlands Cancer Institute

Prof. Dr. M. van Herk (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof.dr. O.S. Hoekstra (Theme 2)
Department of Nuclear Medicine
VU University Medical Center

Prof.dr. P.C. Huijgens (Theme 1 and 2)
Department of Haematology
VU University Medical Center

Dr T.J.M. Hulsebos (Theme 1)
Department of Neurogenetics
Academic Medical Centre / Universiteit van Amsterdam

Dr. K. Jalink (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Prof.dr. H. Joenje (Theme 1)
Department of Human Genetics
VU University Medical Center

Dr. J. Jonkers (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. G.J. Kaspers (Theme 2)
Department of Paediatrics
VU University Medical Center

Prof.dr. C.C.E. Koning (Theme 2)
Department of Radiotherapy
Academic Medical Centre / Universiteit van Amsterdam

Dr. M. Kool (Theme 1)
Department of Human Genetics
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. Y. van Kooyk (Theme 1 and 2)
Department of Molecular Biology and Immunology
VU University Medical Center

Dr. K.K. Krishnadath (Theme 1)
Department of Gastroenterology and Hepatology
Academic Medical Centre / Universiteit van Amsterdam

Dr. A. B.P. van Kuilenburg (Theme 1 and 2)
Department of Clinical Chemistry
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. A.A. Lammertsma (Theme 2)
Department of Nuclear Medicine

VU University Medical Center

Prof.dr. Ch.R. Leemans (Theme 2)
Department of Otolaryngology-Head & Neck Surgery
VU University Medical Center

Prof. dr. A.G.J.M. van Leeuwen (Theme 2)
LaserCenter
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. F.E. van Leeuwen (Theme 2)
Psychosocial Research and Epidemiology
Netherlands Cancer Institute

Dr. F. van Leeuwen (Theme 1)
Department of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. M. van Lohuizen (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Dr. R.M. Luiten (Theme 2)
Department of Immunology
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. J.P. Medema (Theme 1)
Laboratory of Experimental Oncology and Radiotherapy
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. C.J.L.M. Meijer (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. G.A. Meijer (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. S. Meijer (Theme 2)
Department of Surgical oncology
VU University Medical Center

Prof.dr. H. Meijers-Heijboer (Theme 1)
Department of Clinical Genetics
VU University Medical Center

Prof. dr. W.H. Moolenaar (Theme 1)
Department of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. J.M. Middeldorp (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. J.J.C. Neefjes (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Prof. dr. C.J.M. van Noesel (Theme 1)
Department of Pathology
Academic Medical Centre / Universiteit van Amsterdam

Prof.dr. C.J.F. van Noorden (Theme 1 and 2)
Department of Cell Biology & Histology
Academic Medical Centre / Universiteit van
Amsterdam

Prof. dr. M.H.J. van Oers (Theme 1 and 2)
Department of Hematology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.J. Ossenkoppele (Theme 1 and 2)
Department of Haematology
VU University Medical Center

Prof.dr. S.T. Pals (Theme 1 and 2)
Department of Pathology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. A. Perrakis (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Dr. D. Peeper (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. G.J. Peters (Theme 2)
Department of Clinical Oncology
VU University Medical Center

Prof.dr. P.J. Peters (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Prof.dr. P. Postmus (Theme 2)
Department of Pulmonology
VU University Medical Center

Prof.dr. D.J. Richel (Theme 1 and 2)
Department of Medical Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. H.P.J. te Riele (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. S. Rodenhuis (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Dr. E. Roos (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Prof.dr. J.J.M.C.H. de la Rosette (Theme 2)
Department of Urology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. J.H.M. Schellens (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Prof.dr. R.J. Scheper (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Dr. A. Schinkel (Theme 1)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. J.H. Schornagel (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Prof. Dr. T. Schumacher (Theme 1)
Department of Immunology
Netherlands Cancer Institute

Dr. G.J. Schuurhuis (Theme 2)
Department of Hematology
VU University Medical Center

Prof.dr. S. Senan (Theme 2)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. T.K. Sixma (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. B.J. Slotman (Theme 1 and 2)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. E.F. Smit (Theme 2)
Department of Pulmonology
VU University Medical Center

Dr. A. Sonnenberg (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Dr. M. Spaargaren (Theme 1)
Department of Pathology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. C.A. Spek (Theme 1 and 2)
Department of Experimental and Molecular
Medicine
Academic Medical Centre / Universiteit van
Amsterdam

Dr. B. van Steensel (Theme1)
Department of Molecular Biology
Netherlands Cancer Institute

Dr. L. van 't Veer (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. L.J. Valentijn (Theme1)
Department of Human Genetics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. W.P. Vandertop (Theme 2)
Department of Neurosurgery

VU University Medical Center

Prof.dr. A.J.P. Veerman (Theme 2)
Department of Paediatrics
VU University Medical Center

Dr. M. Verheij (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof.dr. R.H.M. Verheijen (Theme 2)
Dept. of Obstetrics & Gynaecology
VU University Medical Center

Prof.dr. R. Versteeg (Theme 1 and 2)
Department of Antropogenetics
Academic Medical Centre / Universiteit van
Amsterdam

Dr. M. van de Vijver (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. H. Wijkstra (Theme 2)
Department of Urology
Academic Medical Centre / Universiteit van
Amsterdam

Staff

Netherlands Cancer Institute

Cell Biology

Dr. J.G. Collard
Dr. C. Jalink
Dr. E. Roos
Dr. A. Sonnenberg

Molecular Carcinogenesis

Prof.dr. R. Bernards
Dr. R. Beijersbergen
Dr. A. Perrakis
Prof.dr. T.K. Sixma

Cellular Biochemistry

Dr. W.J. van Blitterswijk
Dr. N. Divecha
Dr. F. van Leeuwen
Prof.dr. W.H. Moolenaar
Dr. H. Ovaa
Dr. M. Verheij

Immunology

Prof.dr. J. Borst
Dr. J.B.A.G. Haanen
Dr. H. Jacobs
Prof.dr. T.N.M. Schumacher
Dr. F.A. Vyth-Dreese

Molecular Biology

Prof.dr. P. Borst (honorary staff member)
Dr. J. Jonkers
Dr. H. van Luenen
Prof.dr. H. te Riele
Dr. B. van Steensel

Tumor Biology

Dr. R. Agami
Dr. M. Fornerod
Dr. R.J.A.M. Michalides
Prof.dr. J.J. Neefjes
Prof.dr. P.J. Peters

Molecular Genetics

Prof.dr. A.J.M. Berns
Dr. J. Hilkens
Dr. P. Krimpenfort
Prof.dr. M. van Lohuizen
Dr. M. Snoek
Dr. M.A. van der Valk

Experimental therapy

Prof.dr. A.C. Begg
Dr. A. Schinkel
Dr. F.A. Stewart
Prof.dr. M.J. van de Vijver
Dr. L.J. van 't Veer

Radiotherapy

B.M.P. Aleman
Prof.dr. G.M.M. Bartelink
Dr. J.S.A. Belderbos
Dr. R.W. de Boer

Dr. M. Boersma
Dr. I. Bruinvis
B.N.F.M. van Bunningen
Dr. E.M.F. Damen
Dr. L.G.H. Dewit
Dr. R.L.M. Haas
Dr. A.A.M. Hart
Dr. W. Heemsbergen
Dr. M. van Herk
Dr. E.P.M. Jansen
Dr. J.V. Lebesque
Dr. C.A.M. Marijnen
E.A.H. Masselink
Dr. B.J. Mijnheer
Dr. L.M.F. Moonen
Dr. C.R.N. Rasch
Dr. P. Remeijer
Dr. N.S. Russell
J.G. Salverda
Dr. C.Schneider
Dr. J. Stroom
Dr. J.C.M. Theuws
Dr. C. van Vliet-Vroegindewey
Dr. C. Vrieling
Dr. F.W. Wittkämper

Medical Oncology

Dr. J.W. Baars
Dr. P. Baas
Drs. E.M. Bais
Prof.dr. J.H. Beijnen
Dr. J.P. de Boer
Dr. W.W. ten Bokkel Huinink
Dr. W. Boogerd
Dr. H. Boot
Dr. J.A. Burgers
Dr. A. Cats
Prof.dr. G.C. de Gast
L. Gualthérie van Weezel
Dr. J.B.A.G. Haanen
Dr. A. Huitema
Dr. J.M. Kerst
Dr. S.C. Linn
Dr. A. Lukas
Dr. H. Neering
Prof.dr. S. Rodenhuis
Dr. J.H.M. Schellens
Dr. J.H. Schornagel
Dr. M. Smits
Dr. B.G. Taal
Dr. M. van der Weide
Dr. N. van Zandwijk

Surgical Oncology

Prof.dr. B.B.R. Kroon
Dr. A.J.M. Balm
Dr. A. Bex
Dr. M.W.M. van den Brekel
Dr. D.R. Buitelaar
Prof.dr. M.P.M. Burger
Dr. J. ten Cate

Dr. F. van Coevorden
Dr. M.P. Copper
Dr. W. van Driel
Dr. G. Fons
Dr. S. Gonggrijp
Dr. J.J. Hage
Prof.dr. F.J.M. Hilgers
Prof.dr. S. Horenblas
Dr. H. Huitink
Dr. C. Keijzer
H. Klomp
Dr. F.H.M. Kroon
Dr. P.J.F.M. Lohuis
Dr. M.A.C. Lubsen
Dr. W. Meinhardt
Dr. O.E. Nieweg
Dr. H.S.A. Oldenburg
Dr. H.G. van der Poel
Dr. M. de Rie
J.M. Ronday
Dr. E.J.Th. Rutgers
Dr. P.F.E. Schutte
Dr. M. Scramek
Dr. M. Slot
Dr. L.E. Smeele
Dr. T. Stoppa
Dr. I.B. Tan
Dr. A.P. Timmers
Dr. V.J. Verwaal
Dr. M.J. Vrancken Peeters
L.A.E. Woerdeman
Dr. F.A.N. Zoetmulder

**Psychosocial Research and
Epidemiology**

Prof.dr. N.K. Aaronson
Prof.dr. F.S.A.M. van Dam
Prof.dr. W.J. van Harten

Prof.dr. F.E. van Leeuwen
Dr. M.A. Rookus

Pathology

Dr. T. Alderliesten
Dr. J.M. G. Bonfrer
Dr. H. van Boven
Dr. M.P.W. Gallee
Dr. K. Gilhuijs
Dr. C.A. Hoefnagel
Dr. F.B.L. Hogervorst
Dr. D. de Jong
Dr. J. Kluijt
Dr. W. Koops
Dr. R. Kröger
Dr. C. Loo
Dr. W.J. Mooi
S.H. Muller
Dr. P.M. Nederlof
Dr. W.J. Nooijen
F.A. Pameijer
Dr. R. van Pel
Dr. J.L. Peterse
Dr. W. Prevoo
Dr. M. Sinaasappel
Dr. F. Sivo
Dr. J. Teertstra
Dr. O. van Tellingen
Dr. R.A. Valdès Olmos
Dr. L. van 't Veer
Dr. M.L.F. van Velthuisen
Dr. S. Verhoef
Prof.Dr. M. van de Vijver
Dr. J. Wesseling

Radiology

A.P.E. Besnaard
W. Koops
Dr. R. Kröger

VU University Medical Center

Anaesthesiology

Prof.dr. W.W.A. Zuurmond

Clinical Genetics

Dr. S. Agarwal
Prof.dr. H. Joenje
Dr. F. Menko
Prof.dr. H. Meijers-Heijboer
Dr. G. Pals
Dr. Q. Waisfisz
Dr. J. de Winter

Clinical Chemistry

Dr. C.B.M. Oudejans
Prof.dr. M.A. Blankenstein

Gastro-enterology

Dr. M. Craanen
Prof.dr. C Mulder

Haematology

M.E.D. Chamuleau
Dr. A. Dräger
Prof.dr. P.C. Huijgens
Dr. J.J.W.M. Janssen
Prof. dr. G.J. Ossenkoppele
Dr. G.J. Schuurhuis
Dr. L. Smit
Dr. A.A. van de Loosdrecht
Dr. O. Visser
Dr. S. Zweegman
Dr. J.M. Zijlstra

Medical Psychology

Prof.dr.P.T. Cohen-Kettenis
Dr. J. Huisman
Dr. M. Klein
Prof.dr.H.M. Ploeg

Molecular Cell Biology

Prof.dr. R.H.J. Beelen
Prof.dr. G. Kraal
Prof.dr. Y. van Kooyk

Medical Oncology

Prof.dr. E. Boven
Dr. H.J. Broxterman
Dr. J. Buter
Dr. T.D. de Gruijl
Dr. R.J.A. Fijneman
Dr. W.R. Gerritsen
Dr. B.N. Hangalapura
Dr. K. Hoekman
Dr. R. Honeywell
Dr. M.L. Janmaat
Dr. C.R. Jimenez
Dr. F.A.E. Kruyt
Prof.dr. J. Lankelma
Dr. P. Noordhuis
Dr. D. Oosterhoff
Prof.dr. G.J. Peters
Dr. T.V. Pham
Dr. S. Piersma
Dr. J.A. Rodriguez

Dr. C.J. van Groenigen

Dr. V.W. van Beusechem
Dr. H.P. van den Berg
Dr. A.J.M. van den Eertwegh
Dr. J.J. van der Vliet
Prof.dr. H. Verheul
Dr. C. Vermeulen

Neurosurgery

Dr. J.C. Baaijen
Dr. C.M.F. Dirven
Dr. M.L.M. Lamfers
Dr. D.P. Noske
Prof.dr. W.P. Vandertop
Dr. T. Würdinger

Neurology

Prof.dr. J.J. Heimans
Dr. T. Postma
Dr. J.C. Reijneveld

Nuclear Medicine

Dr. R. Boellaard
Dr. E.F.I. Comans
Dr. A.A. Geldof
Dr. N.H. Hendrikse
Dr. J.D.M. Herscheid
Prof.dr. O.S. Hoekstra
Prof.dr. A.A. Lammertsma
Dr. M. Lubberink
Dr. C.F.M. Molthoff
Dr. H.J. Pijpers
Dr. P. Raijmakers
Prof.dr G.A.M.S. van Dongen
Dr. G.W.M. Visser
Dr. A.D. Windhorst
Dr. J.M. Zijlstra

Obstetrics and Gynaecology

Dr. J.C. Dorsman
Prof.dr. P. Kenemans
Dr. S. von Mensdorff-Pouilly
Prof.dr. R.H.M. Verheijen

Ophthalmology

Dr. S. Imhoff
Dr. A. Moll

Oral and maxillofacial surgery and pathology

Prof.dr. I. van der Waal

Otolaryngology / Head and Neck Surgery

Dr. P.A. Borggreven
Dr. B.J.M. Braakhuis
Prof.dr. R.H. Brakenhoff
Dr. R. de Bree
Dr. F. Dijk
Dr. J.M. Festen
Dr. D.J. Kuik
Prof.dr. Dr. Ch.R. Leemans
Prof.dr. H.F. Mahieu
Dr. R.N.P.M. Rinkel
Dr. I. Verdonck-de Leeuw
Prof.dr. G.A.M.S. van Dongen

Dr. D. Vugts

Pathology

Dr. J. Beliën
Prof. dr. E. Bloemena
Dr. H.J. Bontkes
Dr. C.L. Bos
Dr. B. Carvalho
Dr. J.B.A. Crusius
Dr. B. Diosdado
Dr. A.E. Greijer
Dr. D.A.M. Heideman
Dr. E. Hooijberg
Dr. F.J. van Kemenade
Dr. P. Krijnen
Prof.dr. C.J.L.M. Meijer
Prof.dr. G.A. Meijer
Prof.dr. J.M. Middeldorp
Prof.dr. W.J. Mooi
Dr. S.A. Morré
Dr. J.J. Oudejans
Prof.dr. A.S. Peña
Dr. G.L. Scheffer
Prof.dr. R.J. Scheper
Dr. P.J.F. Snijders
Dr. R. Steenbergen
Dr. M. van de Wiel
Prof.dr. P.J. van den Elsen
Dr. P. van den Ijssel
Dr. A.H. van Hattum
Dr. B.M.E. von Blomberg-van der Flier
Dr. B. Ylstra

Paediatrics

Dr. F. Abbink
Dr. C.J.M. Broers
Dr. J. Cloos

Dr. V. de Haas
Dr. E. Dulmen-den Broeder
Dr. I. Hubeek
Prof.dr. G.J. Kaspers
Dr. M.H. van der Berg
Dr. A.M. van Furth
Dr. M.A. Veening
Prof. Dr. A.J.P. Veerman

Pulmonology

Prof.dr. P.E. Postmus
Prof.dr. E.F. Smit
Dr. T.G. Sutedja

Radiology

Prof.dr. J.A. Castelijns

Radiation Oncology

Dr. F.J. Lagerwaard
Dr. M.V.M. Lafleur
Prof.dr. S. Senan
Prof.dr. B.J. Slotman
Dr. P. Sminia
Dr. B. van Triest

Surgical Oncology

Prof.dr. M.A. Cuesta
Prof.dr. S. Meijer
Prof.dr. P.A.M. van Leeuwen

Medical Oncology

Dr. P.J.M. Bakker
Dr. M.P. van den Tol

Urology

Dr. E.C. de Boer
Dr. A.A. Geldof
Dr. R.J.A. Moorselaar

University of Amsterdam

Medical Biochemistry
Prof.dr. J.M.F.G. Aerts

Cell Biology & Histology
Dr. J.A. Aten
Prof. dr. C.J.F. van Noorden
Dr. A. Sonnenberg

Experimental Internal Medicine
Dr. C.A. Spek

Gastro-enterology & Hepatology
Prof.dr. R.P.J. Oude Elferink
Dr. K.K. Krishnadath

Genetic Metabolic Diseases
Dr. A.B.P. van Kuilenburg

Human Genetics
Dr. H.A.M. Geerts
Dr. L.J. Valentijn
Prof.dr. R. Versteeg
Dr. M. Kool

Hematology
Dr. M.J. Kersten
Dr. H. Koene
Prof. dr. M.H.J. van Oers

Immunology
Dr. E.F. Eldering
Dr. R.M. Luiten

LaserCenter
Dr. M.C. Aalders
Prof. dr. A.G.J.M. van Leeuwen

Medical Biochemistry
Prof. dr. J.M.F.G. Aerts

Medical Oncology
Dr. P.J.M. Bakker
Prof.dr. D.J. Richel
Dr. A.M. Westermann
Dr. H. Wilmink

Neurogenetics
Dr. Th.J.M. Hulsebos

Pathology
Prof.dr. S.T. Pals
Dr. M. Spaargaren
Prof. dr. C.J.M. van Noesel

Pediatric Oncology
Dr. H. van den Berg
Prof.dr. H.N. Caron
Dr. A.B.P. van Kuilenburg
Dr. J. de Kraker
Dr. J.H. Merks
Dr. A.Y.N. Schouten-van Meeteren
Prof. dr. G.A.M. Tytgat
Dr. A.C. Verschuur
Dr. M.D. van de Wetering
Dr. J. Zsiros

Radiotherapy
Dr. C. van Bree
Dr. N.A.P. Franken
Prof.dr. C.C.E. Koning
Prof.dr. J.P. Medema

Surgery
Prof.dr. D.J. Gouma
Prof.dr. T.M. van Gulik

Urology
Prof.dr. J.J.M.C.H. de la Rosette
Dr.Ir. H. Wijkstra

international visitors

annex **2**

Annex 2.

International visitors

Aidinis V., Greece

Barbacid M., Spain
Bard S., Halifax, Canada
Baumann M., Germany
Bhatti P., USA
Bjerkvig R., Norway
Belka C., Germany
Bertino J.R., USA
Blow J., UK
Bogess J.F. USA

Califano J., USA
Carmeliet P., Belgium
Clarke P., UK

Davoust J., France
De Bono J.S., UK
DeWeese T.L., USA
Duval A., Germany

Eilers M., Germany
El-Bchiri J., France

Fuss I, USA

Gaudet M., USA
Ghadimi B.M., Germany
Georg D., Austria
Giaccia A., USA
Glickman M., Israel
Goletz S. Germany
Goud B., France
Grafi G., Israel

Harding T., USA
Heard E., France
Hoatlin M.E., USA
Hoogenboom H., Belgium
Holzner B., Austria
Hussain S.M., USA

Ideker T., USA

Kerr D.J., UK
Kioussi C., USA
Knoblich J., Austria
Kolesnick R., USA

Laird P., USA
Landberg G., Sweden
de Lange T., USA

Lories R., Belgium
Lund A., Denmark
Lygerou Z., Greece

Mangelsdorf D., USA
Mattaj I., Germany
Marais R., UK
Mills A., USA
Mills G., USA
Morris A., USA
Murphy T.J. USA

Nakauchi H., Japan
Neri D., Switzerland
Nusse R., USA

Oliveira C, Portugal
O'Reilly R, USA

Pagano M., USA
Paulson J., USA
Papa M.Z., Israel
Parbel A., Germany
Pusztai L., USA

Ross G., UK
Roussel M., USA

Schroeder T, Germany
Seruca R, Portugal
Seoane J., Spain
Shortman K., Australia
Silber S.J., USA
Singh B., USA
Sorger P., USA
Stevens S., USA
Stingl J., UK
Strick T., France

Taghian A., USA

Verma I., USA
Vermorken J.B., Belgium

Walther T., Germany
Weiss R., UK
West C., UK
Wirapati P., Switzerland
Würdinger T, USA

Zapatka M., Germany

PhD theses completed

annex **3**

Annex 3.

Theses completed

In 2007, 37 graduate students completed their graduate training and obtained a PhD degree. Their names, thesis titles, supervisors and institutes are listed below. The institute at which the research described in the theses was carried out is mentioned between brackets and may differ from the university where the PhD graduation took place.

Name	:	Baars A. (VUmc)
Title	:	Active specific immunotherapy for solid tumours
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Pinedo H.M. and Scheper R.J.
Date	:	12 October 2007
Name	:	Bergs J.W.J. (AMC)
Title	:	Hyperthermia, cisplatin and radiation trimodality treatment: In vitro studies on interaction mechanisms
University	:	Universiteit van Amsterdam
(co)Promotors	:	Koning C.C.E. and Franken N.A.P.
Date	:	22 November 2007
Name	:	Bins A. (NKI)
Title	:	Induction and analysis of antigen-specific T cell responses in melanoma patients and animal models
University	:	Universiteit Leiden
(co)Promotors	:	Schumacher T.N.M.
Date	:	15 March 2007
Name	:	Bröker-van Rens L.E. (VUmc)
Title	:	Novel microtubule-stabilizing agents: preclinical and clinical studies
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Giaccone G.
Date	:	9 May 2007
Name	:	Checinska A. (VUmc)
Title	:	Regulation of mitochondria-dependent apoptosis in non-small cell lung cancer: implications for cancer therapy
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Giaccone G., Kruyt, F.A.E. and J.A. Rodriguez
Date	:	9 March 2007
Name	:	van Dalen E.C. (AMC)
Title	:	Anthracycline-induced cardiotoxicity during and after treatment for childhood cancer. Long-term risk, risk factors and prevention
University	:	Universiteit van Amsterdam
(co)Promotors	:	Caron H.N. and Kremer L.C.M.
Date	:	
Name	:	Deurholt T. (AMC)
Title	:	Development of an immortalised human hepatocyte cell line for the AMC bio-artificial liver
University	:	Universiteit van Amsterdam
(co)Promotors	:	Oude Elferink R.P.J. , Chamuleau R.A.F. and Hoekstra R.
Date	:	6 December 2007

Name : **Genest P.-A. (NKI)**
 Title : Analysis of the modified DNA base J and the J-binding proteins in Leishmania
 University : Universiteit van Amsterdam
 (co)Promotors : Borst P.
 Date : 3 July 2007

Name : **Gloerich J. (AMC)**
 Title : Metabolic consequences of branched-chain fatty acid accumulation in health and disease
 University : Universiteit van Amsterdam
 (co)Promotors : Wanders R.J.A. and Wirtz K.W.A.
 Date : 6 December 2007

Name : **Goemans B.F. (VUmc)**
 Title : Targeted therapy in pediatric AML
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Kaspers G.J.L. and Roord J.
 Date : 6 July 2007

Name : **He Y (AMC)**
 Title : Effects of tissue-specific inactivation of glutamine synthetase in the mouse
 University : Universiteit van Amsterdam
 (co)Promotors : Lamers W.H. and Hakvoort T.B.M.
 Date : 4 December 2007

Name : **van Herwaarden (AMC)**
 Title : Physiological and pharmacological roles of Cytochrome P450 3A and Breast Cancer Resistance Protein
 University : Universiteit van Amsterdam
 (co)Promotors : Borst P. and Schinkel A.H.
 Date : 12 June 2007

Name : **Jellema A.P. (VUmc)**
 Title : Radiation-induced xerostomia in head and neck cancer patients
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Slotman B.J. and Langendijk J.A.
 Date : 19 September 2007

Name : **Joerger M. (NKI)**
 Title : Pharmacokinetic and pharmacogenetic profiling in solid cancer patients
 University : Universiteit Utrecht
 (co)Promotors : Schellens J.H.M., and Beijnen J.H.
 Date : 18 December 2007

Name : **Joshi U. (VUmc)**
 Title : Assessment of PET imaging devices: the case of a LSO/NaI PET-SPECT prototype
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Hoekstra O.S. and van Lingen A.
 Date : 25 June 2007

Name : **Knipscheer P. (NKI)**
 Title : Regulation of SUMO modification
 University : Erasmus Universiteit Rotterdam
 (co)Promotors : Sixma T.K.
 Date : 22 March 2007

Name : **Kodach L. (AMC)**
 Title : The role of bone morphogenetic protein pathway in colorectal cancer
 University : Universiteit van Amsterdam
 (co)Promotors : Peppelenbosch M.P. and Hardwick J.H.C.
 Date : 14 December 2007

Name : **Kok H.P. (AMC)**
 Title : Treatment planning for locoregional and intraluminal hyperthermia
 University : Universiteit van Amsterdam
 (co)Promotors : Koning C. E. and Crezee J.

Date : 24 April 2007
 Name : **Komen J (AMC)**
 Title : New insights in phytanic acid metabolism and toxicity
 University : Universiteit van Amsterdam
 (co)Promotors : Wanders R.J.A. and Ferdinandusse S.
 Date : 12 December 2007

Name : **Lont A.P. (VUmc)**
 Title : Refinements in the etiology and management of penile squamous cell carcinoma
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Horenblas S.
 Date : 26 October 2007

Name : **Loupatty F. (AMC)**
 Title : Branched chain amino acids: facts and defects
 University : Universiteit van Amsterdam
 (co)Promotors : Wanders R.J.A. and Duran M.
 Date : 29 May 2007

Name : **Los A. (NKI)**
 Title : Diacylglycerol kinase theta and zeta isoforms: Regulation of activity, protein binding
 University : Universiteit Leiden
 (co)Promotors : Moolenaar W.H.
 Date : 25 January 2007

Name : **Ludwig S. (VUmc)**
 Title : C-type lectins L-SIGN and DC-SIGN
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Van Kooyk Y.
 Date : 20 September 2007

Name : **McDermott L. (NKI)**
 Title : On radiotherapy dose verification with a flat-panel imager
 University : Universiteit van Amsterdam
 (co)Promotors : van Herk M.B.
 Date : 27 March 2007

Name : **van Meeteren L. (NKI)**
 Title : Production of LPA by autotoxin and toxic phospholipases D
 University : Universiteit Leiden
 (co)Promotors : Moolenaar W.H.
 Date : 31 January 2007

Name : **Milano F. (AMC)**
 Title : Developing novel strategies for treating esophageal cancer: dendritic cells immunotherapy, T cell responses and an exploration of the tumor microenvironment
 University : Universiteit van Amsterdam
 (co)Promotors : Peppelenbosch M. P and Boeckxstaens G. E. E.
 Date : 9 October 2007

Name : **Paeßens L.C. (VUmc)**
 Title : Hematopoietic antigen presenting cells in the human thymic cortex: Evidence for a role in selection and removal of apoptotic thymocytes.
 University : Vrije Universiteit Amsterdam
 (co)Promotors : van Kooyk Y.
 Date : 2 October 2007

Name : **Piekarska K. (AMC)**
 Title : The role of peroxisomal metabolism in virulence of *Candida albicans*
 University : Universiteit van Amsterdam
 (co)Promotors : Aerts J.M.F.G. and Distel B.
 Date : 13 December 2007

Name : **Repanas K. (NKI)**
 Title : Structural and functional studies on the LINE-1 retrotransposon endonuclease
 University : Erasmus Universiteit Rotterdam
 (co)Promotors : Sixma T.K.
 Date : 20 September 2007

Name : **Stanulovic V. (AMC)**
 Title : Regulation of glutamine synthetase gene expression in the liver
 University : Universiteit van Amsterdam
 (co)Promotors : Lamers W.H. and Hakvoort T.
 Date : 20 December 2007

Name : **Temmink O. (VUmc)**
 Title : Role of thymidine phosphorylase/platelet derived endothelial cell growth factor inhibition in the cytotoxicity of fluoropyrimidines
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Peters G.J. and Fukushima M
 Date : 3 October 2007

Name : **Theodorou V. (NKI)**
 Title : MMTV insertional mutagenesis in mouse mammary tumors: hunting novel cancer genes with an old tool
 University : Universiteit van Amsterdam
 (co)Promotors : Berns A.J.M.
 Date : 5 April 2007

Name : **van Til N. (AMC)**
 Title : Lentiviral gene therapy for the treatment of inherited liver disease
 University : Universiteit van Amsterdam
 (co)Promotors : Oude Elferink R.P.J. and Seppen J.
 Date : 28 June 2007

Name : **Uitterhoeve A.L.J. (AMC)**
 Title : Radiotherapy and Cisplatin: outcome of combined modality treatment in non-small cell lung cancer
 University : Universiteit van Amsterdam
 (co)Promotors : Koning Caro C. E.
 Date : 4 April 2007

Name : **Vink S. (NKI)**
 Title : Alkylphospholipids combined with radiotherapy; translational studies
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Verheij M.
 Date : 2 November 2007

Name : **Williams C. (AMC)**
 Title : Pex5p and ubiquitin: Regulation of the PTS1 protein import receptor
 University : Universiteit van Amsterdam
 (co)Promotors : Aerts J.F.M.G. and Diste B.
 Date : 9 November 2007

Name : **de Wit E. (NKI)**
 Title : Computational analyses of genome-wide chromatin profiles in *Drosophila melanogaster*
 University : Universiteit van Amsterdam
 (co)Promotors : van Lohuizen M.
 Date : 1 November 2007
 : 4 April 2007

scientific publications

annex 4

Annex 4.

Scientific publications

1. Abdallah AM, Gey van Pittius NC, Champion PA, Cox J, Luirink J, Vandenbroucke-Grauls CMJE, Appelmelk BJ, Bitter W. Type VII secretion--mycobacteria show the way. *Nat Rev Microbiol* 2007; 5(11): 883-891. (VUmc)
2. Adema AD, Radi M, Daft J, Narayanasamy J, Hoebe EK, Alexander LE, Chu CK, Peters GJ. Troxacitabine prodrugs for pancreatic cancer. *Nucleosides Nucleotides Nucleic Acids* 2007; 26(8-9): 1073-1077. (VUmc)
3. Agami R. All roads lead to IKKepsilon. *Cell* 2007; 129: 1043-5. (NKI)
4. Alberici P, De Pater E, Cardoso J, Bevelander M, Molenaar L, Jonkers J, Fodde R. Aneuploidy Arises at Early Stages of Apc-Driven Intestinal Tumorigenesis and Pinpoints Conserved Chromosomal Loci of Allelic Imbalance between Mouse and Human. *Am J Pathol* 2007; 170: 377-87. (NKI)
5. Alderliesten T, Schlieff A, Peterse J, Teertstra H, Muller S, Gilhuijs K. Validation of Semiautomatic Measurement of the Extent of Breast Tumors Using Contrast-Enhanced Magnetic Resonance Imaging. *Invest Radiol* 2007; 42: 42-9. (NKI)
6. Aleman B, Raemaekers J, Tomisic R, Baaijens M, Bortolus R, Lybeert M, van der Maazen R, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys* 2007; 67: 19-30. (NKI)
7. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van 't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE. Late cardiotoxicity after treatment for Hodgkin's lymphoma. *Blood* 2007; 109: 1878-86. (NKI)
8. Aleman BMP, van Leeuwen FE. Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment? *Hematol Oncol Clin North Am* 2007; 21: 961-75. (NKI)
9. Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, Axell T, Bruce AJ, Carpenter W, Eisenberg E, Epstein JB, Holmstrup P, Jontell M, Lozada-Nur F, Nair R, Silverman B, Thongprasom K, Thornhill M, Warnakulasuriya S, van der Waal I. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007; 103 Suppl: S25-12. (VUmc)
10. Al-Toma A, Verbeek WHM, Hadithi M, von Blomberg BME, Mulder CJ. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. *Gut* 2007; 56(10): 1373-1378. (VUmc)
11. Al-Toma A, Verbeek WHM, Mulder CJ. The management of complicated celiac disease. *Dig Dis* 2007; 25(3): 230-236. (VUmc)
12. Al-Toma A, Verbeek WHM, Mulder CJ. Update on the management of refractory coeliac disease. *J Gastrointest Liver Dis* 2007; 16(1): 57-63. (VUmc)
13. Al-Toma A, Verbeek WHM, Visser OJ, Kuijpers KC, Oudejans JJ, Kluin-Nelemans HC, Mulder CJ, Huijgens PC. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. *Dig Liver Dis* 2007; 39(7): 634-641. (VUmc)
14. Al-Toma A, Visser OJ, van Roesel HM, von Blomberg BME, Verbeek WHM, Scholten PE, Ossenkuppele GJ, Huijgens PC, Mulder CJ. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. *Blood* 2007; 109(5): 2243-2249. (VUmc)
15. Alves Nuno L, van Lier RAW, Eldering E. Withdrawal symptoms on display: Bcl-2 members under investigation. *Trends in Immunology* 2007; 28(1): 26-32. (AMC)
16. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. *Ann Surg Oncol* 2007; 35: 1873-9. (NKI)
17. Antonini N, Jones H, Horiot J, Poortmans P, Struikmans H, den Bogaert W, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. *Radiother Oncol* 2007; 82: 265-71. (NKI)
18. Arentsen HC, de La Rosette JJMCH, de Reijke TM, Langbein S. Fluorescence in situ hybridization: a multitarget approach in diagnosis and management of urothelial cancer. *Expert*

- Review of Molecular Diagnostics 2007; 7(1): 11-19. (AMC)
5. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, Gherardi RK, Chazaud B. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. *J Exp Med* 2007; 204(5): 1057-1069. (VUmc)
 6. Assaf C, Gellrich S, Whittaker S, Robson A, Cerroni L, Massone C, Kerl H, Rose C, Chott A, Chimenti S, Hallermann C, Petrella T, Wechsler J, Bagot M, Hummel M, Bullani-Kerl K, Bekkenk MW, Kempf W, Meijer CJLM, Willemze R, Sterry W. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. *J Clin Pathol* 2007; 60(9): 981-989. (VUmc)
 7. Baard J, de Reijke TM, de La Rosette JJMCH. The use of the Acucise technique for ureteropelvic junction obstruction: a trade-off between efficacy and invasiveness? *Current Urology Reports* 2007; 8(2): 134-139. (AMC)
 8. Baas P. Optimising survival in malignant mesothelioma. *Lung Cancer* 2007; 57 Suppl 2: S24-S29. (NKI)
 9. Baas P. Treatment options in stage IIIB non-small cell lung cancer: Making the proper choice. *Ann Surg Oncol* 2007; 5: 287-92. (NKI)
 10. Baer K, Roosevelt M, Clarkson AB, Jr, van Rooijen N, Schnieder T, Frevert U. Kupffer cells are obligatory for Plasmodium yoelii sporozoite infection of the liver. *Cell Microbiol* 2007; 9(2): 397-412. (VUmc)
 11. Bais AG, van Kemenade FJ, Berkhof J, Verheijen RHM, Snijders PJF, Voorhorst F, Babovic M, van Ballegooijen M, Helmerhorst TJ, Meijer CJLM. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. *Int J Cancer* 2007; 120(7): 1505-1510. (VUmc)
 12. Bansback N, Maetzel A, Drummond M, Anis A, Marra C, Conway P, Boers M, Tugwell P, Boonen A. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. *J Rheumatol* 2007; 34(5): 1178-1183. (VUmc)
 13. Barendrecht MM, Mulders AC, van der Poel H, van den Hoff MJ, Schmidt M, Michel MC. Role of transforming growth factor beta in rat bladder smooth muscle cell proliferation. *J Pharmacol Exp Ther* 2007; 322: 117-22. (NKI)
 14. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegerbarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007; 449: 1003-7. (NKI)
 15. Barlesi F, Giaccone G, Gallegoz Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FAE, Rodriguez JA. Global histone modifications predict prognosis of resected non small-cell lung cancer. *J Clin Oncol* 2007; 25(28): 4358-4364. (VUmc)
 16. Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB, Pruimboom-Brees IM, Cherrington NJ, Manautou JE. Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. *Drug Metab Dispos* 2007; 35(10): 1963-1969. (VUmc)
 17. Bart J, Nagengast WB, Coppes RP, Wegman TD, van der Graaf WT, Groen HJ, Vaalburg W, de Vries EG, Hendrikse NH. Irradiation of rat brain reduces P-glycoprotein expression and function. *Br J Cancer* 2007; 97(3): 322-326. (VUmc)
 18. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden LA, Dijkmans BAC, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. *Ann Rheum Dis* 2007; 66(7): 921-926. (VUmc)
 19. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Warlam-Rodenhuis CC, Pierart M, Collette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. *J Clin Oncol* 2007; 25: 3259-65. (NKI)
 20. Bartelink H. Radiotherapy for breast cancer. *EJC Suppl* 2007; 5: 434-5. (NKI)
 21. Bartelink H. Systemic adjuvant therapies and radiotherapy to the conserved breast: Strategies revisited. *Breast* 2007; 16: 84-8. (NKI)
 22. Bast A, Haenen GR, Bruynzeel AM, van der Vijgh WJ. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. *Cardiovasc Toxicol* 2007; 7(2): 154-159. (VUmc)
 23. Bast A, Kaiserova H, den Hartog GJ, Haenen GR, van der Vijgh WJ. Protectors against doxorubicin-induced cardiotoxicity: flavonoids. *Cell Biol Toxicol* 2007; 23(1): 39-47. (VUmc)
 24. Bauer D, Wasmuth S, Hermans P, Hennig M, Meller K, Meller D, van Rooijen N, Tseng SC, Steuhl KP, Heiligenhaus A. On the influence of neutrophils in corneas with necrotizing HSV-1 keratitis following amniotic membrane transplantation. *Exp Eye Res* 2007; 85(3): 335-345. (VUmc)
 25. Bax M, Garcia Vallejo JJ, Jang-Lee J, North SJ, Gilmartin TJ, Hernandez G, Crocker PR, Leffler H, Head SR, Haslam SM, Dell A, van Kooyk Y. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. *J Immunol* 2007; 179(12): 8216-8224. (VUmc)

26. Becking AG, Tuinzing DB, Hage JJ, Gooren LJ. Transgender feminization of the facial skeleton. *Clin Plast Surg* 2007; 34: 557-64. (NKI)
27. Beijnen JH, Schellens JHM. Recent developments in pharmacotherapy of cancer. *Ann Surg Oncol* 2007; 142: 2-7. (NKI)
28. Belderbos J, Baas P, Senan S. Reply: Patterns of nodal recurrence after omission of elective nodal irradiation for limited-stage small-cell lung cancer. *Br J Cancer* 2007; 97: 276. (NKI)
29. Belderbos J, Uitterhoeve L, Van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Giaccone G, Koning C, on behalf of the EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). *Eur J Cancer* 2007; 43: 114-21. (AMC/NKI)
30. Beliveau A, Bassett E, Lo AT, Garbe J, Rubio MA, Bissell MJ, Campisi J, Yaswen P. p53-Dependent integration of telomere and growth factor deprivation signals. *Proc Natl Acad Sci U S A* 2007; 104: 4431-6. (NKI)
31. Bell O, Wirbelauer C, Hild M, Scharf AN, Schwaiger M, MacAlpine DM, Zilbermann F, van Leeuwen F, Bell SP, Imhof A, Garza D, Peters AHFM, Schubeler D. Localized H3K36 methylation states define histone H4K16 acetylation during transcriptional elongation in *Drosophila*. *EMBO J* 2007; 26: 4974-84. (NKI)
32. Bende RJ, Smit LA, van Noesel CJM. Molecular pathways in follicular lymphoma. *Leukemia* 2007; 21(1): 18-29. (AMC)
33. Bende RJ, van Maldegem F, Triesscheijn M, Wormhoudt TAM, Guijt R, van Noesel CJM. Germinal centers in human lymph nodes contain reactivated memory B cells. *Journal of Experimental Medicine* 2007; 204(11): 2655-2665. (AMC)
34. Bergs JWJ, Franken NAP, Haveman J, Geijsen ED, Crezee J, van Bree C. Hyperthermia, cisplatin and radiation trimodality treatment: a promising cancer treatment? A review from preclinical studies to clinical application. *International Journal of Hyperthermia* 2007; 23(4): 329-341. (AMC)
35. Bergs JWJ, Haveman J, ten Cate R, Medema JP, Franken NAP, van Bree C. Effect of 41 degrees C and 43 degrees C on cisplatin radiosensitization in two human carcinoma cell lines with different sensitivities for cisplatin. *Oncology Reports* 2007; 18(1): 219-226. (AMC)
36. Berkers CR, Van Leeuwen FWB, Groothuis TAM, Peperzak V, Van Tilburg EW, Borst J, Neefjes JJ, Ovaas H. Profiling proteasome activity in tissue with fluorescent probes. *Mol Pharm* 2007; 4: 739-48. (NKI)
37. Bernards R. Chairperson's Introduction. *EJC Suppl* 2007; 5(5): 107. (NKI)
38. Bernards R. Finding biomarkers of resistance to targeted cancer therapies. *EJC Suppl* 2007; 5(5): 109-14. (NKI)
39. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. *Cancer Cell* 2007; 12: 395-402. (NKI)
40. Bessems M, Doorschodt BM, Kolkert JLP, Vetelainen RL, van Vliet AK, Vreeling H, van Marle J, van Gulik TM. Preservation of steatotic livers: a comparison between cold storage and machine perfusion preservation. *Liver Transplantation* 2007; 13(4): 497-504. (AMC)
41. Beumer JH, Buckle T, Ouwehand M, Franke NEF, Lopez-Lazaro L, Schellens JHM, Beijnen JH, van Tellingen O. Trabectedin (ET-743, YondelisTM) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. *Invest New Drugs* 2007; 25: 1-7. (NKI)
42. Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, Schellens JHM. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. *Invest New Drugs* 2007; 25: 327-34. (NKI)
43. Beumer JH, Rademaker-Lakhai JM, Rosing H, Hillebrand MJX, Bosch TM, Lopez-Lazaro L, Schellens JHM, Beijnen JH. Metabolism of trabectedin (ET-743, YondelisTM) in patients with advanced cancer. *Cancer Chemother Pharmacol* 2007; 29: 825-37. (NKI)
44. Bex A. Editorial Comment on: Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase the Performance of Established Predictors of Renal Cell Carcinoma-Specific Mortality. *Eur Urol* 2007; 52: 1436-7. (NKI)
45. Bhatti P, Preston DL, Doody MM, Hauptmann M, Kampa D, Alexander BH, Petibone D, Simon SL, Weinstock RM, Bouville A, Yong LC, Freedman DM, Mabuchi K, Linet MS, Edwards AA, Tucker JD, Sigurdson AJ. Retrospective biodosimetry among United States radiologic technologists. *Radiat Res* 2007; 167: 727-34. (NKI)
46. Bijlsma MF, Borensztajn KS, Roelink H, Peppelenbosch MP, Spek CA. Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. *Cellular Signalling* 2007; 19(12): 2596-2604. (AMC)
47. Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ. Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. *Oncol Rep* 2007; 18(1): 287-291. (VUmc)
48. Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Schott S, Laan AC, Peters GJ. In

- vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glyceryl-fluorodeoxyuridine. *Nucleosides Nucleotides Nucleic Acids* 2007; 26(10-12): 1619-1624. (VUmc)
49. Bijnsdorp IV, van den Berg J, Kuipers GK, Wedekind LE, Slotman BJ, van Rijn J, Lafleur MVM, Sminia P. Radiosensitizing potential of the selective cyclooxygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. *J Neurooncol* 2007; 85(1): 25-31. (VUmc)
50. Bilgin YM, van de Watering LMG, Eijnsman L, Versteegh MIM, van Oers MHJ, Brand A.. Is increased mortality associated with post-operative infections after leukocytes containing red blood cell transfusions in cardiac surgery? An extended analysis. *Transfusion Medicine* 2007; 17(4): 304-311. (AMC)
51. Bins A, Mallo H, Sein J, van den Bogaard C, Nooijen W, Vyth-Dreese F, Nuijen B, de Gast GC, Haanen JBAG. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. *J Immunother* 2007; 30: 234-9. (NKI)
52. Bins AD, van Rheenen J, Jalink K, Halstead JR, Divecha N, Spencer DM, Haanen JBAG, Schumacher TNM. Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. *BMC Biotechnol* 2007; 7: 2-891. (NKI)
53. Bins AD, Wolkers MC, van den Boom MD, Haanen JBAG, Schumacher TNM. In vivo antigen stability affects DNA vaccine immunogenicity. *J Immunol* 2007; 179: 2126-33. (NKI)
54. Bipat S, van Leeuwen MS, Ijzermans JN, Comans EFI, Planting AS, Bossuyt PM, Greve JW, Stoker J. Evidence-base guideline on management of colorectal liver metastases in the Netherlands. *Neth J Med* 2007; 65(1): 5-14. (VUmc)
55. Bitter W, van Boxtel R, Groeneweg M, Carballo PS, Zahringer U, Tommassen J, Koster M. Species-specific functioning of the *Pseudomonas XcpQ* secretin: role for the C-terminal homology domain and lipopolysaccharide. *J Bacteriol* 2007; 189(8): 2967-2975. (VUmc)
56. Blank LECM, Koedooder K, van Os R, van de Kar M, van der Veen JH, Koning CCE. Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. *International Journal of Radiation Oncology Biology Physics* 2007; 69(2): 454-458. (AMC)
57. Bleiker EMA, Menko FH, Kluijdt I, Taal BG, Gerritsma MA, Wever LDV, Aaronson NK. Colorectal cancer in the family: Psychosocial distress and social issues in the years following genetic counselling. *Hereditary Cancer Clin Pract* 2007; 5: 59-66. (NKI)
58. Bloemen-van Gurp EJ, Mijneer BJ, Verschueren TA, Lambin P. Total body irradiation, toward optimal individual delivery: dose evaluation with metal oxide field effect transistors, thermoluminescence detectors, and a treatment planning system. *Int J Radiat Oncol Biol Phys* 2007; 69: 1297-304. (NKI)
59. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJM, van den Ende K, Kimpen JL, Strengers JL, Bont LJ. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study. *Pediatrics* 2007; 120(4): e1076-e1081. (VUmc)
60. Blom AB, van Lent PL, Libregts S, Holthuysen AE, van der Kraan PM, van Rooijen N, van den Berg WB. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. *Arthritis Rheum* 2007; 56(1): 147-157. (VUmc)
61. Boelens M, van den Berg A, Vogelzang I, Wesseling J, Postma D, Timens W, Groen H. Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. *J Clin Pathol* 2007; 60: 608-14. (NKI)
62. Boers M, Jacobs JW, van Vliet V, van Riel PL. Consensus Dutch health assessment questionnaire. *Ann Rheum Dis* 2007; 66(1): 132-133. (VUmc)
63. Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. *Ann Rheum Dis* 2007; 66(3): 417-418. (VUmc)
64. Boers M. Missing data in trials: Do we have to keep carrying the last observation forward?. *Arthritis Rheum* 2007; 59(1): 2-3. (VUmc)
65. Boers M. Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. *J Rheumatol* 2007; 34(4): 661-663. (VUmc)
66. Boersema PJ, Divecha N, Heck AJ, Mohammed S. Evaluation and optimization of ZIC-HILIC-RP as an alternative MudPIT strategy. *J Proteome Res* 2007; 6: 937-46. (NKI)
67. Bolling MC, Mekkes JR, Goldschmidt WFM, van Noesel CJM, Jonkman MF, Pas HH. Acquired palmoplantar keratoderma and immunobullous disease associated with antibodies to desmocollin 3. *British Journal of Dermatology* 2007; 157(1): 168-173. (AMC)
68. Bolster MJ, Peer PG, Bult P, Thunnissen FB, Schapers RF, Meijer JW, Strobbe LJ, van Berlo CL, Klinkenbijn JH, Beex LV, Wobbles T, Tjan-Heijnen VC. Risk factors for non-sentinel lymph node metastases in patients with breast cancer The outcome of a multi-institutional study. *Ann Surg Oncol* 2007; 14(1): 181-189. (VUmc)
69. Bontkes HJ, Kramer D, Ruizendaal JJ, Kueter EW, van Tendeloo V, Meijer CJLM, Hooijberg E. Dendritic cells transfected with

- interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. *Gene Ther* 2007; 14(4): 366-375. (VUmc)
70. Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: Can we withhold cranial irradiation? *Cancer* 2007; 109: 306-12. (NKI)
71. Boogerd W. Leptomeningeal metastasis in solid tumours: Is there a role for intrathecal therapy? *EJC Suppl* 2007; 5(5): 41-51. (NKI)
72. Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, Berkhof J, Meijer CJLM, Kimman TG. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. *Vaccine* 2007; 25(33): 6245-6256. (VUmc)
73. Borders AS, Getchell ML, Etscheidt JT, van Rooijen N, Cohen DA, Getchell TV. Macrophage depletion in the murine olfactory epithelium leads to increased neuronal death and decreased neurogenesis. *J Comp Neurol* 2007; 501(2): 206-218. (VUmc)
74. Borders AS, Hersh MA, Getchell ML, van Rooijen N, Cohen DA, Stromberg AJ, Getchell TV. Macrophage-mediated neuroprotection and neurogenesis in the olfactory epithelium. *Physiol Genomics* 2007; 31(3): 531-543. (VUmc)
75. Borensztajn KS, Bijlsma MF, Groot AP, Bruggemann LW, Versteeg HH, Reitsma PH, Peppelenbosch MP, Spek CA. Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. *Experimental Cell Research* 2007; 313(12): 2622-2633. (AMC)
76. Borger JH, Hoening MJ, Boersma LJ, Snijders-Keilholz A, Aleman BMP, Lintzen E, van Brussel S, van der Toorn PP, Alwhouhayb M, van Leeuwen FE. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. *Int J Radiat Oncol Biol Phys* 2007; 69: 1131-8. (NKI)
77. Borggreven PA, Aaronson NK, Verdonck-de Leeuw IM, Muller MJ, Heiligers ML, Bree R, Langendijk JA, Leemans CR. Quality of life after surgical treatment for oral and oropharyngeal cancer: A prospective longitudinal assessment of patients reconstructed by a microvascular flap. *Oral Oncol* 2007; 43: 1034-42. (NKI/VUmc)
78. Borggreven PA, Verdonck-de Leeuw IM, Muller MJ, Heiligers ML, de Bree R, Aaronson NK, Leemans CR. Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. *Eur Arch Otorhinolaryngol* 2007; 264: 651-7. (NKI/VUmc)
79. Borggreven PA, Verdonck-de Leeuw IM, Rinkel RN, Langendijk JA, Roos JC, David EF, de Bree R, Leemans CR. Swallowing after major surgery of the oral cavity or oropharynx: a prospective and longitudinal assessment of patients treated by microvascular soft tissue reconstruction. *Head Neck* 2007; 29(7): 638-647. (VUmc)
80. Borst GR, Sonke JJ, Betgen A, Remeijer P, van Herk M, Lebesque JV. Kilo-voltage cone-beam computed tomography setup measurements for lung cancer patients; first clinical results and comparison with electronic portal-imaging device. *Int J Radiat Oncol Biol Phys* 2007; 68: 555-61. (NKI)
81. Borst J, Ricciardi-Castagnoli P. Shaping immunity in healthy and diseased tissues. *Eur J Immunol* 2007; 37: 2055-8. (NKI)
82. Borst P, de Wolf C, Van De Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. *Pflugers Arch* 2007; 453: 661-73. (NKI)
83. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? *Cell Cycle* 2007; 6: 2782-7. (NKI)
84. Borst P. Bill Slater at 90. *IUBMB Life* 2007; 59: 48-9. (NKI)
85. Bosch AM, Tybout W, van Spronsen FJ, de Valk HW, Wijburg FA, Grootenhuis MA. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria. *Journal of Inherited Metabolic Disease* 2007; 30(1): 29-34. (AMC)
86. Bosch TM, Bakker R, Schellens JHM, Cats A, Smits PH, Beijnen JH. Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. *Mol Diagn Ther* 2007; 11: 105-8. (NKI)
87. Bosma I, Vos MJ, Heimans JJ, Taphoorn MJB, Aaronson NK, Postma TJ, Van Der Ploeg HM, Muller M, Vandertop WP, Slotman BJ, Klein M. The course of neurocognitive functioning in high-grade glioma patients. *Neuro-Oncology* 2007; 9: 53-62. (NKI/VUmc)
88. Bots M, de Bruin E, Rademaker-Koot MTGA, Medema JP. Proteinase inhibitor-9 expression is induced by maturation in dendritic cells via p38 MAP kinase. *Human Immunology* 2007; 68(12): 959-964. (AMC)
89. Bottomley A, Aaronson NK. International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. *J Clin Oncol* 2007; 25: 5082-6. (NKI)
90. Boutaga K, Savelkoul PHM, Winkel EG, van Winkelhoff AJ. Comparison of subgingival bacterial sampling with oral lavage for detection and quantification of periodontal pathogens by real-time polymerase chain reaction. *J Periodontol* 2007; 78(1): 79-86. (VUmc)
91. Bradley PJ, MacLennan K, Brakenhoff RH, Leemans CR. Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications. *Curr Opin Otolaryngol Head Neck Surg* 2007; 15(2): 74-81. (VUmc)
92. Brandon EFA, Sparidans RW, van Ooijen RD, Meijerman I, Lopez-Lazaro L, Manzanares I,

- Beijnen JH, Schellens JHM. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. *Invest New Drugs* 2007; 25: 9-19. (NKI)
93. Breda A, Stepanian SV, Lam JS, Liao JC, Gill IS, Colombo JR, Guazzoni G, Stifelman MD, Perry KT, Celia A, Breda G, Fornara P, Jackman SV, Rosales A, Palou J, Grasso M, Pansadoro V, Disanto V, Porpiglia F, Milani C, Abbou CC, Gaston R, Janetschek G, Soomro NA, de la Rosette JJ, Laguna PM, Schulam PG. Use of haemostatic agents and glues during laparoscopic partial nephrectomy: a multi-institutional survey from the United States and Europe of 1347 cases. *European Urology* 2007; 52(3): 798-803. (AMC)
94. Breda A, Stepanian SV, Liao J, Lam JS, Guazzoni G, Stifelman M, Perry K, Celia A, Breda G, Fornara P, Jackman S, Rosales A, Palou J, Grasso M, Pansadoro V, Disanto V, Porpiglia F, Milani C, Abbou C, Gaston R, Janetschek G, Soomro NA, de la Rosette J, Laguna MP, Schulam PG. Positive margins in laparoscopic partial nephrectomy in 855 cases: a multi-institutional survey from the United States and Europe. *Journal of Urology* 2007; 178(1): 47-50. (AMC)
95. Bredart A, Coens C, Aaronson N, Chie WC, Efficace F, Conroy T, Blazeby JM, Hammerlid E, Costantini M, Joly F, Schraub S, Sezer O, Arraras JI, Rodary C, Costantini A, Mehlitz M, Razavi D, Bottomley A. Determinants of patient satisfaction in oncology settings from European and Asian countries: Preliminary results based on the EORTC IN-PATSAT32 questionnaire. *Eur J Cancer* 2007; 43: 323-30. (NKI)
96. Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven M, de Wolf C, Kuil A, Beijnen J, Scheffer G, Jansen G, Borst P, Schellens J. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. *Mol Pharmacol* 2007; 71: 240-9. (NKI/VUmc)
97. Bremers AJA, Ruers TJM. Prudent application of radiofrequency ablation in resectable colorectal liver metastasis. *Eur J Surg Oncol* 2007; 33: 752-6. (NKI)
98. Brennan M, Migliorati CA, Lockhart PB, Wray D, Al-Hashimi I, Axell T, Bruce AJ, Carpenter W, Eisenberg E, Epstein JB, Holmstrup P, Jontell M, Nair R, Sasser H, Schifter M, Silverman B, Thongprasom K, Thornhill M, Warnakulasuriya S, van der Waal I. Management of oral epithelial dysplasia: a review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007; 103 Suppl: s19-12. (VUmc)
99. Bresser P, Cornelissen MI, van der Bij W, van Noesel CJM, Timens W. Idiopathic pulmonary arterial hypertension in Dutch Caucasian patients is not associated with human herpes virus-8 infection. *Respiratory Medicine* 2007; 101(4): 854-856. (AMC)
100. Breuilh L, Vanhoutte F, Fontaine J, van Stijn CMW, Tillie-Leblond I, Capron M, Faveeuw C, Jouault T, van Die IM, Gosset P, Trottein F. Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. *Infect Immun* 2007; 75(11): 5148-5157. (VUmc)
101. Brink AA, Snijders PJF, Meijer CJLM. HPV detection methods. *Dis Markers* 2007; 23(4): 273-281. (VUmc)
102. Brinkman JM, Bron JL, Wuisman PI, van Diest PJ, Comans EFl, Molthoff CFM. The correlation between clinical, nuclear and histologic findings in a patient with Von Recklinghausen's disease. *World J Surg Oncol* 2007; 5: 130. (VUmc)
103. Broekhuizen CA, de Boer L, Schipper K, Jones CD, Quadir S, Feldman RG, Dankert J, Vandenbroucke-Grauls CMJE, Weening JJ, Zaat SA. Peri-implant tissue is an important niche for *Staphylococcus epidermidis* in experimental biomaterial-associated infection in mice. *Infect Immun* 2007; 75(3): 1129-1136. (VUmc)
104. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, van Leeuwen FE, van 't Veer LJ. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. *Breast Cancer Res* 2007; 9: R26. (NKI)
105. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C, Nogues C, Lasset C, Berthet P, Meijers-Heijboer H, Gerdes AM, Olsson H, Caldes T, van Leeuwen FE, Rookus MA. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. *J Clin Oncol* 2007; 25: 3831-6. (NKI)
106. Broker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JHM, Giaccone G. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. *Clin Cancer Res* 2007; 13: 3906-12. (NKI/VUmc)
107. Brokx HA, Risse EKJ, Paul MA, Grunberg K, Golding RP, Kunst PW, Eerenberg JP, van Mourik JC, Postmus PE, Mooi WJ, Sutedja TG. Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. *J Thorac Cardiovasc Surg* 2007; 133(4): 973-978. (VUmc)
108. Brokx HA, Visser O, Postmus PE, Paul MA. Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. *J Thorac Oncol* 2007; 2(11): 1013-1017. (VUmc)
109. Bronneberg D, Spiekstra SW, Cornelissen LH, Oomens CW, Gibbs S, Baaijens FP, Bouten CV. Cytokine and chemokine release upon prolonged mechanical loading of the epidermis. *Exp Dermatol* 2007; 16(7): 567-573. (VUmc)

110. Brouwers EE, Huitema AD, Bakker EN, Douma JW, Schimmel KJ, van Weringh G, de Wolf PJ, Schellens JHM, Beijnen JH. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. *Int Arch Occup Environ Health* 2007; 80: 689-99. (NKI)
111. Brouwers EEM, Tibben MM, Rosing H, Schellens JHM, Beijnen JH. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry. *Rapid Commun Mass Spectrom* 2007; 21: 1521-30. (NKI)
112. Broxterman HJ, Georgopapadaku NH. Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma. *Drug Resist Updat* 2007; 10(4-5): 182-193. (VUmc)
113. Brueggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJTA, Sambade C, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau-Larue M-H, Kneba M, van Dongen JJM, Beldjord K, Molina TJ. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. *Leukemia* 2007; 21(2): 215-221. (AMC)
114. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, van Tellingen O, van Lohuizen M. Bmi1 controls tumor development in an ink4a/arf-independent manner in a mouse model for glioma. *Cancer Cell* 2007; 12: 328-41. (NKI)
115. Bruner DW, Bryan CJ, Aaronson N, Blackmore CC, Brundage M, Cella D, Ganz PA, Gotay C, Hinds PS, Kornblith AB, Movsas B, Sloan J, Wenzel L, Whalen G. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. *J Clin Oncol* 2007; 25: 5051-7. (NKI)
116. Bruynzeel AM, bou El Hassan MA, Schalkwijk C, Berkhof J, Bast A, Niessen HW, van der Vijgh WJ. Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. *Br J Cancer* 2007; 96(6): 937-943. (VUmc)
117. Bruynzeel AM, bou El Hassan MA, Torun E, Bast A, van der Vijgh WJ, Kruijff FAE. Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells. *Br J Cancer* 2007; 96(3): 450-456. (VUmc)
118. Bruynzeel AM, Niessen HW, Bronzwaer JG, van der Hoeven JJ, Berkhof J, Bast A, van der Vijgh WJ, van Groeningen CJ. The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. *Br J Cancer* 2007; 97(8): 1084-1089. (VUmc)
119. Bruynzeel AM, Vormer-Bonne S, Bast A, Niessen HW, van der Vijgh WJ. Long-term effects of 7-mono-hydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice. *Cancer Chemother Pharmacol* 2007; 60(4): 509-514. (VUmc)
120. Bryan J, Nieweg OE. New boundaries for lymphatic mapping-report of the Fifth International Sentinel Node Conference. *Melanoma Res* 2007; 17: 261-3. (NKI)
121. Bueno-de-Mesquita JM, Van Harten WH, Retel VP, 't Veer LJ, Van Dam FS, Karsenberg K, Douma KF, Van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). *Lancet Oncol* 2007; 8: 1079-87. (NKI)
122. Buffart TE, Carvalho B, Hopmans E, Brehm V, Kranenbarg EK, Schaaij-Visser TB, Eijk PP, van Grieken NC, Ylstra B, van de Velde CJ, Meijer GA. Gastric cancers in young and elderly patients show different genomic profiles. *J Pathol* 2007; 211(1): 45-51. (VUmc)
123. Buffart TE, Carvalho B, Mons T, Reis RM, Moutinho C, Silva P, van Grieken NC, Vieth M, Stolte M, van de Velde CJ, Schrock E, Matthaei A, Ylstra B, Carneiro F, Meijer GA. DNA copy number profiles of gastric cancer precursor lesions. *BMC Genomics* 2007; 8: 345. (VUmc)
124. Buffart TE, Tijssen M, Krugers T, Carvalho B, Smeets SJ, Brakenhoff RH, Grabsch H, Meijer GA, Sadowski HB, Ylstra B. DNA quality assessment for array CGH by isothermal whole genome amplification. *Cell Oncol* 2007; 29(4): 351-359. (VUmc)
125. Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, TenVergert EM, Van Tinteren H, Willemsse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. *J Clin Oncol* 2007; 25: 5403-9. (NKI)
126. Buis DR, Lagerwaard FJ, Dirven CM, Barkhof F, Knol DL, van den Berg R, Slotman BJ, Vandertop WP. Delineation of brain AVMs on MR-Angiography for the purpose of stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys* 2007; 67(1): 308-316. (VUmc)
127. Bulk S, Berkhof J, Rozendaal L, Fransen Daalmeijer NC, Gok M, de Schipper FA, van Kemenade FJ, Snijders PJF, Meijer CJLM. The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. *Br J Cancer* 2007; 96(8): 1234-1236. (VUmc)
128. Bulk S, Bulkman NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RHM, Snijders PJF, Meijer CJLM. Risk of high-grade cervical intra-epithelial

- neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. *Int J Cancer* 2007; 121(2): 361-367. (VUmc)
129. Bulkman NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJF, Meijer CJLM. High-risk HPV type-specific clearance rates in cervical screening. *Br J Cancer* 2007; 96(9): 1419-1424. (VUmc)
130. Bulkman NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RHM, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJF, Meijer CJLM. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. *Lancet* 2007; 370(9601): 1764-1772. (VUmc)
131. Butterworth MB, Edinger RS, Ovaa H, Burg D, Johnson JP, Frizzell RA. The Deubiquitinating Enzyme UCH-L3 Regulates the Apical Membrane Recycling of the Epithelial Sodium Channel. *J Biol Chem* 2007; 282: 37885-93. (NKI)
132. Campone M, Rademaker-Lakhai JM, Bennaoui J, Howell SB, Nowotnik DP, Beijnen JH, Schellens JHM. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. *Cancer Chemother Pharmacol* 2007; 60: 523-33. (NKI)
133. Carbonetti NH, Artamonova GV, van Rooijen N, Ayala VI. Pertussis toxin targets airway macrophages to promote *Bordetella pertussis* infection of the respiratory tract. *Infect Immun* 2007; 75(4): 1713-1720. (VUmc)
134. Cardoso MJ, Cardoso J, Amaral N, Azevedo I, Barreau L, Bernardo M, Christie D, Costa S, Fitzal F, Fougou JL, Johansen J, Macmillan D, Mano MP, Regolo L, Rosa J, Teixeira L, Vrieling C. Turning subjective into objective: The BCCT.core software for evaluation of cosmetic results in breast cancer conservative treatment. *Breast* 2007; 16: 456-61. (NKI)
135. Cardoso MJ, Cardoso J, Santos AC, Vrieling C, Christie D, Liljegren G, Azevedo I, Johansen J, Rosa J, Amaral N, Saaristo R, Sacchini V, Barros H, Oliveira MC. Factors determining esthetic outcome after breast cancer conservative treatment. *Breast J* 2007; 13: 140-6. (NKI)
136. Cardous-Ubbink MC, Heinen RC, Bakker PJM, van den Berg H, Oldenburger F, Caron HN, Voute PA, van Leeuwen FE. Risk of second malignancies in long-term survivors of childhood cancer. *European Journal of Cancer* 2007; 43(2): 351-362. (AMC/NKI)
137. Carette JE, Graat HC, Schagen FHE, Mastenbroek DC, Rots MG, Haisma HJ, Groothuis GM, Schaap GR, Bras J, Kaspers GJL, Wuisman PI, Gerritsen WR, van Beusechem VW. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. *Virology* 2007; 361(1): 56-67. (VUmc)
138. Carter C, Dion C, Schnell S, Coadwell WJ, Graham M, Hepburn L, Morgan G, Hutchings A, Pascall JC, Jacobs H, Miller JR, Butcher GW. A natural hypomorphic variant of the apoptosis regulator *Gimap4/IAN1*. *J Immunol* 2007; 179: 1784-95. (NKI)
139. Cataliotti L, de Wolf C, Holland R, Marotti L, Perry N, Redmond K, Rosselli Del Turco M, Rijken H, Kearney N, Ellis IO, Di Leo A, Orecchia R, Noel A, Andersson M, Audretsch W, Bjurstam N, Blamey RW, Blichert-Toft M, Bosmans H, Burch A, Bussolati G, Christiaens MR, Colleoni M, Cserni G, Cufer T, Cush S, Damilakis J, Drijkoningen M, Ellis P, Foubert J, Gambaccini M, Gentile E, Guedea F, Hendriks J, Jakesz R, Jassem J, Jerczek-Fossa BA, Laird O, Lartigau E, Mattheiem W, O'Higgins N, Pennery E, Rainsbury D, Rutgers E, Smola M, Van Limbergen E, von Smitten K, Wells C, Wilson R. Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. *Eur J Cancer* 2007; 43: 660-75. (NKI)
140. Catsburg A, van der Zwet WC, Morre SA, Ouburg S, Vandenbroucke-Grauls CMJE, Savelkoul PHM. Analysis of multiple single nucleotide polymorphisms (SNP) on DNA traces from plasma and dried blood samples. *J Immunol Methods* 2007; 321(1-2): 135-141. (VUmc)
141. Ceelen M, van Weissenbruch MM, Roos JC, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Body composition in children and adolescents born after in vitro fertilization or spontaneous conception. *J Clin Endocrinol Metab* 2007; 92: 3417-23. (NKI)
142. Celie JW, Rutjes NW, Keuning ED, Soininen R, Heljasvaara R, Pihlajaniemi T, Drager AM, Zweegman S, Kessler FL, Beelen RHJ, Florquin S, Aten J, van den Born J. Subendothelial heparan sulfate proteoglycans become major L-selectin and monocyte chemoattractant protein-1 ligands upon renal ischemia/reperfusion. *Am J Pathol* 2007; 170(6): 1865-1878. (VUmc)
143. Cen LP, Luo JM, Zhang CW, Fan YM, Song Y, So KF, van Rooijen N, Pang CP, Lam DS, Cui Q. Chemotactic effect of ciliary neurotrophic factor on macrophages in retinal ganglion cell survival and axonal regeneration. *Invest Ophthalmol Vis Sci* 2007; 48(9): 4257-4266. (VUmc)
144. Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Nogues C, Luporsi E, Huiart L, Hoogerbrugge N, van Leeuwen FE, Osorio A, Eyfjord J, Radice P, Goldgar DE, Easton DF. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 740-6. (NKI)
145. Checinska A, Hoogeland BS, Rodriguez JA, Giaccone G, Krzycki FAE. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced

- apoptosis by enhancing caspase-3 activation. *Exp Cell Res* 2007; 313(6): 1215-1224. (VUmc)
146. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. *Journal of Clinical Oncology* 2007; 25(5): 579-586. (AMC)
147. Chi JT, Rodriguez EH, Wang Z, Nuyten DSA, Mukherjee S, Van De Rijn M, van de Vijver MJ, Hastie T, Brown PO. Gene expression programs of human smooth muscle cells: Tissue-specific differentiation and prognostic significance in breast cancers. *PLoS Genet* 2007; 3: 1770-84. (NKI)
148. Chianale F, Cutrupi S, Rainero E, Baldanzi G, Porporato PE, Traini S, Filigheddu N, Gnocchi VF, Santoro MM, Parolini O, Van Blitterswijk WJ, Sinigaglia F, Graziani A. Diacylglycerol Kinase- $\{\alpha\}$ Mediates HGF-induced Epithelial Cell Scatter by Regulating Rac Activation and Membrane Ruffling. *Mol Biol Cell* 2007; 18: 4859-71. (NKI)
149. Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR, Laghmani eH, Joenje H, McDonald N, de Winter JP, Wang W, West SC. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. *Mol Cell* 2007; 25(3): 331-343. (VUmc)
150. Cillessen SA, Hess CJ, Hooijberg E, Castricum KC, Kortman P, Denkers F, Vos W, van de Wiel MA, Schuurhuis GJ, Ossenkuppele GJ, Meijer CJLM, Oudejans JJ. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma. *Clin Cancer Res* 2007; 13(23): 7012-7021. (VUmc)
151. Claes P, Wintzen M, Sermijn E, Lacor P, Velkeniers B. A true story of "organ-based medicine", or when did we stop thinking?. *Eur J Intern Med* 2007; 18(3): 173-174. (VUmc)
152. Clark K, Langeslag M, Figdor CG, van Leeuwen FN. Myosin II and mechanotransduction: a balancing act. *Trends Cell Biol* 2007; 17: 178-86. (NKI)
153. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. *Exp Cell Res* 2007; 313: 133-45. (NKI)
154. Codrea MC, Jimenez CR, Heringa J, Marchiori E. Tools for computational processing of LC-MS datasets: a user's perspective. *Comput Methods Programs Biomed* 2007; 86(3): 281-290. (VUmc)
155. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. Resolving the resolution of array CGH. *Genomics* 2007; 89(5): 647-653. (VUmc)
156. Coolen NA, Verkerk M, Reijnen L, Vlieg M, van den Bogaardt AJ, Breetveld M, Gibbs S, Middelkoop E, Ulrich MM. Culture of keratinocytes for transplantation without the need of feeder layer cells. *Cell Transplant* 2007; 16(6): 649-661. (VUmc)
157. Copper MP, Triesscheijn M, Tan IB, Ruevekamp MC, Stewart FA. Photodynamic therapy in the treatment of multiple primary tumours in the head and neck, located to the oral cavity and oropharynx. *Clin Otolaryngol* 2007; 32: 185-9. (NKI)
158. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk KM, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. *Blood* 2007; 109(9): 3658-3666. (VUmc)
159. Cornelissen R, Senan S, Antonisse IE, Liem H, Tan YK, Rudolphus A, Aerts JG. Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. *Radiat Oncol* 2007; 2: 2. (VUmc)
160. Corten EM, Schellekens PP, Oey PL, Hage JJ, Kerst A, Kon M. Function of the clavicular part of the pectoralis major muscle after transplantation of its sternocostal part. *Ann Plast Surg* 2007; 58: 392-6. (NKI)
161. Coupe VM, Berkhof J, Verheijen RHM, Meijer CJLM. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. *BJOG* 2007; 114(4): 416-424. (VUmc)
162. Couper KN, Blount DG, Hafalla JC, van Rooijen N, de Souza JB, Riley EM. Macrophage-mediated but gamma interferon-independent innate immune responses control the primary wave of Plasmodium yoelii parasitemia. *Infect Immun* 2007; 75(12): 5806-5818. (VUmc)
163. Cover KS, Lagerwaard FJ, Senan S. Color intensity projections: a simple way to display changes in astronomical images. *Publications of the Astronomical Society of the Pacific* 2007; 119: 523-526. (VUmc)
164. Cover KS, Lagerwaard FJ, van den Berg R, Buis DR, Slotman BJ. Color intensity projection of digitally subtracted angiography for the visualization of brain arteriovenous malformations. *Neurosurgery* 2007; 60(3): 511-514. (VUmc)
165. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher O, Johnson N, dos Santos Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, Risch A, Wang-Gohrke S, Schurmann P, Bogdanova N, Dork T, Fagerholm R, Aaltonen K, Blomqvist C, Nevanlinna H, Seal S, Renwick A, Stratton MR, Rahman N, Sangrajrang S, Hughes D, Odefrey F, Brennan P, Spurdle AB, Chenevix-Trench G,

- Beesley J, Mannermaa A, Hartikainen J, Kataja V, Kosma VM, Couch FJ, Olson JE, Goode EL, Broeks A, Schmidt MK, Hogervorst FB, van't Veer LJ, Kang D, Yoo KY, Noh DY, Ahn SH, Wedren S, Hall P, Low YL, Liu J, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Sigurdson AJ, Stredrick DL, Alexander BH, Struwing JP, Pharoah PD, Easton DF. A common coding variant in CASP8 is associated with breast cancer risk. *Nat Genet* 2007; 39: 352-8. (NKI)
166. Craanen ME, Comans EFI, Paul MA, Smit EF. Endoscopic ultrasound guided fine-needle aspiration and 18FDG-positron emission tomography in the evaluation of patients with non-small cell lung cancer. *Interact Cardiovasc Thorac Surg* 2007; 6(4): 433-436. (VUmc)
167. Crijns APG, de Graeff P, Geerts D, ten Hoor KA, Hollema H, van der Sluis T, Hofstra RMW, de Bock GH, de Jong S, van der Zee AGJ, de Vries EGE. MEIS and PBX homeobox proteins in ovarian cancer. *European Journal of Cancer* 2007; 43(17): 2495-2505. (AMC)
168. Cserni G, Bianchi S, Vezzosi V, Arisio R, Bori R, Peterse JL, Sapino A, Castellano I, Drijckoningen M, Kulka J, Eusebi V, Foschini MP, Bellocq JP, Marin C, Thorstenson S, Amendoeira I, Reiner-Concin A, Decker T, Lacerda M, Figueiredo P, Fejes G. Sentinel lymph node biopsy in staging small (up to 15 mm) breast carcinomas. Results from a European multi-institutional study. *Pathol Oncol Res* 2007; 13: 5-14. (NKI)
169. Cserni G, Bianchi S, Vezzosi V, Arisio R, Bori R, Peterse JL, Sapino A, Drijckoningen M, Kulka J, Eusebi V, Foschini MP, Bellocq JP, Marin C, Thorstenson S, Amendoeira I, Reiner-Concin A, Decker T. Sentinel lymph node biopsy and non-sentinel node involvement in special type breast carcinomas with a good prognosis. *Eur J Cancer* 2007; 43: 1407-14. (NKI)
170. Cserni G, Bianchi S, Vezzosi V, Arisio R, Peterse JL, Sapino A, Castellano I, Drijckoningen M, Kulka J, Eusebi V, Foschini MP, Bellocq JP, Marin C, Thorstenson S, Amendoeira I, Reiner-Concin A, Decker T, Lacerda M, Figueiredo P. Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients. *Am J Surg* 2007; 194: 288-93. (NKI)
171. da Costa MP, Garcia Vallejo JJ, van Thienen JV, Fernandez-Borja M, van Gils JM, Beckers C, Horrevoets AJ, Hordijk PL, Zwaginga JJ. P-selectin glycoprotein ligand-1 is expressed on endothelial cells and mediates monocyte adhesion to activated endothelium. *Arterioscler Thromb Vasc Biol* 2007; 27(5): 1023-1029. (VUmc)
172. Danesi R, Pasqualetti G, Giovannetti E, del Tacca M. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer. *J Thorac Oncol* 2007; 2(5 Suppl): S27-S30. (VUmc)
173. Dasgupta S, Navarrete AM, Bayry J, Delignat S, Wootla B, Andre S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TBH, Moris A, Saint-Remy JM, Kazatchkine MD, Kaveri BSV, Lacroix-Desmazes S. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. *Proc Natl Acad Sci U S A* 2007; 104(21): 8965-8970. (VUmc)
174. de Boer NK, Derijks LJ, Keizer-Garritsen JJ, Lambooy LH, Ruitenbeek W, Hooymans PM, van Bodegraven AA, de Jong DJ. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease. *J Clin Pharmacol* 2007; 47(2): 187-191. (VUmc)
175. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. *Nat Clin Pract Gastroenterol Hepatol* 2007; 4(12): 686-694. (VUmc)
176. de Boer NK, Wong DR, Jharap B, de Graaf P, Hooymans PM, Mulder CJ, Rijmen F, Engels LG, van Bodegraven AA. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. *Am J Gastroenterol* 2007; 102(12): 2747-2753. (VUmc)
177. de Bree E, de Bree R, Manios A TD. Mucosal melanoma of the nasal cavity. *Hellenic Otorhinolaryngol Head Neck Surgery* 2007; 28: 136-140. (VUmc)
178. de Bree E, van Ruth S, Dewit LGH, Zoetmulder FAN. High risk of colostomy with primary radiotherapy for anal cancer. *Ann Surg Oncol* 2007; 14: 100-8. (NKI)
179. de Bree E, van Ruth S, Schotborgh CE, Baas P, Zoetmulder FA. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with Doxorubicin and Cisplatin. *Ann Surg Oncol* 2007; 14: 3019-26. (NKI)
180. de Bree R, Reith R, Quak JJ, Uyl-de Groot CA, van Agthoven M, Leemans CR. Free radial forearm flap versus pectoralis major myocutaneous flap reconstruction of oral and oropharyngeal defects: a cost analysis. *Clin Otolaryngol* 2007; 32(4): 275-282. (VUmc)
181. de Bree R, van der Putten L, Hoekstra OS, Kuik DJ, Uyl-de Groot CA, van Tinteren H, Leemans CR, Boers M. A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. *Contemp Clin Trials* 2007; 28(6): 705-712. (VUmc)
182. de Bree R, van der Waal I, Leemans CR. Management of Frey syndrome. *Head Neck* 2007; 29(8): 773-778. (VUmc)
183. de Bruin EC, van de Pas S, van de Velde CJH, van Krieken JHJM, Peltenburg LTC, Marijnen CAM, Medema JP. Gene expression profiling reveals two separate mechanisms regulating apoptosis in rectal carcinomas in vivo. *Apoptosis* 2007; 12(9): 1671-1680. (AMC/NKI)
184. de Castro SMM, Singhal D, Aronson DC, Busch ORC, van Gulik TM, Obertop H, Gouma DJ.

- Management of solid-pseudopapillary neoplasms of the pancreas: a comparison with standard pancreatic neoplasms. *World Journal of Surgery* 2007; 31(5): 1130-1135. (AMC)
185. de Gorter DJJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, Pals ST, Spaargaren M. Bruton's tyrosine kinase and phospholipase C gamma 2 mediate chemokine-controlled B cell migration and homing. *Immunity* 2007; 26(1): 93-104. (AMC)
186. de Gorter DJJ, Vos JCM, Pals ST, Spaargaren M. The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Raf. *Journal of immunology* 2007; 178(3): 1405-1414. (AMC)
187. de Graaf P, Knol DL, Moll AC, Imhof SM, Schouten-van Meeteren AY, Castelijns JA. Eye size in retinoblastoma: MR imaging measurements in normal and affected eyes. *Radiology* 2007; 244(1): 273-280. (VUmc)
188. de Graaf P, van der Valk P, Moll AC, Imhof SM, Schouten-van Meeteren AY, Castelijns JA. Retinal dysplasia mimicking intraocular tumor: MR imaging findings with histopathologic correlation. *AJNR Am J Neuroradiol* 2007; 28(9): 1731-1733. (VUmc)
189. de Gunst MM, Gallegoz Ruiz MI, Giaccone G, Rodriguez JA. Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. *Mol Cancer* 2007; 6: 56. (VUmc)
190. de Haan A, Toor A, Hage JJ, Veeger HE, Woerdeman LAE. Function of the Pectoralis Major Muscle After Combined Skin-Sparing Mastectomy and Immediate Reconstruction by Subpectoral Implantation of a Prosthesis. *Ann Plast Surg* 2007; 59: 605-10. (NKI)
191. de Haas TGKJ, Kool M. Clinicopathological features of medulloblastoma: an overview with an emphasis on molecular biology. *Clinical Neuropathology* 2007; 26(3): 93-110. (AMC)
192. de Heer K, Silbermann MH, Koene HR, Biemond BJ, Muller HP, van Oers MHJ. Systematische diagnostiek van erythrocytose. *Nederlands Tijdschrift voor Geneeskunde* 2007; 151(32): 1770-1776. (AMC)
193. de Heer P, de Bruin EC, Klein-Kranenburg E, Aalbers RIJM, Marijnen CAM, Putter H, De Bont HJ, Nagelkerke JF, Van Krieken JHJM, Verspaget HW, Van De Velde CJH, Kuppen PJK. Caspase-3 activity predicts local recurrence in rectal cancer. *Clin Cancer Res* 2007; 13: 5810-5. (NKI)
194. de Heer P, Gosens MJ, de Bruin EC, Dekker-Ensink NG, Putter H, Marijnen CAM, van den Brule AJ, van Krieken JH, Rutten HJ, Kuppen PJ, Van De Velde CJH. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. *Clin Cancer Res* 2007; 13: 2955-60. (NKI)
195. De Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Berg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D, Ahlman H, Arnold R, Bechstein WO, Cadiot G, Caplin M, Christ E, Chung D, Couvelard A, Delle Fave G, Falchetti A, Goretzki P, Gross D, Hochhauser D, Hyrdel R, Jensen R, Kaltsas G, Timur F, Kianmanesh R, Knapp W, Knigge UP, Komminoth P, Rner M, Kos K, Kvols L, Lewington V, Lopes JM, Manfredi R, McNicol AM, Mitry E, Nikou G, Nilsson O, O'Connor J, Pape UF, Pavel M, Perren A, Ckinger U, Ramage J, Ricke J, Ruszniewski P, Salazar R, Sauvanet A, Scarpa A, Sevilla Garcia MI, Iler T, Sundin A, Taal B, Van Cutsem E, Vullierme MP, Wildi S, Yao JC, Shi S. Well-differentiated pancreatic tumor/carcinoma: Insulinoma. *Neuroendocrinology* 2007; 84: 183-8. (NKI)
196. de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, Sander B, Thorns C, Campo E, Molina T, Norton A, Hagenbeek A, Horning S, Lister A, Raemaekers J, Gascoyne RD, Salles G, Weller E. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium. *Journal of Clinical Oncology* 2007; 25(7): 805-812. (AMC/NKI)
197. de Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, van Bochove A, van Tinteren H, Smit EF. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. *Eur J Cancer* 2007; 43(16): 2345-2350. (VUmc)
198. De Jong WK, Van Der Heijden HFM, Pruijm J, Dalesio O, Oyen WJG, Groen HJM. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: A two-center study. *J Thor Oncol* 2007; 2: 1007-12. (NKI)
199. de Jongh CM, Verberk MM, Spiekstra SW, Gibbs S, Kezic S. Cytokines at different stratum corneum levels in normal and sodium lauryl sulphate-irritated skin. *Skin Res Technol* 2007; 13(4): 390-398. (VUmc)
200. de Kogel CE, Schellens JHM. Imatinib. *Oncologist* 2007; 12: 1390-4. (NKI)
201. de Kort SJ, Kenny N, van Dijk P, Gevers S, Richel DJ, Willems DL. Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians. *European Journal of Cancer* 2007; 43(13): 1983-1989. (AMC)
202. de Leest HT, Steen KSS, Lems WF, Bijlsma JW, van de Laar MA, Huisman AM, Vonkeman HE, Houben HH, Kadir SW, Kostense PJ, van Tulder MW, Kuipers EJ, Boers M, Dijkmans BAC. Eradication of *Helicobacter pylori* does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind,

- randomized, placebo-controlled trial. *Helicobacter* 2007; 12(5): 477-485. (VUmc)
203. de Leng WW, Jansen M, Carvalho R, Polak M, Musler AR, Milne AN, Keller JJ, Menko FH, de Rooij FW, Iacobuzio-Donahue CA, Giardiello FM, Weterman MA, Offerhaus GJ. Genetic defects underlying Peutz-Jeghers syndrome (PJS) and exclusion of the polarity-associated MARK/Par1 gene family as potential PJS candidates. *Clin Genet* 2007; 72(6): 568-573. (VUmc)
204. de Maat MF, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ, Meijer GA, van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar RA, Hoon DS. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. *J Clin Oncol* 2007; 25(31): 4887-4894. (VUmc)
205. de Marco C, Zaffaroni N, Comijn E, Tesei A, Zoli W, Peters GJ. Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. *Int J Oncol* 2007; 31(4): 907-913. (VUmc)
206. de Mooij Y, Burger MPM, Schilthuis MS, Buist M, van der Velden J. Partial urethral resection in the surgical treatment of vulvar cancer does not have a significant impact on urinary continence. A confirmation of an authority-based opinion. *Int J Gynecol Cancer* 2007; 17: 294-7. (NKI)
207. de Reijke T, de la Rosette JJMCH, Sternberg C. Treatment approaches in patients with hormone resistant prostate cancer. *Urologia Polska* 2007; 60(2): 108-114. (AMC)
208. de Reuver PR, Busch ORC, Rauws EA, Lameris JS, van Gulik ThM, Gouma DJ. Long-term results of a primary end-to-end anastomosis in peroperative detected bile duct injury. *Journal of Gastrointestinal Surgery* 2007; 11(3): 296-302. (AMC)
209. de Reuver PR, Grossmann I, Busch OR, Obertop H, van Gulik TM, Gouma DJ. Referral pattern and timing of repair are risk factors for complications after reconstructive surgery for bile duct injury. *Annals of Surgery* 2007; 245(5): 763-770. (AMC)
210. de Reuver PR, Rauws EA, Bruno MJ, Lameris JS, Busch OR, van Gulik TM, Gouma DJ. Survival in bile duct injury patients after laparoscopic cholecystectomy: a multidisciplinary approach of gastroenterologists, radiologists, and surgeons. *Surgery* 2007; 142(1): 1-9. (AMC)
211. de Ridder J, Kool J, Uren A, Bot J, Wessels L, Reinders M. Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes. *Bioinformatics* 2007; 23: i131-i141. (NKI)
212. de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast. *Histopathology* 2007; 51: 227-38. (NKI)
213. de Sanjose S, Bosch R, Schouten T, Verkuijden S, Nieters A, Foretova L, Maynadie M, Cocco PL, Staines A, Becker N, Brennan P, Benavente Y, Boffetta P, Meijer CJLM, Middeldorp JM. Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. *Int J Cancer* 2007; 121(8): 1806-1812. (VUmc)
214. de Steenwinkel JE, van Vianen W, ten Kate MT, Verbrugh HA, van Agtmael MA, Schiffelers RM, Bakker-Woudenberg IA. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated *Mycobacterium avium* infection in mice. *J Antimicrob Chemother* 2007; 60(5): 1064-1073. (VUmc)
215. de Swart RL, Ludlow M, de Witte L, Yanagi Y, van Amerongen G, McQuaid S, Yuksel S, Geijtenbeek TBH, Duprex WP, Osterhaus AD. Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. *PLoS Pathog* 2007; 3(11): e178. (VUmc)
216. de Vet HC, Ostelo RW, Terwee CB, van der Roer N, Knol DL, Beckerman H, Boers M, Bouter LM. Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. *Qual Life Res* 2007; 16(1): 131-142. (VUmc)
217. de Vries AC, Meijer GA, Looman CW, Casparie MK, Hansen BE, van Grieken NC, Kuipers EJ. Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. *Gut* 2007; 56(12): 1665-1670. (VUmc)
218. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BAC, Aarden LA, van der Horst-Bruinsma IE. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. *Ann Rheum Dis* 2007; 66(9): 1252-1254. (VUmc)
219. de Vries NA, Ouwehand M, Buckle T, Beijnen JH, van Tellinggen O. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. *Biomed Chromatogr* 2007; 21: 1191-200. (NKI)
220. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellinggen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. *Clin Cancer Res* 2007; 13: 6440-9. (NKI)
221. de Vries RR, Bex A, Horenblas S. Peritonitis carcinomatosa in a patient with recurrent "superficial" bladder cancer treated with cystectomy and nephroureterectomy. *Urology* 2007; 69: 184. (NKI)
222. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, Hulsmans HJ, de Craen AJ, Breedveld FC, Dijkmans BAC, Allaart CF, Huizinga TW. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with

- rheumatoid arthritis and with joint damage. *Ann Rheum Dis* 2007; 66(8): 1033-1037. (VUmc)
223. de Wit E, Greil F, van Steensel B. High-resolution mapping reveals links of HP1 with active and inactive chromatin components. *PLoS Genet* 2007; 3: e38. (NKI)
224. de Witt CA, de Bree R, Verdonck-de Leeuw IM, Quak JJ, Leemans CR. Donor site morbidity of the fasciocutaneous radial forearm flap: what does the patient really bother?. *Eur Arch Otorhinolaryngol* 2007; 264(8): 929-934. (VUmc)
225. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TBH, Gallay P. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. *Proc Natl Acad Sci U S A* 2007; 104(49): 19464-19469. (VUmc)
226. de Witte L, Nabatov AA, Pion M, Fluitsma D, de Jong MAWP, de Gruijl TD, Piguët V, van Kooyk Y, Geijtenbeek TBH. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. *Nat Med* 2007; 13(3): 367-371. (VUmc)
227. de Witte MA, Toebes M, Song JY, Wolkers MC, Schumacher TNM. Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. *Blood* 2007; 109: 3830-8. (NKI)
228. de Wolf CJ, Yamaguchi H, van der Heijden I, Wielinga PR, Hundscheid SL, Ono N, Scheffer GL, de Haas M, Schuetz JD, Wijnholds J, Borst P. cGMP transport by vesicles from human and mouse erythrocytes. *FEBS J* 2007; 274: 439-50. (NKI/VUmc)
229. Debicki K, Mandjes M, Van Uitert M. A tandem queue with L,vy input: A new representation of the downstream queue length. *Probability in the Engineering and Informational Sciences* 2007; 21: 83-107. (NKI)
230. Deenik W, van der Holt B, Verhoef GE, Schattenberg AV, Verdonck LF, Daenen SM, Zachee P, Westveer PH, Smit WM, Wittebol S, Schouten HC, Lowenberg B, Ossenkoppele GJ, Cornelissen JJ. High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia A prospective randomized phase III study. *Ann Hematol* 2007; 86(2): 117-125. (VUmc)
231. Deganello A, Manciooco V, Dolivet G, Leemans CR, Spriano G. Infrahyoid fascio-myocutaneous flap as an alternative to free radial forearm flap in head and neck reconstruction. *Head Neck* 2007; 29(3): 285-291. (VUmc)
232. Dekker JJ, Hage JJ, Karim RB, Bloemena E. Do histologic changes in the skin-lined neovagina of male-to-female transsexuals really occur? *Ann Plast Surg* 2007; 59: 546-9. (NKI/VUmc)
233. den Dulk M, Collette L, Van de Velde CJ, Marijnen CAM, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bosset JF. Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921. *Eur J Cancer* 2007; 43: 1821-8. (NKI)
234. den Dulk M, Marijnen CA, Putter H, Rutten HJ, Beets GL, Wiggers T, Nagtegaal ID, Van de Velde CJ. Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial. *Ann Surg* 2007; 246: 83-90. (NKI)
235. den Dulk M, Verheij M, Cats A, Jansen EPM, Hartgrink HH, Van De Velde CJH. The essentials of locoregional control in the treatment of gastric cancer. *Scand J Surg* 2006; 95: 236-42. (NKI)
236. den Haan JMM, Kraal G, Bevan MJ. Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. *J Immunol* 2007; 178(9): 5429-5433. (VUmc)
237. Diederens BM, de Jong CM, Marmouk F, Kluytmans JA, Peeters MF, van der Zee A. Evaluation of real-time PCR for the early detection of *Legionella pneumophila* DNA in serum samples. *J Med Microbiol* 2007; 56(Pt 1): 94-101. (VUmc)
238. Diederens BM, van der Valk P, Kluytmans JA, Peeters MF, Hendrix R. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. *Eur Respir J* 2007; 30(2): 240-244. (VUmc)
239. Dieleman EMT, Senan S, Vincent A, Lagerwaard FJ, Slotman BJ, van Sörnsen de Koste JR. Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. *Int J Radiat Oncol Biol Phys* 2007; 67: 775-80. (NKI/VUmc)
240. Dinant S, de Graaf W, Verwer BJ, Bennink RJ, van Lienden KP, Gouma DJ, van Vliet AK, van Gulik TM. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. *Journal of Nuclear Medicine* 2007; 48(5): 685-692. (AMC)
241. Dinant S, Vetelainen RL, Florquin S, van Vliet AK, van Gulik TM. IL-10 attenuates hepatic I/R injury and promotes hepatocyte proliferation. *Journal of Surgical Research* 2007; 141(2): 176-182. (AMC)
242. Diosdado B, van Bakel H, Strengman E, Franke L, van Oort E, Mulder CJ, Wijmenga C, Wapenaar MC. Neutrophil recruitment and barrier impairment in celiac disease: a genomic study. *Clin Gastroenterol Hepatol* 2007; 5(5): 574-581. (VUmc)
243. DiPasquale DM, Cheng M, Billich W, Huang SA, van Rooijen N, Hornberger TA, Koh TJ. Urokinase-type plasminogen activator and macrophages are required for skeletal muscle hypertrophy in mice. *Am J Physiol Cell Physiol* 2007; 293(4): C1278-C1285. (VUmc)
244. Dittrich C, Zandvliet AS, Gneist M, Huitema ADR, King AAJ, Wanders J. A phase I and pharmacokinetic study of indisulam in combination with carboplatin. *Br J Cancer* 2007; 96: 559-66. (NKI)

245. Dorsman JC, Levitus M, Rockx D, Roomans MA, Oostra AB, Haitjema A, Bakker ST, Steltenpool J, Schuler D, Mohan S, Schindler D, Arwert F, Pals G, Mathew CG, Waisfisz Q, de Winter JP, Joenje H. Identification of the Fanconi anemia complementation group I gene, FANCI. *Cell Oncol* 2007; 29(3): 211-218. (VUmc)
246. Douma KF, Karsenberg K, Hummel MJ, Bueno-de-Mesquita JM, Van Harten WH. Methodology of constructive technology assessment in health care. *Int J Technol Assess Health Care* 2007; 23: 162-8. (NKI)
247. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, schoff J, Gutjahr T, Habben K, van de Vijver MJ. Standardization of HER2 testing: Results of an international proficiency-testing ring study. *Mod Pathol* 2007; 20: 584-91. (NKI)
248. Duc Q, Breetveld M, Middelkoop E, Scheper RJ, Ulrich MM, Gibbs S. A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. *Br J Dermatol* 2007; 157(1): 33-40. (VUmc)
249. Dutertre S, Ulens C, Buttner R, Fish A, Van Elk R, Kendel Y, Hopping G, Alewood PF, Schroeder C, Nicke A, Smit AB, Sixma TK, Lewis RJ. AChBP-targeted (alpha)-conotoxin correlates distinct binding orientations with nAChR subtype selectivity. *EMBO J* 2007; 26: 3858-67. (NKI)
250. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor 1 activity in human ovarian cancer cells. *Biochem Pharmacol* 2007; 74(2): 191-201. (VUmc)
251. Eichhorn PJ, Creighton MP, Wilhelmsen K, van Dam H, Bernards R. A RNA Interference Screen Identifies the Protein Phosphatase 2A Subunit PR55gamma as a Stress-Sensitive Inhibitor of c-SRC. *PLoS Genet* 2007; 3: e218. (NKI)
252. Ekhardt C, Gebretensae A, Rosing H, Rodenhuis S, Beijnen JH, Huitema AD. Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 854: 345-9. (NKI)
253. El-Emir E, Dearling JL, Huhlov A, Robson MP, Boxer G, Neri D, van Dongen GAMS, Trachsel E, Begent RH, Pedley RB. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. *Br J Cancer* 2007; 96(12): 1862-1870. (VUmc)
254. Ellenbroek SI, Collard JG. Rho GTPases: functions and association with cancer. *Clin Exp Metastasis* 2007; 24: 657-72. (NKI)
255. Elliott S, Sturman B, Anderson S, Brouwers E, Beijnen J. ICP-MS: When sensitivity does matter. *LC-GC North America* 2007; 25: 36-43. (NKI)
256. Elzinga EH, van der Laken CJ, Comans EFI, Lammertsma AA, Dijkmans BAC, Voskuyl AE. 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. *Mol Imaging Biol* 2007; 9(6): 357-360. (VUmc)
257. Engelsma D, Rodriguez JA, Fish A, Giaccone G, Fornerod M. Homodimerization antagonizes nuclear export of survivin. *Traffic* 2007; 8: 1495-502. (NKI/VUmc)
258. Engwegen JY, Mehra N, Haanen JBAG, Bonfrer JMG, Schellens JHM, Voest EE, Beijnen JH. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. *Lab Invest* 2007; 87: 161-72. (NKI)
259. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, Bernards R. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. *Proc Natl Acad Sci U S A* 2007; 104: 17777-82. (NKI)
260. Erdogan D, Busch ORC, Gouma DJ, van Gulik TM. Prevention of biliary leakage after partial liver resection using topical hemostatic agents. *Digestive Surgery* 2007; 24(4): 294-299. (AMC)
261. Erdogan D, Busch ORC, van Delden OM, Bennink RJ, ten Kate FJW, Gouma DJ, van Gulik TM. Management of liver hemangiomas according to size and symptoms. *Journal of Gastroenterology and Hepatology* 2007; 22(11): 1953-1958. (AMC)
262. Erdogan D, van Delden OM, Rauws EAJ, Busch ORC, Lameris JS, Gouma DJ, van Gulik TM. Results of percutaneous sclerotherapy and surgical treatment in patients with symptomatic simple liver cysts and polycystic liver disease. *World Journal of Gastroenterology* 2007; 13(22): 3095-3100. (AMC)
263. Esme DL, Beekman WH, Hage JJ, Nipshagen MD. Combined Use of Ultrasonic-Assisted Liposuction and Semicircular Periareolar Incision for the Treatment of Gynecomastia. *Ann Plast Surg* 2007; 59: 629-34. (NKI)
264. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bielig S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefler R, Kane J, Kecmanovic D, Kelley S, Kuhn J, LaMont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F,

- Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. *Ann Surg Oncol* 2007; 14: 128-33. (NKI)
265. Estourgie SH, Valdés Olmos RA, Nieweg OE, Hoefnagel CA, Rutgers EJT, Kroon BBR. Excision biopsy of breast lesions changes the pattern of lymphatic drainage. *Br J Surg* 2007; 94: 1088-91. (NKI)
266. Evans PAS, Pott Ch, Groenen PJTA, Salles G, Davi F, Berger F, Garcia JF, van Krieken JHJM, Pals S, Kluin Ph, Schuurin E, Spaargaren M, Boone E, Gonzalez D, Martinez B, Villuendas R, Gameiro P, Diss TC, Mills K, Morgan GJ, Carter GI, Milner BJ, Pearson D, Hummel M, Jung W, Ott M, Canioni D, Beldjord K, Bastard C, Delfau-Larue MH, van Dongen JJM, Molina TJ, Cabecadas J.: Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. *Leukemia* 2007; 21(2): 207-214. (AMC)
267. Evrard GX, Langer GG, Perrakis A, Lamzin VS. Assessment of automatic ligand building in ARP/wARP. *Acta Crystallogr D Biol Crystallogr* 2007; 63: 108-17. (NKI)
268. Falconi M, ckinge U, Kwekkeboom DJ, Manfredi R, rner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Iler T, berg K, Scoazec JY, Ahlman H, Arnold R, Bechstein WO, Cadiot G, Caplin M, Christ E, Chung D, Couvelard A, De Herder WW, Delle Fave G, Eriksson B, Falchetti A, Ferone D, Gross D, Hochhauser D, Hyrdel R, Jensen R, Kaltsas G, timur F, Kianmanesh R, Knapp W, Knigge UP, Komminoth P, Kos K, Lewington V, Lopes JM, McNicol AM, Mitry E, Niederle B, Nikou G, Nilsson O, O'Connor J, O'Toole D, Pauwels S, Pavel M, Perren A, Ramage J, Rindi G, Ruszniewski P, Salazar R, Sauvanet A, Scarpa A, Sevilla Garcia MI, Sundin A, Taal B, Van Cutsem E, Vullierme MP, Wiedenmann B, Yao JC, Zgliczynski S. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. *Neuroendocrinology* 2007; 84: 196-211. (NKI)
269. Feitsma AL, Worthington J, van der Helm-van Mil AH, Plant D, Thomson W, Ursun J, van Schaardenburg D, van der Horst-Bruinsma IE, van Rood JJ, Huizinga TW, Toes RE, de Vries RR. Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development. *Proc Natl Acad Sci U S A* 2007; 104(50): 19966-19970. (VUmc)
270. Felson DT, Furst DE, Boers M. Rationale and strategies for reevaluating the ACR20. *J Rheumatol* 2007; 34(5): 1184-1187. (VUmc)
271. Ferlito A, Johnson JT, Rinaldo A, Pratt LW, Fagan JJ, Weir N, Suarez C, Folz BJ, Bien S, Towpik E, Leemans CR, Bradley PJ, Kowalski LP, Herranz J, Gavilan J, Olofsson J. European surgeons were the first to perform neck dissection. *Laryngoscope* 2007; 117(5): 797-802. (VUmc)
272. Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JMM, Salles G, Noordijk EM, Creemers G, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. *New England Journal of Medicine* 2007; 357(19): 1916-1927. (AMC/NKI)
273. Fijneman RJA, Carvalho B, Postma C, Mongera S, van Hinsbergh V, Meijer GA. Loss of 1p36, gain of 8q24, and loss of 9q34 are associated with stroma percentage of colorectal cancer. *Cancer Lett* 2007; 258(2): 223-229. (VUmc)
274. Fischer C, Jonckx B, Mazzone M, Zaccagna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, de Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P. Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. *Cell* 2007; 131(3): 463-475. (VUmc)
275. Fitton I, Steenbakkens RJ, Zijp L, Duppen JC, Comans EF, Muller SH, Nowak PJ, Rasch CR, van Herk M. Retrospective attenuation correction of PET data for radiotherapy planning using a free breathing CT. *Radiother Oncol* 2007; 83: 42-8. (NKI/VUmc)
276. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, Gao H, van Rooijen N, Huber-Lang MS, Neubig RR, Ward PA. Phagocyte-derived catecholamines enhance acute inflammatory injury. *Nature* 2007; 449(7163): 721-725. (VUmc)
277. Foijer F, Delzenne-Goette E, Dekker M, Te Riele H. In vivo significance of the G2 restriction point. *Cancer Res* 2007; 67: 9244-7. (NKI)
278. Fons G, Burger MP, Ten Kate FJ, van der Velden J. Identification of potential prognostic markers for vulvar cancer using immunohistochemical staining of tissue microarrays. *Int J Gynecol Pathol* 2007; 26: 188-93. (NKI)
279. Fontijn D, Adema AD, Bhakat KK, Pinedo HM, Peters GJ, Boven E. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells. *Mol Cancer Ther* 2007; 6(10): 2807-2815. (VUmc)
280. Fontijn D, Duynndam MC, BeliÛn JAM, Gallegoz Ruiz MI, Pinedo HM, Boven E. The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis. *Melanoma Res* 2007; 17(3): 155-168. (VUmc)
281. Franceschi S, Smith JS, van den Brule A, Herrero R, Arslan A, Anh PT, Bosch FX, Hieu NT,

- Matos E, Posso H, Qiao YL, Shin HR, Sukvirach S, Thomas JO, Sniijders PJF, Munoz N, Meijer CJLM. Cervical infection with Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four continents A cross-sectional study. *Sex Transm Dis* 2007; 34(8): 563-569. (VUmc)
282. Fransman W, Peelen S, Hilhorst S, Roeleveld N, Heederik D, Kromhout H. A pooled analysis to study trends in exposure to antineoplastic drugs among nurses. *Ann Occup Hyg* 2007; 51: 231-9. (NKI)
283. Frost MH, Bonomi AE, Cappelleri JC, Schunemann HJ, Moynihan TJ, Aaronson NK. Applying quality-of-life data formally and systematically into clinical practice. *Mayo Clin Proc* 2007; 82: 1214-28. (NKI)
284. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, van Rooijen N, Stemmer-Rachamimov AO, Hochberg FH, Weissleder R, Martuza RL, Chiocca EA. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. *Cancer Res* 2007; 67(19): 9398-9406. (VUmc)
285. Galea I, Bernardes-Silva M, Forse PA, van Rooijen N, Liblau RS, Perry VH. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. *J Exp Med* 2007; 204(9): 2023-2030. (VUmc)
286. Gallegoz Ruiz MI, Floor K, Rijmen F, Grunberg K, Rodriguez JA, Giaccone G. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. *Cell Oncol* 2007; 29(3): 257-264. (VUmc)
287. Gallegoz Ruiz MI, Floor K, Vos W, Grunberg K, Meijer GA, Rodriguez JA, Giaccone G. Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. *Histopathology* 2007; 51(5): 631-637. (VUmc)
288. Gallegoz Ruiz MI, van Cruijssen H, Smit EF, Grunberg K, Meijer GA, Rodriguez JA, Ylstra B, Giaccone G. Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases. *J Thorac Oncol* 2007; 2(1): 12-21. (VUmc)
289. Gast MCW, Bonfrer JMG, van Dulken EJ, de Kock L, Rutgers EJ, Schellens JHM, Beijnen JH. SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity. *Cancer Biomark* 2006; 2: 235-48. (NKI)
290. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Eilman MH et al. Outcome measurements in scleroderma: results from a delphi exercise. *J Rheumatol* 2007; 34(3): 501-509. (VUmc)
291. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. *J Invest Dermatol* 2007; 127(8): 2031-2041. (VUmc)
292. Geenen MM, Cardous-Ubbink MC, Kremer LCM, van den Bos C, van der Pal HJH, Heinen RC, Jaspers MWM, Koning CCE, Oldenburger F, Langeveld NE, Hart Augustinus AM, Bakker PJM, Caron HN, van Leeuwen FE: Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. *JAMA-journal of the american medical association* 2007; 297(24): 2705-2715. (AMC/NKI)
293. Geerts D, Wallick CJ, Koomoa DLT, Koster J, Versteeg R, Go RCV, Bachmann AS. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. *Clinical Cancer Research* 2007; 13(21): 6312-6319. (AMC)
294. Geiger TR, Peeper DS. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. *Cancer Res* 2007; 67: 6221-9. (NKI)
295. Geisberger R, Kiermayer C, Hömig C, Conrad M, Schmidt J, Zimmer-Strobl U, Brielmeier M. B- and T-cell-specific inactivation of thioredoxin reductase 2 does not impair lymphocyte development and maintenance. *Biol Chem* 2007; 388: 1083-90. (NKI)
296. Genden EM, Ferlito A, Silver CE, Jacobson AS, Werner JA, Suarez C, Leemans CR, Bradley PJ, Rinaldo A. Evolution of the management of laryngeal cancer. *Oral Oncol* 2007; 43(5): 431-439. (VUmc)
297. Genest PA, Borst P. Analysis of telomere length variation in Leishmania over time. *Mol Biochem Parasitol* 2007; 151: 213-5. (NKI)
298. Genest PA, Ter Riet B, Cijssouw T, van Luenen HGAM, Borst P. Telomeric localization of the modified DNA base J in the genome of the protozoan parasite Leishmania. *Nucleic Acids Res* 2007; 35: 2116-24. (NKI)
299. Gerard A, Mertens AE, van der Kammen RA, Collard JG. The Par polarity complex regulates Rap1- and chemokine-induced T cell polarization. *J Cell Biol* 2007; 176: 863-75. (NKI)
300. Gibcus JH, Menkema L, Mastik MF, Hermsen MA, de Bock GH, van Velthuysen MLF, Takes RP, Kok K, Alvarez Marcos CA, van der Laan BF, Van Den Brekel MWM, Langendijk JA, Kluin PM, van der Wal JE, Schuurin E. Amplicon mapping and expression profiling identify the fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. *Clin Cancer Res* 2007; 13: 6257-66. (NKI)
301. Gierman HJ, Indemans MHG, Koster J, Goetze S, Seppen J, Geerts D, van Driel R,

- Versteeg R. Domain-wide regulation of gene expression in the human genome. *Genome Research* 2007; 17(9): 1286-1295. (AMC)
302. Giles JT, Mease P, Boers M, Bresnihan B, Conaghan PG, Heald A, Maksymowych WP, Maillefert JF, Simon L, Tsuji W, Wakefield R, Woodworth T, Schumacher HR, Bingham CO, III. Assessing single joints in arthritis clinical trials. *J Rheumatol* 2007; 34(3): 641-647. (VUmc)
303. Gilijamse M, Leemans CR, Winters HA, Schulten EA, van der Waal I. Metastasizing ameloblastoma. *Int J Oral Maxillofac Surg* 2007; 36(5): 462-464. (VUmc)
304. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit H, van Meerbeeck J, Nankivell M, Parmar M, Pugh C, Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. *Lancet* 2007; 369: 1929-37. (NKI)
305. Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten V, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters GJ. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. *Br J Cancer* 2007; 96(5): 769-775. (VUmc)
306. Giovannetti E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G, Ricciardi S, del Tacca M, Danesi R. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. *Pharmacol Res* 2007; 55(4): 343-349. (VUmc)
307. Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, Wessels LA, van Laar R, van Krieken JH, Baars JW, Raemaekers J, Kluin PM, van't Veer LJ, de Jong D. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. *J Clin Oncol* 2007; 25: 390-8. (NKI)
308. Go AT, Visser A, Mulders MA, Blankenstein MA, van Vugt JM, Oudejans CBM. 44 SNPs expressed by placental RNA: Assessment for use in noninvasive prenatal diagnosis of trisomy 21. *Clin Chem* 2007; 53(12): 2223-2224. (VUmc)
309. Go AT, Visser A, Mulders MA, Twisk JW, Blankenstein MA, van Vugt JM, Oudejans CBM. C21ORF105, A chromosome 21-encoded mRNA, is not a discriminative marker gene for prediction of Down syndrome in maternal plasma. *Prenat Diagn* 2007; 27(2): 146-149. (VUmc)
310. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, Han KH, Speyer I, van der Lubbe PA, Seys PE, Breedveld FC, Dijkmans BAC. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). *Ann Rheum Dis* 2007; 66(9): 1227-1232. (VUmc)
311. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallée C, de Beus WM, de Sonnaville PB, Ewals JA, Breedveld FC, Dijkmans BA. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007; 146(6): 406-415. (VUmc)
312. Goetze S, Mateos-Langerak J, Gierman HJ, de Leeuw W, Giromus O, Indemans MHG, Koster J, Ondrej V, Versteeg R, van Driel R. The three-dimensional structure of human interphase chromosomes is related to the transcriptome map. *Molecular and Cellular Biology* 2007; 27(12): 4475-4487. (AMC)
313. Gok M, Coupe VM, Berkhof J, Verheijen RHM, Helmerhorst TJ, Hogewoning CJ, Snijders PJF, Meijer CJLM. HPV16 and increased risk of recurrence after treatment for CIN. *Gynecol Oncol* 2007; 104(2): 273-275. (VUmc)
314. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007; 2(8): 706-714. (VUmc)
315. Gómez-Gaviro M, Domínguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E, Fourie A, Tugores A, Valenzuela F, Mollinedo F, Sánchez-Madrid F, Díaz-González G. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. *J Immunol* 2007; 178: 8053-63. (NKI)
316. Gonzalez NC, Allen J, Blanco VG, Schmidt EJ, van Rooijen N, Wood JG. Alveolar macrophages are necessary for the systemic inflammation of acute alveolar hypoxia. *J Appl Physiol* 2007; 103(4): 1386-1394. (VUmc)
317. Goor KM, Peeters AJ, Mahieu HF, Langendijk JA, Leemans CR, Verdonck-de Leeuw IM, van Agthoven M. Cordectomy by CO2 laser or radiotherapy for small T1a glottic carcinomas: costs, local control, survival, quality of life, and voice quality. *Head Neck* 2007; 29(2): 128-136. (VUmc)
318. Goosens M, Smulders SA, Smeenk FW, Daniels-Gooszen AW, Donkers-van Rossum AB, Edelbroek MA, Huysmans DA, Michels AJ, van Straten BA, Postmus PE. Influence of introduction of positron emission tomography on adherence to mediastinal staging protocols and performance of mediastinoscopy. *J Oncol Pract* 2007; 3: 242-247. (VUmc)
319. Gosens MJ, van Krieken JH, Marijnen CA, Meershoek-Klein Kranenbarg E, Putter H, Rutten HJ, Bujko K, Van de Velde CJ, Nagtegaal ID. Improvement of staging by combining tumor and treatment parameters: the value for prognostication in rectal cancer. *Clin Gastroenterol Hepatol* 2007; 5: 997-1003. (NKI)

320. Graat HC, Carette JE, Schagen FHE, Vassilev LT, Gerritsen WR, Kaspers GJL, Wuisman PI, van Beusechem VW. Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. *Mol Cancer Ther* 2007; 6(5): 1552-1561. (VUmc)
321. Grande-Garcia A, Echarri A, de Rooij J, Alderson NB, Waterman-Storer CM, Valdivielso JM, Del Pozo MA. Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. *J Cell Biol* 2007; 177: 683-91. (NKI)
322. Gravas S, Laguna P, Kiemeny LALM, de La Rosette JJMCH. Durability of 30-minute high-energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: A study of 213 patients with and without urinary retention. *Urology* 2007; 69(5), 854-858. (AMC)
323. Gravas S, Melekos MD, Laguna MP, de La Rosette JJMCH. Evaluation of photoselective vaporization of the prostate. *Aging Health* 2007; 3(6): 723-730. (AMC)
324. Gray M, Palispis W, Popovich PG, van Rooijen N, Gupta R. Macrophage depletion alters the blood-nerve barrier without affecting Schwann cell function after neural injury. *J Neurosci Res* 2007; 85(4): 766-777. (VUmc)
325. Greil F, de Wit E, Bussemaker HJ, van Steensel B. HP1 controls genomic targeting of four novel heterochromatin proteins in *Drosophila*. *EMBO J* 2007; 26: 741-51. (NKI)
326. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Goktuna SI, Neuenhahn M, Fierer J, Paxian S, van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. *Cell* 2007; 130(5): 918-931. (VUmc)
327. Griekspoor A, Zwart W, Neefjes J, Michalides R. Visualizing the action of steroid hormone receptors in living cells. *Nucl Recept Signal* 2007; 5: e003. (NKI)
328. Gringhuis SI, den Dunnen JT, Litjens M, van Het HB, van Kooyk Y, Geijtenbeek TBH. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. *Immunity* 2007; 26(5): 605-616. (VUmc)
329. Groeneveld AB, Vandenbroucke-Grauls CMJE. One swallow does not make a summer: can herpes simplex virus-1 cause pneumonia and acute lung injury?. *Am J Respir Crit Care Med* 2007; 175(9): 865-866. (VUmc)
330. Groenvold M, Fayers PM, Petersen MA, Sprangers MAG, Aaronson NK, Mouridsen HT. Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. *Breast Cancer Res Treat* 2007; 103: 185-95. (NKI)
331. Grootenboers DA, Poortmans PM, Haas RLM. Radiotherapy preserves fingers in the management of subungual squamous cell carcinoma, obviating the need for amputation. *Radiother Oncol* 2007; 85: 473-6. (NKI)
332. Grootenhuis MA, de Boone J, van der Kooij AJ. Living with muscular dystrophy: health related quality of life consequences for children and adults. *Health and Quality of Life Outcomes* 2007; 5: 31. (AMC)
333. Grootenhuis MA, Koopman HM, Verrrips EGH, Vogels AGC, Last BF. Health-related quality of life problems of children aged 8-11 years with a chronic disease. *Developmental Neurorehabilitation* 2007; 10(1): 27-33. (AMC)
334. Grootenhuis MA, Mokkink LB, Lee van der JH, Offringa M, Praag van BMS, Heymans HSA. Omgang en gevolgen van chronische aandoeningen bij kinderen. *Tijdschrift voor Kindergeneeskunde* 2007; 75(4): 138-142. (AMC)
335. Guillou H, Lecureuil C, Anderson K, Suire S, Ferguson GJ, Ellson C, Gray A, Divecha N, Hawkins P, Stephens L. Use of the GRP1 PH domain as a tool to measure the relative levels of PtdIns(3,4,5)P3 through a protein-lipid overlay approach. *J Lipid Res* 2007; 48: 726-32. (NKI)
336. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BAC, Allaart CF, Lems WF. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. *Ann Rheum Dis* 2007; 66(11): 1508-1512. (VUmc)
337. Gulmans J, Vollenbroek-Hutten MM, Gemert-Pijnen JE, Van Harten WH. Evaluating quality of patient care communication in integrated care settings: a mixed method approach. *Int J Qual Health Care* 2007; 19: 281-8. (NKI)
338. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya EV, Merlino G. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. *Proc Natl Acad Sci U S A* 2007; 104: 10968-73. (NKI)
339. Ha M, Mabuchi K, Sigurdson AJ, Freedman DM, Linet MS, Doody MM, Hauptmann M. Smoking cigarettes before first childbirth and risk of breast cancer. *Am J Epidemiol* 2007; 166: 55-61. (NKI)
340. Haanen J, Schumacher T. Vaccine leads to memory loss [News and views]. *Nat Med* 2007; 13: 248-50. (NKI)
341. Haasbeek CJ, Lagerwaard FJ, Cuijpers JP, Slotman BJ, Senan S. Is adaptive treatment planning required for stereotactic radiotherapy of stage I non-small-cell lung cancer?. *Int J Radiat Oncol Biol Phys* 2007; 67(5): 1370-1374. (VUmc)
342. Hadithi M, Al-Toma A, Oudejans JJ, van Bodegraven AA, Mulder CJ, Jacobs M. The value of double-balloon enteroscopy in patients with

- refractory celiac disease. *Am J Gastroenterol* 2007; 102(5): 987-996. (VUmc)
343. Hadithi M, de Boer H, Meijer JW, Willekens F, Kerckhaert JA, Heijmans R, Pena AS, Stehouwer CD, Mulder CJ. Coeliac disease in Dutch patients with Hashimoto's thyroiditis and vice versa. *World J Gastroenterol* 2007; 13(11): 1715-1722. (VUmc)
344. Hadithi M, von Blomberg BME, Crusius JBA, Bloemena E, Kostense PJ, Meijer JW, Mulder CJ, Stehouwer CD, Pena AS. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. *Ann Intern Med* 2007; 147(5): 294-302. (VUmc)
345. Hage JJ, Karim RB, Laub DR, Sr. On the origin of pedicled skin inversion vaginoplasty: life and work of Dr Georges Burou of Casablanca. *Ann Plast Surg* 2007; 59: 723-9. (NKI)
346. Hage JJ. How capsizing, flipping, and flying of traditional knots can result in new endoscopic knots: A geometric review. *J Am Coll Surg* 2007; 205: 717-23. (NKI)
347. Hage JJ. Inversed, capsized, and flipped knots: Unravelling a geometrical tangle. *Knee Surg Sports Traumatol Arthrosc* 2007; 15: 1514-5. (NKI)
348. Hajdo-Milasinovic A, Ellenbroek SI, van Es S, van der Vaart B, Collard JG. Rac1 and Rac3 have opposing functions in cell adhesion and differentiation of neuronal cells. *J Cell Sci* 2007; 120: 555-66. (NKI)
349. Hallaert DYH, Spijker R, Jak M, Derks IAM, Alves NL, Wensveen FM, de Boer JP, de Jong D, Green SR, van Oers MHJ, Eldering E. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. *Cell death and differentiation* 2007; 14(11): 1958-1967. (AMC/NKI)
350. Hameyer D, Loonstra A, Eshkind L, Schmitt S, Antunes C, Groen A, Bindels E, Jonkers J, Krimpenfort P, Meuwissen R, Rijswijk L, Bex A, Berns A, Bockamp E. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. *Physiol Genomics* 2007; 31: 32-41. (NKI)
351. Hansen HR, Wolfs JL, Bruggemann L, Sommeijer DW, Bevers E, Hauer AD, Kuiper J, Spek CA, Spronk HMH, Reitsma PH, ten Cate H. Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice. *Blood Coagulation & Fibrinolysis* 2007; 18(7): 627-636. (AMC)
352. Hardenberg G, Planelles L, Schwarte CM, van Bostelen L, Le Huong T, Hahne M, Medema JP. Specific TLR ligands regulate APRIL secretion by dendritic cells in a PKR-dependent manner. *European Journal of Immunology* 2007; 37(10): 2900-2911. (AMC)
353. Harmsen S, Meijerman I, Beijnen JH, Schellens JHM. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. *Cancer Treat Rev* 2007; 33: 369-80. (NKI)
354. Hartog H, Wesseling J, Boezen HM, van der Graaf WTA. The insulin-like growth factor 1 receptor in cancer: Old focus, new future. *Eur J Cancer* 2007; 43: 1895-904. (NKI)
355. Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJL, Locatelli F, Noelle P, Polychronopoulou S, Ravindranath Y, Razzouk B et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. *Blood* 2007; 109(11): 4641-4647. (VUmc)
356. Hatzinger M, Langbein S, de la Rosette J, Sohn M, Aiken P. Die Nephropexie im Wandel der Zeit. Aspekte einer historischen Operationstechnik. *Urologe* 2007; 46(2): 166-169. (AMC)
357. Haupt R, Spinetta JJ, Ban I, Barr RD, Beck JD, Byrne J, Calaminus G, Coenen E, Chesler M, D'Angio GJ, Eiser C, Feldges A, Gibson F, Lackner H, Masera G, Massimo L, Magyarosy E, Otten J, Reaman G, Valsecchi MG, Veerman AJP, Penn A, Thorvildsen A, et al. Long term survivors of childhood cancer: cure and care The Erice statement. *Eur J Cancer* 2007; 43(12): 1778-1780. (VUmc)
358. Hayes MM, Peterse JL, Yavuz E, Vischer GH, Eusebi V. Squamous cell carcinoma in situ of the breast: a light microscopic and immunohistochemical study of a previously undescribed lesion. *Am J Surg Pathol* 2007; 31: 1414-9. (NKI)
359. Heemsbergen WD, Hoogeman MS, Witte MG, Peeters ST, Incrocci L, Lebesque JV. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. *Int J Radiat Oncol Biol Phys* 2007; 67: 1418-24. (NKI)
360. Heessen S, Fornerod M. The inner nuclear envelope as a transcription factor resting place. *EMBO Rep* 2007; 8: 914-9. (NKI)
361. Heideman DA, Waterboer T, Pawlita M, Delis-van Diemen P, Nindi I, Leijte JA, Bonfrer JMG, Horenblas S, Meijer CJ, Snijders PJ. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. *J Clin Oncol* 2007; 25: 4550-6. (NKI/VUmc)
362. Heijink DM, Kleibeuker JH, Jalving M, Boersma-Van Ek W, Koornstra JJ, Wesseling J, De Jong S. Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas. *Cell Oncol* 2007; 29: 409-19. (NKI)
363. Hekking LH, van den Born J. Feasibility of mesothelial transplantation during experimental peritoneal dialysis and peritonitis. *Int J Artif Organs* 2007; 30(6): 513-519. (VUmc)
364. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, Errami A, Schouten JP,

- Meijer CJLM, Snijders PJF, Steenbergen RDM. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. *Br J Cancer* 2007; 97(10): 1457-1464. (VUmc)
365. Henriksen JR, Lokke C, Hammero M, Geerts D, Versteeg R, Flaegstad T, Einvik C. Comparison of RNAi efficiency mediated by tetracycline-responsive H1 and U6 promoter variants in mammalian cell lines. *Nucleic Acids Research* 2007; 35(9): p.e67. (AMC)
366. Hermsen BB, Olivier RI, Verheijen RHM, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. *Br J Cancer* 2007; 96(9): 1335-1342. (NKI/VUmc)
367. Hermsen BB, Verheijen RHM, Menko FH, Gille JJ, van Uffelen K, Blankenstein MA, Meijer S, van Diest PJ, Kenemans P, von Mensdorff-Pouilly S. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. *Eur J Cancer* 2007; 43(10): 1556-1563. (VUmc)
368. Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RHM. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. *J Clin Oncol* 2007; 25(11): 1383-1389. (VUmc)
369. Hess CJ, Berkhof J, Denkers F, Ossenkoppele GJ, Schouten JP, Oudejans JJ, Waisfisz Q, Schuurhuis GJ. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. *J Clin Oncol* 2007; 25(10): 1209-1215. (VUmc)
370. Hilarius DL, Kloeg PH, Detmar SB, Muller MJ, Aaronson NK. Level of agreement between patient self-report and observer ratings of health-related quality of life communication in oncology. *Patient Educ Couns* 2007; 65: 95-100. (NKI)
371. Hilge M, Aelen J, Perrakis A, Vuister GW. Structural basis for Ca²⁺ regulation in the Na⁺/Ca²⁺ exchanger. *Ann N Y Acad Sci* 2007; 1099: 7-15. (NKI)
372. Hislop AD, Rensing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ. A CD8⁺ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. *J Exp Med* 2007; 204: 1863-73. (NKI)
373. Hoebbers FJP, Heemsbergen W, Balm AJM, van Zanten M, Schornagel JH, Rasch CRN. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. *Radiother Oncol* 2007; 84: 42-7. (NKI)
374. Hoekstra OS, de Langen AS, Smit EF. Mediastinal staging of NSCLC and 18FDG PET. *J Thorac Oncol* 2007; 2(8): 187-188. (VUmc)
375. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgerit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovinsky J, Russell A, Saag KG, Svensson B, Westhovens R, Zeidler H, Bijlsma JW. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis* 2007; 66(12): 1560-1567. (VUmc)
376. Holling TM, Bergevoet MW, Wilson L, van Eggermond MC, Schooten E, Steenbergen RDM, Snijders PJF, Jager MJ, van den Elsen PJ. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. *J Immunol* 2007; 179(8): 5317-5325. (VUmc)
377. Honeywell R, Laan AC, van Groenigen CJ, Strocchi E, Ruitter R, Giaccone G, Peters GJ. The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 847(2): 142-152. (VUmc)
378. Hooning MJ, Dorresteijn LD, Aleman BMP, Boogerd W, Klijn JG, van Leeuwen FE. Long-term risk of cardiovascular events in 10-year survivors of breast cancer. *J Natl Cancer Inst* 2007; 99: 365-75. (NKI)
379. Hospers GA, Punt CJA, Tesselaar ME, Cats A, Havenga K, Leer JWH, Marijnen CAM, Jansen EPM, Van Krieken HHJM, Wiggers T, Van De Velde CJH, Mulder NH. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. *Ann Surg Oncol* 2007; 14: 2773-9. (NKI)
380. Houtenbos I, Westers TM, Dijkhuis A, de Grijpl TD, Ossenkoppele GJ, van de Loosdrecht AA. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. *Clin Cancer Res* 2007; 13(1): 307-315. (VUmc)
381. Huang Y, Li Z, van Rooijen N, Wang N, Pang CP, Cui Q. Different responses of macrophages in retinal ganglion cell survival after acute ocular hypertension in rats with different autoimmune backgrounds. *Exp Eye Res* 2007; 85(5): 659-666. (VUmc)
382. Huertas-Perez JF, Heger M, Dekker H, Krabbe H, Lankelma J, Ariese F. Simple, rapid, and sensitive liquid chromatography-fluorescence method for the quantification of tranexamic acid in blood. *J Chromatogr A* 2007; 1157(1-2): 142-150. (VUmc)
383. Huisman A, Ploeger LS, Dullens HF, Jonges TN, BeliÛn JAM, Meijer GA, Poulin N, Grizzle WE, van Diest PJ. Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3-D by confocal laser scanning microscopy. *Prostate* 2007; 67(3): 248-254. (VUmc)
384. Huitink JM, Balm AJM, Keijzer C, Buitelaar DR. Awake fibrecapnic intubation in head and neck cancer patients with difficult airways: new findings

- and refinements to the technique. *Anaesthesia* 2007; 62: 214-9. (NKI)
385. Hulsebos TJM, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. *American Journal of Human Genetics* 2007; 80(4): 805-810. (AMC)
386. Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, de Esch IJP, Richel D, Wijtmans M. Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. *Journal of Medicinal Chemistry* 2007; 50(10): 2424-2431. (AMC)
387. Huvneers S, van den Bout I, Sonneveld P, Sancho A, Sonnenberg A, Danen EHJ. Integrin $\alpha 3$ controls activity and oncogenic potential of primed c-Src. *Cancer Res* 2007; 67: 2693-700. (NKI)
388. Idema S, Geldof AA, Dirven CM, van der Jagt M, Gerritsen WR, Vandertop WP, Lamfers MLM. Evaluation of adenoviral oncolytic effect on glioma spheroids by 18F-DG positron-emission tomography. *Oncol Res* 2007; 16(10): 471-477. (VUmc)
389. Idema S, Lamfers MLM, van Beusechem VW, Noske DP, Heukelom S, Moeniralm S, Gerritsen WR, Vandertop WP, Dirven CM. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. *J Gene Med* 2007; 9(12): 1046-1056. (VUmc)
390. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. *J Nucl Med* 2007; 48(1): 81-87. (VUmc)
391. Jacobs JW, de Nijs RN, Lems WF, Geusens PP, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BAC, Bijlsma JW. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. *J Rheumatol* 2007; 34(5): 1051-1057. (VUmc)
392. Jansen EPM, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M. Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. *Br J Cancer* 2007; 97: 712-6. (NKI)
393. Jansen EPM, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H, Verheij M, Cats A. A Phase I-II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric Cancer. *Int J Radiat Oncol Biol Phys* 2007; 69: 1424-8. (NKI)
394. Jansen EPM, Saunders MP, Boot H, Oppedijk V, Dubbelman R, Porritt B, Cats A, Stroom J, Valdes Olmos R, Bartelink H, Verheij M. Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys* 2007; 67: 781-5. (NKI)
395. Jansen RS, Rosing H, de Wolf CJ, Beijnen JH. Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007; 21: 4049-59. (NKI)
396. Jaspers MWM, van den Bos C, Heinen RC, Bakker PJM, Geenen MM, Kremer LC, van Leeuwen F, Caron HN. Development of a national protocol to screen Dutch cancer survivors on late cancer treatment effects. *International Journal of Medical Informatics* 2007; 76(4): 297-305. (AMC/NKI)
397. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer. *Int J Radiat Oncol Biol Phys* 2007; 69(3): 751-760. (VUmc)
398. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Unilateral versus bilateral irradiation in squamous cell head and neck cancer in relation to patient-rated xerostomia and sticky saliva. *Radiother Oncol* 2007; 85(1): 83-89. (VUmc)
399. Jensen RT, Niederle B, Mitry E, Ramage JK, Iler T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O'Connor JM, Pauwels S, Ppael G, Ahlman H, Arnold R, Bechstein WO, Cadiot G, Caplin M, Christ E, Chung D, Couvelard A, De Herder WW, Delle Fave G, Eriksson B, Falchetti A, Falconi M, Ferone D, Goretzki P, Hochhauser D, Hyrdel R, Jensen R, Kaltsas G, timur F, Kianmanesh R, Knapp W, Knigge UP, Komminoth P, rner M, Kos K, Kvols L, Kwekkeboom DJ, Lopes JM, Manfredi R, McNicol AM, Niederle B, Nikou G, Nilsson O, berg K, O'Toole D, Pauwels S, Pape UF, Pavel M, ckinge U, Ricke J, Rindi G, Ruzsniowski P, Salazar R, Sauvanet A, Scoazec JY, Sevilla Garcia MI, Taal B, Van Cutsem E, Vullierme MP, Wiedenmann B, Wildi S, Yao JC, ski S. Gastrinoma (duodenal and pancreatic). *Neuroendocrinology* 2007; 84: 173-82. (NKI)
400. Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Bechstein WO, Christ E, Taal BG, Knigge U, Ahlman H, Kwekkeboom DJ, O'Toole D. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). *Neuroendocrinology* 2006; 84: 165-72. (NKI)
401. Jiang X-G, Holsheimer J, Manola L, Wagner G, Wijkstra H, Knipscheer B, Meuleman EJH. Application of correlation techniques in the analysis of corpus cavernosum electromyographic signals. *Asian Journal of Andrology* 2007; 9(3): 369-376. (AMC)
402. Jiang X-G, Holsheimer J, Wagner G, Mulders P, Wijkstra H, Meuleman E. A reproducibility study of corpus cavernosum electromyography in young healthy volunteers under controlled conditions. *Journal of Sexual Medicine* 2007; 4(1): 183-190. (AMC)
403. Jimenez CR, El Filali Z, Knol JC, Li KW, Hoekman K, Kruyt FAE, Giaccone G, Smit AB.

- Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF mass spectrometry. *Prot Clin Applic* 2007; 1(6): 598-604. (VUmc)
404. Jimenez CR, Koel-Simmelink M, Pham TV, van der Voort L, Teunissen CE. Endogenous peptide profiling of cerebrospinal fluid by MALDI/TOF mass spectrometry: Optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. *Prot Clin Applic* 2007; 1(11): 1385-1392. (VUmc)
405. Jimenez CR, Piersma S, Pham TV. High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery. *Biomarkers in Medicine* 2007; 1(4): 541-565. (VUmc)
406. Jimenez CR. Mass spectrometry-based proteomics trends in tools and strategies. *Eur Pharm Revs* 2007; : 24-25. (VUmc)
407. Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van der Vijgh WJ, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JHM. Population pharmacokinetics and pharmacodynamics of Paclitaxel and Carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. *Clin Cancer Res* 2007; 13: 6410-8. (AMC/NKI/VUmc)
408. Joerger M, Huitema ADR, Huizing MT, Willemse PH, De Graeff A, Rosing H, Schellens JHM, Beijnen JH, Vermorken JB. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. *Br J Clin Pharmacol* 2007; 64: 622-33. (NKI)
409. Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. *Clinical Pharmacokinetics* 2007; 46(12): 1051-1068. (AMC/NKI)
410. Johansson M, Rocha N, Zwart W, Jordens I, Janssen L, Kuijl C, Oikkonen VM, Neefjes J. Activation of endosomal dynein motors by stepwise assembly of Rab7-RILP-p150Glued, ORP1L, and the receptor (beta)III spectrin. *J Cell Biol* 2007; 176: 459-71. (NKI)
411. Johansson M, Tan T, de Visser KE, Coussens LM. Immune cells as anti-cancer therapeutic targets and tools. *J Cell Biochem* 2007; 101: 918-26. (NKI)
412. Jong K, Marchiori E, van der Vaart A, Chin SF, Carvalho B, Tijssen M, Eijk PP, van den IJssel P, Grabsch H, Quirke P, Oudejans JJ, Meijer GA, Caldas C, Ylstra B. Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors. *Oncogene* 2007; 26(10): 1499-1506. (VUmc)
413. Jonker JW, Musters S, Vlaming ML, Plosch T, Gooijert KE, Hillebrand MJ, Rosing H, Beijnen JH, Verkade HJ, Schinkel AH. Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. *Am J Physiol Cell Physiol* 2007; 292: C2204-C2212. (NKI)
414. Jonkers J, Derksen PW. Modeling metastatic breast cancer in mice. *J Mammary Gland Biol Neoplasia* 2007; 12: 191-203. (NKI)
415. Jonkman A, Kaanders JH, Terhaard CH, Hoebbers FJ, van den Ende PL, Wijers OB, Verhoef LC, de Jong MAWP, Leemans CR, Langendijk JA. Multicenter validation of recursive partitioning analysis classification for patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. *Int J Radiat Oncol Biol Phys* 2007; 68(1): 119-125. (NKI/VUmc)
416. Joosse SA, van Beers EH, Nederlof PM. Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material. *BMC Cancer* 2007; 7: 43. (NKI)
417. Joosten J, Ruers T. Local radiofrequency ablation techniques for liver metastases of colorectal cancer. *Crit Rev Oncol Hematol* 2007; 62: 153-63. (NKI)
418. Jorritsma A, Gomez-Eerland R, Dokter M, van de Kastele W, Zoet YM, Doxiadis II, Rufer N, Romero P, Morgan RA, Schumacher TNM, Haanen JBAG. Selecting highly affine and well expressed TCRs for gene therapy of melanoma. *Blood* 2007; 110: 3564-72. (NKI)
419. Joshi U, Raijmakers PG, Riphagen II, Teule GJ, van Lingen A, Hoekstra OS. Attenuation-corrected vs nonattenuation-corrected 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in oncology: a systematic review. *Mol Imaging Biol* 2007; 9(3): 99-105. (VUmc)
420. Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, Fink K, Henrickson SE, Shayakhmetov DM, Di Paolo NC, van Rooijen N, Mempel TR, Whelan SP, von Andrian UH. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. *Nature* 2007; 450(7166): 110-114. (VUmc)
421. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Use of positron emission tomography for response assessment of lymphoma: consensus

of the Imaging Subcommittee of International Harmonization Project in Lymphoma. *J Clin Oncol* 2007; 25(5): 571-578. (VUmc)

422. Kaiserova H, Simunek T, van der Vijgh WJ, Bast A, Kvasnickova E. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. *Biochim Biophys Acta* 2007; 1772(9): 1065-1074. (VUmc)

423. Kalb R, Neveling K, Hoehn H, Schneider H, Linka Y, Batish SD, Hunt C, Berwick M, Callen E, Surrallles J, Casado JA, Bueren J, Dasi A, Soulier J, Gluckman E, Zwaan CM, van Spaendonk R, Pals G, de Winter JP, Joenje H, Grompe M, Auerbach AD, Hanenberg H et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. *Am J Hum Genet* 2007; 80(5): 895-910. (VUmc)

424. Kalverda B, Fornerod M. The nuclear life of nucleoporins. *Dev Cell* 2007; 13: 164-5. (NKI)

425. Kang SH, Kim GR, Seong M, Baek SH, Seol JH, Bang OS, Ova H, Tatsumi K, Komatsu M, Tanaka K, Chung CH. Two novel ubiquitin-fold modifier 1 (Ufm1)-specific Proteases, UfSP1 and UfSP2. *J Biol Chem* 2007; 282: 5256-62. (NKI)

426. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. *Blood* 2007; 110(10): 3540-3546. (VUmc)

427. Kartachova M, Van Zandwijk N, Burgers S, Van Tinteren H, Verheij M, Valdes Olmos RA. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. *J Clin Oncol* 2007; 25: 2534-9. (NKI)

428. Kaspers GJL, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. *Haematologica* 2007; 92(11): 1519-1532. (VUmc)

429. Kater AP, van Oers MHJ, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. *Blood* 2007; 110(8): 2811-2818. (AMC)

430. Keating E, Goncalves P, Lemos C, Costa F, Campos I, Smith SB, Bridges CC, Martel F. Progesterone inhibits folic acid transport in human trophoblasts. *J Membr Biol* 2007; 216(2-3): 143-152. (VUmc)

431. Kedde M, Strasser MJ, Boldajipour B, Vrieling JA, Slanchev K, le Sage C, Nagel R, Voorhoeve PM, van Duijse J, Orom UA, Lund AH, Perrakis A, Raz E, Agami R. RNA-Binding Protein Dnd1 Inhibits MicroRNA Access to Target mRNA. *Cell* 2007; 131: 1273-86. (NKI)

432. Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. *J Rheumatol* 2007; 34(3): 623-633. (VUmc)

433. Keijzer C, Perez RS, de Lange JJ. Detection of carbon monoxide production as a result of the interaction of five volatile anesthetics and desiccated soda lime with an electrochemical carbon monoxide sensor in an anesthetic circuit compared to gas chromatography. *J Clin Monit Comput* 2007; 21: 257-64. (NKI)

434. Keijzer C, Perez RSGM, de Lange JJ. Compound A and carbon monoxide production from sevoflurane and seven different types of carbon dioxide absorbent in a patient model. *Acta Anaesthesiol Scand* 2007; 51: 31-7. (NKI)

435. Keller AM, Groothuis TA, Veraar EAM, Marsman M, Wenniger LMDB, Janssen H, Neeffjes J, Borst J. Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. *Proc Natl Acad Sci U S A* 2007; 104: 5989-94. (NKI)

436. Kempers MJE, van der Sluijs Veer L, Nijhuis-van der Sanden RWG, Lanting CI, Kooistra L, Wiedijk BM, Last BF, de Vijlder JJM, Grootenhuys MA, Vulsma T. Neonatal screening for congenital hypothyroidism in the Netherlands: cognitive and motor outcome at 10 years of age. *Journal of Clinical Endocrinology and Metabolism* 2007; 92(3): 919-924. (AMC)

437. Kenemans P. Quality of life in breast cancer patients. *Gynecol Endocrinol* 2007; 23(7): 366-367. (VUmc)

438. Kennedy TC, McWilliams A, Edell E, Sutedja TG, Downie G, Yung R, Gazdar A, Mathur PN. Bronchial intraepithelial neoplasia/early central airways lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007; 132(3 Suppl): 221S-233S. (VUmc)

439. Kesisis G, Broxterman HJ, Giaccone G. Angiogenesis inhibitors Drug selectivity and target specificity. *Curr Pharm Des* 2007; 13(27): 2795-2809. (VUmc)

440. Kessler JH, Mullauer FB, de Roo GM, Medema JP. Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. *Cancer Letters* 2007; 251(1): 132-145. (AMC)

441. Ketema M, Wilhelmsen K, Kuikman I, Janssen H, Hodzic D, Sonnenberg A. Requirements for the localization of nesprin-3 at the nuclear envelope and its interaction with plectin. *J Cell Sci* 2007; 120: 3384-94 891. (NKI)

442. Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. *Transfusion* 2007; 47(9): 1725-1732. (VUmc)
443. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. *Cochrane Database Syst Rev* 2007; (1): CD006356. (VUmc)
444. Klaamas K, Kurtenkov O, von Mensdorff-Pouilly S, Shljapnikova L, Miljukhina L, Brjalin V, Lipping A. Impact of *Helicobacter pylori* infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. *Immunol Invest* 2007; 36(4): 371-386. (VUmc)
445. Klarenbeek BR, Veenhof AAFA, de Lange ESM, Bemelman WA, Bergamaschi R, Heres P, Lacy AM, van den Broek WT, van der Peet DL, Cuesta MA. The Sigma-trial protocol: a prospective double-blind multi-centre comparison of laparoscopic versus open elective sigmoid resection in patients with symptomatic diverticulitis. *BMC Surgery* 2007; 7: 16. (AMC)
446. Klein SK, Biemond BJ, van Oers MHJ. Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA). *Annals of Hematology* 2007; 86(12): 917-918. (AMC)
447. Klerk CPW, Overmeer RM, Niers TMH, Versteeg HH, Richel DJ, Buckle T, van Noorden CJF, van Tellingen O. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. *Biotechniques* 2007; 43(1 Suppl. S): 7-13, 30. (AMC)
448. Klerk CPW, Smorenburg SM, Spek CA, van Noorden CJF. Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation. *Journal of Cellular and Molecular Medicine* 2007; 11(3): 561-568. (AMC)
449. Klusmann JH, Reinhardt D, Hasle H, Kaspers GJL, Creutzig U, Hahlen K, van den Heuvel-Eibrink MM, Zwaan CM. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. *Leukemia* 2007; 21(7): 1584-1587. (VUmc)
450. Knijnenburg TA, de Winde JH, Daran JM, Daran-Lapujade P, Pronk JT, Reinders MJ, Wessels LFA. Exploiting combinatorial cultivation conditions to infer transcriptional regulation. *BMC Genomics* 2007; 8: 25. (NKI)
451. Knipp S, Hildebrand B, Kundgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. *Cancer* 2007; 110: 345-52. (NKI)
452. Knipscheer P, Sixma TK. Protein-protein interactions regulate Ubl conjugation. *Curr Opin Struct Biol* 2007; 17: 665-73. (NKI)
453. Knipscheer P, van Dijk WJ, Olsen JV, Mann M, Sixma TK. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. *EMBO J* 2007; 26: 2797-807. (NKI)
454. Knoester H, Grootenhuis MA, Bos AP. Outcome of paediatric intensive care survivors. *European Journal of Pediatrics* 2007; 166(11): 1119-1128. (AMC)
455. Knöll R, Postel R, Wang J, Krätzner R, Hennecke G, Vacaru AM, Vakeel P, Schubert C, Murthy K, Rana BK, Kube D, Il G, fer K, Hayashi T, Holm T, Kimura A, Schork N, Toliat MR, rnberg P, Schultheiss HP, Schaper W, Schaper J, Bos E, Hertog JD, Van Eeden FJM, Peters PJ, Hasenfuss G, Chien KR, Bakkers J. Laminin- α 4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. *Circulation* 2007; 116: 515-25. (NKI)
456. Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E, de Boer JP, Verheij M, van Ostrom C, de Vries A, van 't Veer L, de Jong D. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. *Blood* 2007; 110(4): 1116-1122. (AMC/NKI)
457. Kocak Z, Borst GR, Zeng J, Zhou S, Hollis DR, Zhang J, Evans ES, Folz RJ, Wong T, Kahn D, Belderbos JSA, Lebesque JV, Marks LB. Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis. *Int J Radiat Oncol Biol Phys* 2007; 67: 178-86. (NKI)
458. Kok HP, van den Berg CAT, van Haaren PMA, Crezee J. Artefacts in intracavitary temperature measurements during regional hyperthermia. *Physics in Medicine and Biology* 2007; 52(17): 5157-5171. (AMC)
459. Kok HP, van Haaren PMA, van de Kamer JB, Crezee J. Theoretical comparison of intraluminal heating techniques. *International Journal of Hyperthermia* 2007; 23(4): 395-411. (AMC)
460. Kolaczowska E, Lelito M, Kozakiewicz E, van Rooijen N, Plytycz B, Arnold B. Resident peritoneal leukocytes are important sources of MMP-9 during zymosan peritonitis: superior contribution of macrophages over mast cells. *Immunol Lett* 2007; 113(2): 99-106. (VUmc)
461. Kolkman RGM, Steenbergen W, van Leeuwen TG. Reflection mode photoacoustic measurement of speed of sound. *Optics Express* 2007; 15(6): 3291-3300. (AMC)
462. Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, Fayers P, Johnson C, Ramage J, Scott N, West K. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. *Eur J Cancer* 2007; 43: 1810-20. (NKI)
463. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A,

- Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. *Lancet* 2007; 370: 135-42. (NKI)
464. Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. *Cancer Letters* 2007; 256(2): 218-228. (AMC)
465. Koppen A, Ait-Aissa R, Koster J, van Sluis PG, Ora I, Caron HN, Volckmann R, Versteeg R, Valentijn LJ. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. *European Journal of Cancer* 2007; 43(16): 2413-2422. (AMC)
466. Korswagen L, Voerman HJ, Peterse JL. Ischemic duodenitis without involvement of the large abdominal arteries. *Endoscopy* 2007; 39: E271. (NKI)
467. Kosterink JG, McLaughlin PM, Lub-de Hooge MN, Hendrikse HH, van Zanten J, van Garderen E, Harmsen MC, de Leij LF. Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model. *J Immunol* 2007; 179(2): 1362-1368. (VUmc)
468. Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, Kammer W, Berkers CR, Burg D, Overkleef H, Ovaa H, Driessen C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. *Leukemia* 2007; 21: 84-92. (NKI)
469. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. *Breast Cancer Res* 2007; 9: R65. (NKI)
470. Kremer LCM, Cardous-Ubbink MC, Geenen MM, van Leeuwen FE, Caron HN. Health outcomes in long-term survivors of childhood cancer - Reply. *JAMA-Journal of the American Medical Association* 2007; 298(14): 1635-1636. (AMC)
471. Kreulen M, Smeulders MJC, Veeger HEJ, Hage JJ. Movement patterns of the upper extremity and trunk associated with impaired forearm rotation in patients with hemiplegic cerebral palsy compared to healthy controls. *Gait and Posture* 2007; 25: 485-92. (NKI)
472. Kriege M, Brekelmans CTM, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard APE, Tilanus-Linthorst MMA, Seynaeve C, Bartels CCM, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RAEM, De Koning HJ, Rutgers EJT, Klijn JGM. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. *Breast Cancer Res Treat* 2007; 102: 357-63. (NKI)
473. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J, Berns A. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. *Nature* 2007; 448: 943-6. (NKI)
474. Krishnadath KK. Novel findings in the pathogenesis of esophageal columnar metaplasia or Barrett's esophagus. *Current Opinion in Gastroenterology* 2007; 23(4): 440-445. (AMC)
475. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, Clarke AR, Van Leeuwen FWB, ndez-Benito V, Dantuma NP, Portis JL, Collinge J, Tabrizi SJ. Disease-Associated Prion Protein Oligomers Inhibit the 26S Proteasome. *Mol Cell* 2007; 26: 175-88. (NKI)
476. Kroon FH, van Beek GJ, van Damme PA. [Cranio-maxillofacial traumatology] Traumatologie van het aangezicht. *Ned Tijdschr Tandheelkd* 2007; 114: 23-33. (NKI)
477. Krstev S, Ji BT, Shu XO, Blair A, Zheng W, Lubin J, Vermeulen R, Haupfmann M, Rothman N, Gao YT, Mustafa D, Chow WH. Occupation and adult-onset asthma among Chinese women in a population-based cohort. *Ann Surg Oncol* 2007; 50: 265-73. (NKI)
478. Kruse JJ, Stewart FA. Gene expression arrays as a tool to unravel mechanisms of normal tissue radiation injury and prediction of response. *World J Gastroenterol* 2007; 13: 2669-74. (NKI)
479. Kruse JJCM, Bomhoff-Wijdenes IFM, Poele JAMT, Stewart FA. Fractalkine: An important candidate for directing periglomerular leukocyte accumulation in irradiated mouse kidneys. *Acta Oncol* 2007; 46: 945-50. (NKI)
480. Kuhlmann KFD, van Poll D, de Castro SMM, van Heck NT, Busch ORC, van Gulik TM, Obertop H, Gouma DJ. Initial and long-term outcome after palliative surgical drainage of 269 patients with malignant biliary obstruction. *EJSO : European Journal of Surgical Oncology* 2007; 33(6): 757-762. (AMC)
481. Kuhlmann KFD, van Tilt JWO, Boermeester MA, de Reuver PR, Tzvetanova ID, Offerhaus GJA, ten Kate FJW, Busch ORC, van Gulik TM, Gouma DJ, Crawford HC. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. *Cancer Epidemiology Biomarkers & Prevention* 2007; 16(5): 886-891. (AMC)
482. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Van Leeuwen FWB, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. *Blood* 2007; 110: 3281-90. (NKI)
483. Kuijli C, Savage ND, Marsman M, Tuin AW, Janssen L, Egan DA, Ketema M, van den

- Nieuwendijk R, van den Eeden SJF, Geluk A, Poot A, van der Marel G, Beijersbergen RL, Overkleef H, Ottenhoff THM, Neeffjes J. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. *Nature* 2007; 450: 725-30. (NKI)
484. Kuipers GK, Slotman BJ, Wedekind LE, Stoter TR, Berg J, Sminia P, Lafleur MVM. Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. *Int J Radiat Biol* 2007; 83(10): 677-685. (VUmc)
485. Kuipers HF, van den Elsen PJ. Immunomodulation by statins: inhibition of cholesterol vs isoprenoid biosynthesis. *Biomed Pharmacother* 2007; 61(7): 400-407. (VUmc)
486. Kumar KA, Garcia CR, Chandran VR, van Rooijen N, Zhou Y, Winzeler E, Nussenzweig V. Exposure of Plasmodium sporozoites to the intracellular concentration of potassium enhances infectivity and reduces cell passage activity. *Mol Biochem Parasitol* 2007; 156(1): 32-40. (VUmc)
487. Kummerlin Intan PED, Borrego J, Wink MH, van Dijk MM, Wijkstra H, de La Rosette JJMCH, Laguna MP. Nephron-sparing surgery and percutaneous biopsies in renal-cell carcinoma: a global impression among endourologists. *Journal of Endourology* 2007; 21(7): 709-713. (AMC)
488. Kunkler I, van Tienhoven G, Dixon M, Prescott R, Russell N, Canney P, Dunlop J. Postmastectomy radiotherapy should not be standard of care for women with 1-3 involved nodes. *Radiother Oncol* 2007; 84: 103-4. (NKI)
489. Kunst PW, Lee P, Paul MA, Senan S, Smit EF. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer. *J Thorac Oncol* 2007; 2(10): 912-915. (VUmc)
490. Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE, Schellens JH. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. *Clin Cancer Res* 2007; 13: 3276-85. (NKI)
491. Kuppens IELM, Witteveen PO, Schot M, Schuessler VM, Daehling A, Beijnen JH, Voest EE, Schellens JHM. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. *Invest New Drugs* 2007; 25: 227-35. (NKI)
492. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, Miljukhina L, Shljapnikova L, Chuzmarov V. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. *Acta Oncol* 2007; 46(3): 316-323. (VUmc)
493. Lagarde SM, ten Kate FJW, Richel DJ, Offerhaus GJA, van Lanschot JJB. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. *Annals of Surgical Oncology* 2007; 14(2): 977-991. (AMC)
494. Lagerveld BW, ter Wee RD, de La Rosette JJMCH, Spaan JAE, Wijkstra H. Vascular fluorescence casting and imaging cryomicrotomy for computerized three-dimensional renal arterial reconstruction. *BJU International* 2007; 100(2): 387-391. (AMC)
495. Lagerwaard FJ, Senan S. Lung cancer: intensity-modulated radiation therapy, four-dimensional imaging and mobility management. *Front Radiat Ther Oncol* 2007; 40: 239-252. (VUmc)
496. Lai C, Horlings HM, van de Vijver MJ, van Beers EH, Nederlof PM, Wessels LFA, Reinders MJT. SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets. *BMC Bioinformatics* 2007; 8: 422. (NKI)
497. Lamers-Kuijper E, Schwarz M, Rasch C, Mijnheer B. Intensity-modulated vs. conformal radiotherapy of parotid gland tumors: potential impact on hearing loss. *Med Dosim* 2007; 32: 237-45. (NKI)
498. Lamfers MLM, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van der Valk P, van Beusechem VW, Gerritsen WR, Vandertop WP, Dirven CM. Differential Effects of Combined Ad5- $\{\Delta\}$ 24RGD and Radiation Therapy in In vitro versus In vivo Models of Malignant Glioma. *Clin Cancer Res* 2007; 13(24): 7451-7458. (VUmc)
499. Lamme B, Boermeester MA, Straatsburg IH, van Buijtenen JM, Boerma D, Offerhaus GJA, Gouma DJ, van Gulik TM. Early versus late surgical drainage for obstructive pancreatitis in an experimental model. *British Journal of Surgery* 2007; 94(7): 849-854. (AMC)
500. Lange MM, den Dulk M, Bossema ER, Maas CP, Peeters KC, Rutten HJ, Klein Kranenburg E, Marijnen CA, Van de Velde CJ. Risk factors for faecal incontinence after rectal cancer treatment. *Br J Surg* 2007; 94: 1278-84. (NKI)
501. Langerak P, Nygren AO, Krijger PH, van den Berk PC, Jacobs H. A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification. *J Exp Med* 2007; 204: 1989-98. (NKI)
502. Langeslag M, Clark K, Moolenaar W, van Leeuwen F, Jalink K. Activation of TRPM7 Channels by Phospholipase C-coupled Receptor Agonists. *J Biol Chem* 2007; 282: 232-9. (NKI)
503. Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO, III, Hughes M, Altman D, Buyse M, Galbraith S, Wells G. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. *J Rheumatol* 2007; 34(3): 607-615. (VUmc)
504. Last BF, Stam H, Onland-van Nieuwenhuizen A-M, Grootenhuis MA. Positive effects of a psycho-educational group intervention for children

- with a chronic disease: first results. *Patient Education and Counseling* 2007; 65(1): 101-112. (AMC)
505. Le Pechoux C, Dunant A, Pignon JP, de Ruyscher D, Mornex F, Senan S, Casas F, Price A, Milleron B. Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. *J Clin Oncol* 2007; 25(7): e10-e11. (VUmc)
506. Le Sage C, Nagel R, Agami R. Diverse ways to control p27(Kip1) function: miRNAs come into play. *Cell Cycle* 2007; 6: 2742-9. (NKI)
507. Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafre SA, Farace MG, Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. *EMBO J* 2007; 26: 3699-708. (NKI)
508. Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, Kubicka S, Schirmacher P, Jonkers J, Rudolph KL. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. *Gastroenterology* 2007; 132: 1465-75. (NKI)
509. Lee P, Brokx HA, Postmus PE, Sutedja TG. Dual digital video-autofluorescence imaging for detection of pre-neoplastic lesions. *Lung Cancer* 2007; 58(1): 44-49. (VUmc)
510. Lee P, Sutedja TG. Lung cancer screening: has there been any progress? Computed tomography and autofluorescence bronchoscopy. *Curr Opin Pulm Med* 2007; 13(4): 243-248. (VUmc)
511. Leijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. *Eur Urol* 2007; 52: 488-94. (NKI)
512. Leijte JA, Kroon BK, Valdes Olmos RA, Nieweg OE, Horenblas S. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. *Eur Urol* 2007; 52: 170-7. (NKI)
513. Leijte JAP, Horenblas S. Inguinal Metastasis in Penile Cancer: Diagnosis and Management {A figure is presented}. *EAU-EBU Update Series* 2007; 5: 145-52. (NKI)
514. Leijte JAP, Horenblas S. Rebuttal from Authors re: Eric Wespes. The Management of Regional Lymph Nodes in Patients with Penile Carcinoma and Reliability of Sentinel Node Biopsy. *Eur Urol* 2007; 52: 15-6 and re: Vincenzo Ficarra and Antonio Galfano. Should the Dynamic Sentinel Node Biopsy (DSNB) be Considered the Gold Standard in the Evaluation of Lymph Node Status in Patients with Penile Carcinoma? *Eur Urol* 2007; 52: 20-1. (NKI)
515. Lemos C, Peters GJ, Jansen G, Martel F, Calhau C. Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds. *Eur J Nutr* 2007; 46(6): 329-336. (VUmc)
516. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. *Arthritis Rheum* 2007; 56(11): 3518-3522. (VUmc)
517. Leon X, Lopez M, Pineiro Z, Langendijk JA, Leemans CR, Quer M. External validation of a risk group defined by recursive partitioning analysis in patients with head and neck carcinoma treated with surgery and postoperative radiotherapy. *Head Neck* 2007; 29(9): 815-821. (VUmc)
518. Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, Zaccolo M, Jalink K, Li M, Nelson DJ, Schuetz JD, Naren AP. Spatiotemporal Coupling of cAMP Transporter to CFTR Chloride Channel Function in the Gut Epithelia. *Cell* 2007; 131: 940-51. (NKI)
519. Li J, Peters PJ, Bai M, Dai J, Bos E, Kirchhausen T, Kandror KV, Hsu VW. An ACAP1-containing clathrin coat complex for endocytic recycling. *J Cell Biol* 2007; 178: 453-64. (NKI)
520. Li L, McVety S, Younan R, Liang P, Du Sart D, Gordon PH, Hutter P, Hogervorst FBL, Chong G, Foulkes WD. Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC). *Hum Mutat* 2007; 27: a388. (NKI)
521. Li Y, Wessels LFA, de Ridder D, Reinders MJT. Classification in the presence of class noise using a probabilistic Kernel Fisher method. *Pattern Recognit* 2007; 40: 3349-57. (NKI)
522. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, Moats R, Berns A, Shi W, Zhou Z, Nikitin AY, Roy-Burman P. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. *Cancer Res* 2007; 67: 7525-33. (NKI)
523. Liedorp M, Sanchez E, van Hoogstraten I, von Blomberg BME, Barkhof F, Polman CH, Killestein J. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up. *J Neurol Neurosurg Psychiatry* 2007; 78(10): 1146-1148. (VUmc)
524. Ligthart-Melis GC, van de Poll MC, Dejong CH, Boelens PG, Deutz NE, van Leeuwen PAM. The route of administration (enteral or parenteral) affects the conversion of isotopically labeled L-[2-15N]glutamine into citrulline and arginine in humans. *JPEN J Parenter Enteral Nutr* 2007; 31(5): 343-348. (VUmc)
525. Lindeboom JA, Kuijper CF, van Furth M. Inguinal lymphadenitis caused by mycobacterium haemophilum in an immunocompetent child. *Pediatr Infect Dis J* 2007; 26(1): 84-86. (VUmc)
526. Lindeboom JA, Mathura KR, Aartman IH, Kroon FH, Milstein DM, Ince C. Influence of the

- application of platelet-enriched plasma in oral mucosal wound healing. *Clin Oral Implants Res* 2007; 18: 133-9. (NKI)
527. Lindqvist A, Van Zon W, Rosenthal CK, Wolthuis RMF. Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. *PLoS Biol* 2007; 5: e123; 1127-1137. (NKI)
528. Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, Yan Z, Xue Y, Oostra AB, Auerbach AD, Hoatlin ME, Schindler D, Joenje H, de Winter JP, Takata M, Meetei AR, Wang W. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. *EMBO J* 2007; 26(8): 2104-2114. (VUmc)
529. Linn SC, Jonkers J. Treating the genetic make-up of breast cancer: a new fashion? *Expert Rev Anticancer Ther* 2007; 7: 1065-7. (NKI)
530. Linssen C, Schook RM, The AM, Lammers E, Festen JM, Postmus PE. A web site on lung cancer: who are the users and what are they looking for?. *J Thorac Oncol* 2007; 2(9): 813-818. (VUmc)
531. Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. *Proc Natl Acad Sci U S A* 2007; 104: 12111-6. (NKI)
532. Ljumanovic R, Langendijk JA, van Waddingen M, Schenk B, Knol DL, Leemans CR, Castelijns JA. MR imaging predictors of local control of glottic squamous cell carcinoma treated with radiation alone. *Radiology* 2007; 244(1): 205-212. (VUmc)
533. Ljumanovic R, Pouwels PJ, Langendijk JA, Knol DL, van der Valk P, Leemans CR, Castelijns JA. Has the degree of contrast enhancement with MR imaging in laryngeal carcinoma added value to anatomic parameters regarding prediction of response to radiation therapy?. *AJNR Am J Neuroradiol* 2007; 28(8): 1540-1546. (VUmc)
534. Lo Galbo AM, de Bree R, Kuik DJ, Lips PT, Mary B, von Blomberg BME, Langendijk JA, Leemans CR. The prevalence of hypothyroidism after treatment for laryngeal and hypopharyngeal carcinomas: are autoantibodies of influence?. *Acta Oto-Laryngol* 2007; 127(3): 312-317. (VUmc)
535. Lont AP, Kroon BK, Gallee MP, Van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. *J Urol* 2007; 177: 947-52. (NKI)
536. Loonen MP, Hage JJ, Kon M. Bibliographic characteristics of plastic surgeons in The Netherlands: a 55-year survey. *J Plast Reconstr Aesthet Surg* 2007; 60: 1067-73. (NKI)
537. Loonen MP, Hage JJ, Kon M. Publications of plastic surgery research 1972 through 2004: a longitudinal trend analysis of three international journals. *J Plast Reconstr Aesthet Surg* 2007; 60: 934-45. (NKI)
538. Loonen MP, Hage JJ, Kon M. Value of citation numbers and impact factors for analysis of plastic surgery research. *Plast Reconstr Surg* 2007; 120: 2082-91. (NKI)
539. Lorenz KJ, Groll K, Ackerstaff AH, Hilgers FJM, Maier H. Hands-free speech after surgical voice rehabilitation with a Provox voice prosthesis: Experience with the Provox FreeHands HME tracheostoma valver system. *Eur Arch Otorhinolaryngol* 2007; 264: 151-7. (NKI)
540. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. *J Clin Oncol* 2007; 25: 3144-50. (NKI)
541. Los A, de Widt J, Topham M, van Blitterswijk W, Divecha N. Protein kinase C inhibits binding of diacylglycerol kinase-[zeta] to the retinoblastoma protein. *Biochim Biophys Acta (MCR)* 2007; 1773: 352-7. (NKI)
542. Lo-Ten-Foe JR, de Smet AM, Diederem BM, Kluytmans JA, van Keulen PH. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant *Enterobacter cloacae* and *Acinetobacter baumannii* strains. *Antimicrob Agents Chemother* 2007; 51(10): 3726-3730. (VUmc)
543. Louwe RJ, Wendling M, Van Herk MB, Mijnheer BJ. Three-dimensional heart dose reconstruction to estimate normal tissue complication probability after breast irradiation using portal dosimetry. *Med Phys* 2007; 34: 1354-63. (NKI)
544. Lubin JH, Alavanja MC, Caporaso N, Brown LM, Brownson RC, Field RW, Garcia-Closas M, Hartge P, Hauptmann M, Hayes RB, Kleinerman R, Kogevinas M, Krewski D, Langholz B, Letourneau EG, Lynch CF, Malats N, Sandler DP, Schaffrath-Rosario A, Schoenberg JB, Silverman DT, Wang Z, Wichmann HE, Wilcox HB, Zielinski JM. Cigarette smoking and cancer risk: modeling total exposure and intensity. *Am J Epidemiol* 2007; 166: 479-89. (NKI)
545. Lundberg P, Welander PV, Edwards CK, III, van Rooijen N, Cantin E. Tumor necrosis factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encephalitis independently of signaling via TNF receptor 1 or 2. *J Virol* 2007; 81(3): 1451-1460. (VUmc)
546. Luo JM, Cen LP, Zhang XM, Chiang SW, Huang Y, Lin D, Fan YM, van Rooijen N, Lam DS, Pang CP, Cui Q. PI3K/akt, JAK/STAT and MEK/ERK pathway inhibition protects retinal ganglion cells

- via different mechanisms after optic nerve injury. *Eur J Neurosci* 2007; 26(4): 828-842. (VUmc)
547. Maas KW, El Sharouni SY, Smit EF, Schramel FM. Sequencing chemotherapy, radiotherapy and surgery in combined modality treatment of stage III nonsmall cell lung cancer. *Curr Opin Pulm Med* 2007; 13(4): 297-304. (VUmc)
548. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten H, Boonstra H, Aaronson NK. Predictors of prophylactic bilateral salpingo-oophorectomy versus hynecological screening uptake in BRCA1/2 mutation carriers. *J Clin Oncol* 2007; 25: 301-7. (NKI)
549. Maher JM, Dieter MZ, Aleksunes LM, Slitt AL, Guo G, Tanaka Y, Scheffer GL, Chan JY, Manautou JE, Chen Y, Dalton TP, Yamamoto M, Klaassen CD. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. *Hepatology* 2007; 46(5): 1597-1610. (VUmc)
550. Maksymowych WP, Landewe R, Boers M, Garnero P, Geusens P, El-Gabalawy H, Heinegard D, Kraus VB, Lohmander S, Matyas J, Saxne T, van der Heijde D. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. *J Rheumatol* 2007; 34(3): 634-640. (VUmc)
551. Mallant M, Hadithi M, Al-Toma AB, Kater M, Jacobs M, Manoliu R, Mulder C, van Waesberghe JH. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. *World J Gastroenterol* 2007; 13(11): 1696-1700. (VUmc)
552. Manohar S, Vaartjes SE, van Hespden JCG, Klaase JM, van den Engh FM, Steenberg W, van Leeuwen TG. Initial results of in vivo non-invasive cancer imaging in the human breast using near-infrared photoacoustics. *Optics Express* 2007; 15(19): 12277-12285. (AMC)
553. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). *Oncologist* 2007; 12: 927-41. (NKI)
554. Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JHM. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. *Mol Cancer Ther* 2007; 6: 3307-13. (NKI)
555. Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. *Br J Cancer* 2007; 97: 577-81. (NKI)
556. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. *European Journal of Haematology* 2007; 78(Suppl. 67): 5-14. (AMC)
557. Margadant C, van Opstal A, Boonstra J. Focal adhesion signaling and actin stress fibers are dispensable for progression through the ongoing cell cycle. *J Cell Sci* 2007; 120: 66-76. (NKI)
558. Marijnen CA. External beam radiotherapy and high dose rate brachytherapy for medically unfit and elderly patients. *Clin Oncol (R Coll Radiol)* 2007; 19: 706-10. (NKI)
559. Masztalerz A, Zeelenberg I, Wijnands Y, de Bruijn R, Drager A, Janssen H, Roos E. Synaptotagmin 3 deficiency in T cells impairs recycling of the chemokine receptor CXCR4 and thereby inhibits CXCL12 chemokine-induced migration. *J Cell Sci* 2007; 120: 219-28. (NKI)
560. Maurice-Stam H, Grootenhuis MA, Brons PPT, Caron HN, Last BF. Psychosocial indicators of health-related quality of life in children with cancer 2 months after end of successful treatment. *Journal of Pediatric Hematology Oncology* 2007; 29(8): 540-550. (AMC)
561. Maurice-Stam H, Grootenhuis MA, Caron HN, Last BF. Course of life of survivors of childhood cancer is related to quality of life in young adulthood. *Journal of Psychosocial Oncology* 2007; 25(3): 43-58. (AMC)
562. Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. *Int J Cancer* 2007; 120(12): 2609-2612. (VUmc)
563. McDermott LN, Wendling M, Sonke JJ, van Herk M, Mijnheer BJ. Replacing pretreatment verification with in vivo EPID dosimetry for prostate IMRT. *Int J Radiat Oncol Biol Phys* 2007; 67: 1568-77. (NKI)
564. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klusman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. *Blood* 2007; 109(3): 1185-1192. (VUmc)
565. McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T, Green J, van Egmond M, Leusen JH, Lazarou M, van de Winkel J, Jones TS, Crabb BS, Holder AA, Pleass RJ. The importance of human FcγRI in mediating protection to malaria. *PLoS Pathog* 2007; 3(5): e72. (VUmc)
566. Mebius RE. Lymphoid organogenesis: Educating stroma. *Immunol Cell Biol* 2007; 85(2): 79-80. (VUmc)
567. Mebius RE. Vitamins in control of lymphocyte migration. *Nat Immunol* 2007; 8(3): 229-230. (VUmc)

568. Meijer GA. The 13th Fanconi anemia gene identified: FANCI--importance of the 'Fanconi anemia pathway' for cellular oncology. *Cell Oncol* 2007; 29(3): 181-182. (VUmc)
569. Meijerink MR, van Crujjsen H, Hoekman K, Kater M, van Schaik C, van Waesberghe JH, Giaccone G, Manoliu RA. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. *Eur Radiol* 2007; 17(7): 1700-1713. (VUmc)
570. Meijerman I, Sanderson LM, Smits PH, Beijnen JH, Schellens JHM. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. *Drug Metab Rev* 2007; 39: 45-60. (NKI)
571. Meijnen P, Bartelink H. Multifocal ductal carcinoma in situ of the breast: a contraindication for breast-conserving treatment? *J Clin Oncol* 2007; 25: 5548-9. (NKI)
572. Meijnen P, Oldenburg HSA, Loo CE, Nieweg OE, Peterse JL, Rutgers EJ. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. *Br J Surg* 2007; 94: 952-6. (NKI)
573. Meinhardt W. Sentinel Node Evaluation in Prostate Cancer{A figure is presented}. *EAU-EBU Update Series* 2007; 5: 223-31. (NKI)
574. Meleti M, Leemans CR, Mooi WJ, van der Waal I. Oral malignant melanoma: the amsterdam experience. *J Oral Maxillofac Surg* 2007; 65(11): 2181-2186. (VUmc)
575. Meleti M, Leemans CR, Mooi WJ, Vescovi P, van der Waal I. Oral malignant melanoma: a review of the literature. *Oral Oncol* 2007; 43(2): 116-121. (VUmc)
576. Meleti M, Mooi WJ, Casparie MK, van der Waal I. Melanocytic nevi of the oral mucosa - no evidence of increased risk for oral malignant melanoma: an analysis of 119 cases. *Oral Oncol* 2007; 43(10): 976-981. (VUmc)
577. Menendez-Benito V, Neefjes J. Autophagy in MHC class II presentation: sampling from within. *Immunity* 2007; 26: 1-3. (NKI)
578. Meuleman E, Jiang X, Holsheimer J, Wagner G, Knipscheer B, Wijkstra H. Corpus cavernosum electromyography with revised methodology: an explorative study in patients with erectile dysfunction and men with reported normal erectile function. *Journal of Sexual Medicine* 2007; 4(1): 191-198. (AMC)
579. Meyer S, Tefsen B, Imberty A, Geyer R, van Die IM. The C-type lectin L-SIGN differentially recognizes glycan antigens on egg glycosphingolipids and soluble egg glycoproteins from *Schistosoma mansoni*. *Glycobiology* 2007; 17(10): 1104-1119. (VUmc)
580. Michels E, Vandesompele J, de Preter K, Hoebeek J, Vermeulen J, Schramm A, Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, de Paepe A, Versteeg R, Eggert A, Laureys G, van Roy N, Speleman F. ArrayCGH-based classification of neuroblastoma into genomic subgroups. *Genes Chromosomes & Cancer* 2007; 46(12): 1098-1108. (AMC)
581. Milano F, Rygiel AM., Buttar N, Bergman JJGHM., Sondermeijer C, van Baal JWPM., ten Brinke A, Kapsenberg M, van Ham SM, Peppelenbosch MP, Krishnadath KK. An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. *Cancer Immunology Immunotherapy* 2007; 56(12): 1967-1977. (AMC)
582. Milano F, van Baal JWPM, Buttar NS, Rygiel AM, de Kort F, DeMars CJ, Rosmolen WD, Bergman JJGHM, van Marle J, Wang KK, Peppelenbosch MP, Krishnadath KK. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. *Gastroenterology* 2007; 132(7): 2412-2421. (AMC)
583. Milano F, van Baal JWPM, Rygiel AM, Bergman JJGHM, van Deventer SJH, Kapsenberg ML, Peppelenbosch MP, Krishnadath KK. An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+monocytes. *Journal of Immunological Methods* 2007; 321(1-2): 94-106. (AMC)
584. Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rodel C, Schoenberg M, Shipley W. Radiotherapy for bladder cancer. *Urology* 2007; 69: 80-92. (NKI)
585. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, Van De Vijver M, Massague J. Lung metastasis genes couple breast tumor size and metastatic spread. *Proc Natl Acad Sci U S A* 2007; 104: 6740-5. (NKI)
586. Missotten GS, Korse CM, van Dehn C, Linders TC, Keunen JE, Jager MJ, Bonfrer JM. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. *Tumour Biol* 2007; 28: 63-9. (NKI)
587. Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson BC, Milosevic M, Lo KW, van Rooijen N, Busson P, Bastianutto C, Liu FF. Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. *Mol Ther* 2007; 15(5): 921-929. (VUmc)
588. Mochtar CA, Kauer PC, Laguna MP, de la Rosette JJMCH. Urinary leakage after laparoscopic radical prostatectomy: a systematic review. *Journal of Endourology* 2007; 21(11): 1371-1379. (AMC)
589. Mokkink LB, van der Lee JH, Grootenhuys MA, Offringa M, Praag van BMS, Heymans HSA. Sociaal-maatschappelijke gevolgen en kwaliteit van leven in Nederland bij kinderen en jongvolwassenen opgegroeid met een chronische aandoening. *Tijdschrift voor Kindergeneeskunde* 2007; 75(04): 229-235. (AMC)
590. Mokkink LB, van der Lee JH, Grootenhuys MA, Offringa M, Praag van BMS, Heymans HSA.

- Omvang en gevolgen van chronische aandoeningen bij kinderen. Tijdschrift voor Kindergeneeskunde 2007; 75(4): 138-142. (AMC)
591. Mol AJ, Geldof AA, Meijer GA, van der Poel HG, van Moorselaar RJ. New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration. J Cancer Res Clin Oncol 2007; 133: 687-95. (NKI/VUmc)
592. Molenaar S, Sprangers M, Oort F, Rutgers E, Luiten E, Mulder J, van Meeteren M, de Haes H. Exploring the black box of a decision aid: what information do patients select from an interactive Cd-Rom on treatment options in breast cancer? Patient Educ Couns 2007; 65: 122-30. (NKI)
593. Molenkamp BG, Sluijter BJ, Oosterhof B, Meijer S, van Leeuwen PAM. Non-radical diagnostic biopsies do not negatively influence melanoma patient survival. Ann Surg Oncol 2007; 14(4): 1424-1430. (VUmc)
594. Molenkamp BG, van Leeuwen PAM, Meijer S, Sluijter BJ, Wijnands PG, Baars A, van den Eertwegh AJM, Scheper RJ, de Gruijl TD. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007; 13(10): 2961-2969. (VUmc)
595. Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJLM, van den Eertwegh AJM, Scheper RJ, von Blumberg BME, Bontkes HJ. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007; 121(8): 1749-1755. (VUmc)
596. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, von Blumberg BME, Scheper RJ, van den Eertwegh AJM. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007; 25(7): 862-868. (VUmc)
597. Molling JW, Moreno M, van der Vliet HJ, von Blumberg BME, van den Eertwegh AJM, Scheper RJ, Bontkes HJ. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J Immunol Methods 2007; 322(1-2): 70-81. (VUmc)
598. Mols F, Aaronson NK, Vingerhoets AJ, Coebergh JW, Vreugdenhil G, Lybeert ML, van de Poll-Franse LV. Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer 2007; 109: 1659-67. (NKI)
599. Molthoff CFM, Klabbers BM, Berkhof J, Felten JT, van Gelder M, Windhorst AD, Slotman BJ, Lammertsma AA. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT). Mol Imaging Biol 2007; 9(6): 340-347. (VUmc)
600. Monnikhof EM, Elias SG, Vlems FA, van der Tweel I, Schuit AJ, Voskuil DW, van Leeuwen FE. Physical Activity and Breast Cancer: A Systematic Review. Epidemiology 2007; 18: 137-57. (NKI)
601. Mooij MJ, Drenkard E, Llamas MA, Vandembroucke-Grauls CMJE, Savelkoul PHM, Ausubel FM, Bitter W. Characterization of the integrated filamentous phage Pf5 and its involvement in small-colony formation. Microbiology 2007; 153(Pt 6): 1790-1798. (VUmc)
602. Mook S, van't Veer LJ, Rutgers EJT, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using mammaprint?: From development to the MINDACT trial. Cancer Genomics Proteomics 2007; 4: 147-56. (NKI)
603. Moons LMG, Kuipers EJ, Rygiel AM, Groothuismink AZM, Geldof H, Bode WA, Krishnadath KK, Bergman JJGHM, van Vliet AHM, Siersema PD, Kusters JG. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. American Journal of Gastroenterology 2007; 102(11): 2373-2379. (AMC)
604. Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Eur J Cancer 2007; 43: 331-40. (NKI)
605. Moran JM, Balter JM, Ben David MA, Marsh RB, van Herk M, Pierce LJ. Short-term displacement and reproducibility of the breast and nodal targets under active breathing control. Int J Radiat Oncol Biol Phys 2007; 68: 541-6. (NKI)
606. Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RHM, von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2007; 257(1): 47-55. (VUmc)
607. Morre SA, Catsburg A, de Boer M, Spaargaren J, de Vries HJ, Schirm J, Savelkoul PHM, van Steenberghe J, Swaan C. Monitoring the potential introduction of the Swedish Chlamydia trachomatis variant (swCT) in the Netherlands. Euro Surveill 2007; 12(10): E9-E10. (VUmc)
608. Moshaver B, van der Pol MA, Westra AH, Ossenkuppele GJ, Zweegman S, Schuurhuis GJ. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk Lymphoma 2007; : 1-15. (VUmc)
609. Mott K, Brick DJ, van Rooijen N, Ghiasi H. Macrophages are important determinants of acute ocular HSV-1 infection in immunized mice. Invest Ophthalmol Vis Sci 2007; 48(12): 5605-5615. (VUmc)
610. Mulier S, Ni Y, Frich L, Burdío F, Denys AL, de Wispelaere J-F, Dupas B, Habib N, Hoey M,

- Jansen MC, Lacrosse M, Leveillee R, Miao Y, Mulier P, Mutter D, Ng KK, Santambrogio R, Stippel D, Tamaki K, van Gulik TM, Marchal G, Michel L. Experimental and clinical radiofrequency ablation: proposal for standardized description of coagulation size and geometry. *Annals of Surgical Oncology* 2007; 14(4): 1381-1396. (AMC)
611. Muncan V, Faro A, Haramis APG, Hurlstone A, Wienholds E, van Es J, Korving J, Begthel H, Zivkovic D, Clevers H. T-cell factor 4 (Tcf712) maintains proliferative compartments in zebrafish intestine. *EMBO Rep* 2007; 8: 966-73. (NKI)
612. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, Esposito G, Delucchi F, Arcarese M, Alvarez R, Siddiqi S, Emmanuel GN, Wu W, Fischer K, Martindale JJ, Glembotski CC, Leri A, Kajstura J, Magnuson N, Berns A, Beretta RM, Houser SR, Schaefer EM, Anversa P, Sussman MA. Pim-1 regulates cardiomyocyte survival downstream of Akt. *Nat Med* 2007; 13: 1467-75. (NKI)
613. Muris JJ, Ylstra B, Cillessen SA, Ossenkoppele GJ, Kluin-Nelemans JC, Eijk PP, Nota B, Tijssen M, de Boer WP, van de Wiel MA, van den IJssel P, Jansen P, de Bruin PC, van Krieken JH, Meijer GA, Meijer CJLM, Oudejans JJ. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. *Br J Haematol* 2007; 136(1): 38-47. (VUmc)
614. Musat E, Poortmans P, Van den Bogaert W, Struikmans H, Fourquet A, Bartelink H, Kirkove C, Budach V, Pierart M, Collette L. Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. *Eur J Cancer* 2007; 43: 718-24. (NKI)
615. Musschenga AW, Van Luijn HE, Keus RB, Aaronson NK. Are risks and benefits of oncological research protocols both incommensurable and uncompensable? *Account Res* 2007; 14: 179-96. (NKI)
616. Mutsaerts E, Zoetmulder F, Hart A, van Coevorden F. Perioperative morbidity in hepatic surgery. *Hepatogastroenterology* 2007; 54: 458-62. (NKI)
617. Nabatov AA, Masharsky AE, Verevchkin SV, Emelyanov AV, Lukashov VV, Heimer R, Ryder RW, Goudsmit J, Kozlov AP. The rate of epidemiological and virological changes during the transition from nascent to concentrated HIV epidemic stage in the former Soviet Union countries. *AIDS Res Hum Retroviruses* 2007; 23(2): 183-192. (VUmc)
618. Nabatov AA, Pollakis G, Linnemann T, Paxton WA, de Baar MP. Statins disrupt CCR5 and RANTES expression levels in CD4+ T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1. *PLoS ONE* 2007; 2(5): e470. (VUmc)
619. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong Jr, Hollema H, Brouwers AH, van Dongen GAMS, Perk LR, Lub-de Hooge MN. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. *J Nucl Med* 2007; 48(8): 1313-1319. (VUmc)
620. Nagtegaal ID, Gosens MJ, Marijnen CA, Rutten HJ, Van de Velde CJ, van Krieken JH. Combinations of tumor and treatment parameters are more discriminative for prognosis than the present TNM system in rectal cancer. *J Clin Oncol* 2007; 25: 1647-50. (NKI)
621. Naik SH, Sathe P, Park HY, Metcalf D, Proietto AI, Dakic A, Carotta S, O'Keefe M, Bahlo M, Papenfuss A, Kwak JY, Wu L, Shortman K. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. *Nat Immunol* 2007; 8: 1217-26. (NKI)
622. Neijssen J, Pang B, Neefjes J. Gap junction-mediated intercellular communication in the immune system. *Prog Biophys Mol Biol* 2007; 94: 207-18. (NKI)
623. Nestor M, Ekberg T, Dring J, van Dongen GAMS, Wester K, Tolmachev V, Anniko M. Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay. *Tumour Biol* 2007; 28(5): 253-263. (VUmc)
624. Nguyen K, van Die IM, Grundahl KM, Kawar ZS, Cummings RD. Molecular cloning and characterization of the *Caenorhabditis elegans* alpha1,3-fucosyltransferase family. *Glycobiology* 2007; 17(6): 586-599. (VUmc)
625. Nicassio F, Corrado N, Vissers JHA, Areces LB, Bergink S, Marteijn JA, Geverts B, Houtsmuller AB, Vermeulen W, Di Fiore PP, Citterio E. Human USP3 Is a Chromatin Modifier Required for S Phase Progression and Genome Stability. *Current Biology* 2007; 17: 1972-7. (NKI)
626. Niers TMH, Klerk CPW, DiNisio M, van Noorden CJF, Buller HR, Reitsma PH, Richel DJ. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. *Critical Reviews in Oncology hematology* 2007; 61(3): 195-207. (AMC)
627. Nieweg OE. [Critical remarks regarding guidelines based on scientific research] Kanttekeningen bij op wetenschappelijk onderzoek gebaseerde richtlijnen. *Ned Tijdschr Geneesk* 2007; 151: 1272-5. (NKI)
628. Nijsten SM, Mijnheer BJ, Dekker AL, Lambin P, Minken AW. Routine individualised patient dosimetry using electronic portal imaging devices. *Radiother Oncol* 2007; 83: 65-75. (NKI)
629. Nijsten SM, van Elmpt WJ, Jacobs M, Mijnheer BJ, Dekker AL, Lambin P, Minken AW. A global calibration model for a-Si EPIDs used for transit dosimetry. *Med Phys* 2007; 34: 3872-84. (NKI)
630. Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, Sevilla Garcia MI, Knapp WH, timur F, Sauvanet A, Pauwels S, Kwekkeboom DJ, Caplin M, Ahlman H, Arnold R, Bechstein WO, Cadiot G, Christ E, Chung D, Couvelard A, De

- Herder WW, Delle Fave G, Eriksson B, Falchetti A, Falconi M, Ferone D, Goretzki P, Gross D, Hochhauser D, Hyrdel R, Jensen R, Kaltsas G, Kianmanesh R, Knigge UP, Komminoth P, rner M, Kos K, Kvols L, Lewington V, Lopes JM, Manfredi R, Mitry E, Niederle B, Nikou G, berg K, O'Connor J, O'Toole D, Pape UF, Perren A, ckinge U, Ramage J, Ricke J, Rindi G, Ruzsniwski P, Salazar R, Scarpa A, Scoazec JY, Iler T, Sundin A, Taal B, Vullierme MP, Wiedenmann B, Wildi S, Zgliczynski S. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). *Neuroendocrinology* 2007; 84: 212-5. (NKI)
631. Nindl I, Kohler A, Gottschling M, Forschner T, Lehmann M, Meijer CJLM, Sniijders PJF, Stockfleth E. Extension of the typing in a general-primer-PCR reverse-line-blotting system to detect all 25 cutaneous beta human papillomaviruses. *J Virol Methods* 2007; 146(1-2): 1-4. (VUmc)
632. Nio D, Diks J, Bemelman WA, Wisselink W, Legemate DA. Laparoscopic vascular surgery: a systematic review. *European Journal of Vascular and Endovascular Surgery* 2007; 33(3): 263-271. (AMC)
633. Noorda EM, van Kreijl RH, Vrouwenraets BC, Nieweg OE, Muller M, Kroon BB, Aaronson NK. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. *Eur J Surg Oncol* 2007; 33: 776-82. (NKI)
634. Notenboom V, Hibbert RG, Rossum-Fikkert SE, Olsen JV, Mann M, Sixma TK. Functional characterization of Rad18 domains for Rad6, ubiquitin, DNA binding and PCNA modification. *Nucleic Acids Res* 2007; 35: 5819-30. (NKI)
635. Nowee ME, Dorsman JC, Piek JM, Kosma VM, Hamalainen K, Verheijen RHM, van Diest PJ. HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. *Histopathology* 2007; 51(5): 666-673. (VUmc)
636. Nowee ME, Sniijders AM, Rockx DA, de Wit RM, Kosma VM, Hamalainen K, Schouten JP, Verheijen RHM, van Diest PJ, Albertson DG, Dorsman JC. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. *J Pathol* 2007; 213(1): 46-55. (VUmc)
637. Nuver TT, Hoogeman MS, Remeijer P, Van Herk MB, Lebesque JV. An adaptive off-line procedure for radiotherapy of prostate cancer. *Int J Radiat Oncol Biol Phys* 2007; 67: 1559-67. (NKI)
638. Nuyten DSA, van de Vijver MJ. Gene expression signatures to predict the development of metastasis in breast cancer. *Breast Dis* 2007; 26: 149-56. (NKI)
639. Nyst HJ, van Veen RL, Tan IB, Peters R, Spaniol S, Robinson DJ, Stewart FA, Levendag PC, Sterenberg HJ. Performance of a dedicated light delivery and dosimetry device for photodynamic therapy of nasopharyngeal carcinoma: Phantom and volunteer experiments. *Lasers Surg Med* 2007; 39: 647-53. (NKI)
640. Oelke M, Hoefner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. *European Urology* 2007; 52(3): 827-834. (AMC)
641. Oerlemans R, Vink J, Dijkmans BAC, Assaraf YG, van Miltenburg M, van der Heijden J, Ifergan I, Lems WF, Scheper RJ, Kaspers GJL, Cloos J, Jansen G. Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. *Ann Rheum Dis* 2007; 66(10): 1289-1295. (VUmc)
642. Offerhaus GJ, Schipper MEI, Lazenby AJ, Montgomery E, Morsink FHM, Bende RJ, Musler AR, van Lier RAW, van Noesel CJM. Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity? *Immunology Letters* 2007; 114(1): 31-37. (AMC)
643. Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law CL, Gerber HP. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. *Blood* 2007; 110(13): 4370-4372. (VUmc)
644. Ohnmacht C, Pullner A, van Rooijen N, Voehringer D. Analysis of eosinophil turnover in vivo reveals their active recruitment to and prolonged survival in the peritoneal cavity. *J Immunol* 2007; 179(7): 4766-4774. (VUmc)
645. Ono N, van der Heijden I, Scheffer GL, Van De Wetering K, Van Deemter E, de Haas M, Boerke A, Gadella BM, De Rooij DG, Neefjes JJ, Groothuis TA, Oomen L, Brocks L, Ishikawa T, Borst P. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. *Biochem J* 2007; 406: 31-40. (NKI/VUmc)
646. Oostendorp RL, Beijnen JH, Schellens JH, Telling O. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. *Biomed Chromatogr* 2007; 21: 747-54. (NKI)
647. Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JHM. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. *Cancer Chemother Pharmacol* 2007; 59: 855-60. (NKI)
648. Ora I, Van Tinteren H, Bergeron C, de Kraker J. Progression of localised Wilms' tumour during preoperative chemotherapy is an independent prognostic factor: A report from the SIOP 93-01 nephroblastoma trial and study. *Eur J Cancer* 2007; 43: 131-6. (NKI)

649. Ortin-Perez J, Van Rijk MC, Valdés Olmos RA, Vidal-Sicart S, Nieweg OE, Vilalta A, Kroon BBR, Pons F. Lymphatic mapping and sentinel node biopsy in Merkel's cell carcinoma. *Eur J Surg Oncol* 2007; 33: 119-22. (NKI)
650. O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, De Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP, Caplin M, Jensen R, Eriksson B, Ahlman H, Arnold R, Bechstein WO, Cadiot G, Caplin M, Christ E, Chung D, Couvelard A, De Herder WW, Delle Fave G, Eriksson B, Falchetti A, Falconi M, Ferone D, Goretzki P, Gross D, Hochhauser D, Jensen R, Kaltsas G, timur F, Kianmanesh R, Knapp W, Knigge UP, Komminoth P, rner M, Kos K, Kvols L, Kwekkeboom DJ, Lewington V, Lopes JM, Manfredi R, McNicol AM, Mitry E, Niederle B, Nilsson O, berg K, O'Connor J, O'Toole D, Pauwels S, Pape UF, Pavel M, Perren A, ckingier U, Ramage J, Ricke J, Rindi G, Ruszniewski P, Salazar R, Sauvanet A, Scarpa A, Scoazec JY, Sevilla Garcia MI, Iler T, Sundin A, Taal B, Van Cutsem E, Vullierme MP, Wiedenmann B, Wildi S, Yao JC, Zgliczynski S. Rare functioning pancreatic endocrine tumors. *Neuroendocrinology* 2007; 84: 189-95. (NKI)
651. Otten MA, Leusen JH, Rudolph E, van der Linden JA, Beelen RHJ, van de Winkel JG, van Egmond M. FcR gamma-chain dependent signaling in immature neutrophils is mediated by FcalphaRI, but not by FcgammaRI. *J Immunol* 2007; 179(5): 2918-2924. (VUmc)
652. Ovaa H. Active-site directed probes to report enzymatic action in the ubiquitin proteasome system. *Nat Rev Cancer* 2007; 7: 613-20. (NKI)
653. Padilla ND, van Vliet AK, Schoots IG, Seron MV, Maas MA, Peltenburg EEP, de Vries A, Niessen HWM, Hack CE, van Gulik TM. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. *Surgery* 2007; 142(5): 722-733. (AMC)
654. Paessens LC, Garcia Vallejo JJ, Fernandes RJ, van Kooyk Y. The glycosylation of thymic microenvironments A microscopic study using plant lectins. *Immunol Lett* 2007; 110(1): 65-73. (VUmc)
655. Pals ST, de Gorter DJJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. *Blood* 2007; 110(9): 3102-3111. (AMC)
656. Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. *J Med Virol* 2007; 79(11): 1710-1721. (VUmc)
657. Patel KJ, Joenje H. Fanconi anemia and DNA replication repair. *DNA Repair (Amst)* 2007; 6(7): 885-890. (VUmc)
658. Patnaik P, Herrero R, Morrow RA, Munoz N, Bosch FX, Bayo S, El GB, Caceres E, Chichareon SB, Castellsague X, Meijer CJLM, Snijders PJF, Smith JS. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. *Sex Transm Dis* 2007; 34(12): 1019-1024. (VUmc)
659. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, Van de Velde CJ. The TME Trial After a Median Follow-up of 6 Years: Increased Local Control But No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma. *Ann Surg* 2007; 246: 693-701. (NKI)
660. Pegtel DM, Ellenbroek SI, Mertens AE, van der Kammen RA, de Rooij J, Collard JG. The partiam1 complex controls persistent migration by stabilizing microtubule-dependent front-rear polarity. *Curr Biol* 2007; 17: 1623-34. (NKI)
661. Pegtel DM, Subramanian A, Meritt D, Tsai CH, Sheen TS, Golub TR, Thorley-Lawson DA. IFN- γ -stimulated genes and Epstein-Barr virus gene expression distinguish WHO type II and III nasopharyngeal carcinomas. *Cancer Res* 2007; 67: 474-81. (NKI)
662. Peters FP, Brakenhoff KPM, Curvers WL, Rosmolen WD, ten Kate FJW, Krishnadath KK, Fockens P, Bergman JJGHM. Endoscopic cap resection for treatment of early Barrett's neoplasia is safe: a prospective analysis of acute and early complications in 216 procedures. *Diseases of the Esophagus* 2007; 20(6): 510-515. (AMC)
663. Peters FP, Krishnadath KK, Rygiel AM, Curvers WL, Rosmolen WD. Stepwise radical endoscopic resection of the complete Barrett's esophagus with early neoplasia successfully eradicates pre-existing genetic abnormalities. *American Journal of Gastroenterology* 2007; 102(9): 1853-1861. (AMC)
664. Peters FR, Kara MA, Curvers WL, Rosmolen WD, Fockens P, Krishnadath KK, ten Kate FJW, Bergman JJGHM. Multiband mucosectomy for endoscopic resection of Barrett's esophagus: feasibility study with matched historical controls. *European Journal of Gastroenterology & Hepatology* 2007; 19(4): 311-315. (AMC)
665. Peters GJ, Clavel M, Noordhuis P, Geysen GJ, Laan AC, Guastalla J, Edzes HT, Vermorken JB. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule. *J Chemother* 2007; 19(2): 212-221. (VUmc)
666. Peters MJL, Vis M, van Halm V, Wolbink GJ, Voskuyl AE, Lems WF, Dijkmans BAC, Twisk JW, de Koning MH, van de Stadt RJ, Nurmohamed MT. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. *Ann Rheum Dis* 2007; 66(7): 958-961. (VUmc)
667. Peters RPH, van Agtmael MA, Gierveld S, Danner SA, Groeneveld AB, Vandenbroucke-Grauls CMJE, Savelkoul PHM. Quantitative detection of Staphylococcus aureus and Enterococcus faecalis DNA in blood to diagnose bacteremia in patients in

- the intensive care unit. *J Clin Microbiol* 2007; 45(11): 3641-3646. (VUmc)
668. Piek JM, Kenemans P, Zweemer RP, van Diest PJ, Verheijen RHM. Ovarian carcinogenesis, an alternative theory. *Gynecol Oncol* 2007; 107(2): 355. (VUmc)
669. Piet AH, Lagerwaard FJ, Kunst PW, van Sornsen de Koste JR, Slotman BJ, Senan S. Can mediastinal nodal mobility explain the low yield rates for transbronchial needle aspiration without real-time imaging?. *Chest* 2007; 131(6): 1783-1787. (VUmc)
670. Pieterse AH, Stiggelbout AM, Baas-Thijssen MCM, Van De Velde CJH, Marijnen CAM. Benefit from preoperative radiotherapy in rectal cancer treatment: Disease-free patients' and oncologists' preferences. *Br J Cancer* 2007; 97: 717-24. (NKI)
671. Pindyurin AV, Moorman C, de Wit E, Belyakin SN, Belyaeva ES, Christophides GK, Kafatos FC, van Steensel B, Zhimulev IF. SUUR joins separate subsets of PcG, HP1 and B-type lamin targets in *Drosophila*. *J Cell Sci* 2007; 120: 2344-51. (NKI)
672. Planelles L, Castillo-Gutiérrez S, Medema JP, Morales-Luque A, Merle-Béral H, Hahne M. APRIL but not BlyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. *Haematologica - The Hematology Journal* 2007; 92(9): 1284-1285. (AMC)
673. Poley JW, Wagner A, Hoogmans MM, Menko FH, Tops C, Kros JM, Reddingius RE, Meijers-Heijboer HE, Kuipers EJ, Dinjens WN. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. *Cancer* 2007; 109(11): 2349-2356. (VUmc)
674. Polle SW, Bemelman WA. Surgery insight: minimally invasive surgery for IBD. *Nature Clinical Practice Gastroenterology & Hepatology* 2007; 4(6): 324-335. (AMC)
675. Polle SW, Dunker MS, Slors JFM, Sprangers MA, Cuesta MA, Gouma DJ, Bemelman WA. Body image, cosmesis, quality of life, and functional outcome of hand-assisted laparoscopic versus open restorative proctocolectomy: long-term results of a randomized trial. *Surgical Endoscopy and Other Interventional Techniques* 2007; 21(8): 1301-1307. (AMC)
676. Polle SW, Wind J, Fuhring JW, Hofland J, Gouma DJ, Bemelman WA. Implementation of a fast-track perioperative care program: what are the difficulties? *Digestive Surgery* 2007; 24(6): 441-449. (AMC)
677. Ponnappan S, Ovaa H, Ponnappan U. Lower expression of catalytic and structural subunits of the proteasome contributes to decreased proteolysis in peripheral blood T lymphocytes during aging. *Int J Biochem Cell Biol* 2007; 39: 799-809. (NKI)
678. Ponsioen B, van Zeijl L, Moolenaar W, Jalink K. Direct measurement of cyclic AMP diffusion and signaling through connexin43 gap junctional channels. *Exp Cell Res* 2007; 313: 415-23. (NKI)
679. Poorter RL, de Bree R, Leemans CR, van der Valk P, Slotman BJ, Langendijk JA. Re-irradiation of a second localization of idiopathic midline destructive disease in the head and neck area. *Eur Arch Otorhinolaryngol* 2007; 264(12): 1521-1523. (VUmc)
680. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M. The ubiquitin-specific protease USP28 is required for MYC stability. *Nat Cell Biol* 2007; 9: 765-74. (NKI)
681. Postma C, Terwischa S, Hermsen MA, van der Sijp Jr, Meijer GA. Gain of chromosome 20q is an indicator of poor prognosis in colorectal cancer. *Cell Oncol* 2007; 29(1): 73-75. (VUmc)
682. Postma TJB, Alers JC, Terpstra S, Zuurbier A. Medical technology decisions in The Netherlands: How to solve the dilemma of technology foresight versus market research? *Technological Forecasting and Social Change* 2007; 74: 1823-33. (NKI)
683. Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF, Jr, Yokomise H. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. *J Thorac Oncol* 2007; 2(8): 686-693. (VUmc)
684. Poyck PPC, Hoekstra R, Chhatta A, ten Bloemendaal L, van Wijk ACWA, Galavotti D, van Gulik TM, Chamuleau RAFM. Time-related analysis of metabolic liver functions, cellular morphology, and gene expression of hepatocytes cultured in the bioartificial liver of the Academic Medical Center in Amsterdam (AMC-BAL). *Tissue Engineering* 2007; 13(6): 1235-1246. (AMC)
685. Poyck PPC, Hoekstra R, van Wijk ACWA., Attanasio C, Calise F, Chamuleau RAFM, van Gulik TM. Functional and morphological comparison of three primary liver cell types cultured in the AMC bioartificial liver. *Liver Transplantation* 2007; 13(4): 589-598. (AMC)
686. Poyck PPC, Pless G, Hoekstra R, Roth S, van Wijk ACWA, Schwartzlander R, van Gulik TM, Sauer IM, Chamuleau RAFM. In vitro comparison of two bioartificial liver support systems: MELS CellModule and AMC-BAL. *International Journal of Artificial Organs* 2007; 30(3): 183-191. (AMC)
687. Pramana J, Pimentel N, Hofland I, Wessels LF, van Velthuysen ML, Atsma D, Rasch CR, van den Brekel MW, Begg AC. Heterogeneity of gene expression profiles in head and neck cancer. *Head Neck* 2007; 29: 1083-9. (NKI)
688. Pramana J, van den Brekel MW, van Velthuysen ML, Wessels LF, Nuyten DS, Hofland I, Atsma D, Pimentel N, Hoebbers FJ, Rasch CR, Begg AC. Gene Expression Profiling to Predict Outcome after Chemoradiation in Head and Neck Cancer. *Int J Radiat Oncol Biol Phys* 2007; 69: 1544-52. (NKI)

689. Prasad GA, Wang KK, Buttar NS, Wongkeesong L-M, Krishnadath KK, Nichols FC, Lutzke LS, Borkenhagen LS. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. *Gastroenterology* 2007; 132(4): 1226-1233. (AMC)
690. Price JD, Simpfendorfer KR, Mantena RR, Holden J, Heath WR, van Rooijen N, Strugnell RA, Wijburg OL. Gamma interferon-independent effects of interleukin-12 on immunity to *Salmonella enterica* serovar Typhimurium. *Infect Immun* 2007; 75(12): 5753-5762. (VUmc)
691. Prinsen CF, Fles R, Wijnen-Dubbers CW, de Valk HA, Klaassen CH, Mravunac M, Horrevorts AM, Thunnissen FB. Baseline human papillomavirus status of women with abnormal smears in cervical screening: a 5-year follow-up study in The Netherlands. *BJOG* 2007; 114(8): 951-957. (VUmc)
692. Puppa LD, Savaskan NE, Bräuer AU, Behne D, Kyriakopoulos A. The role of selenite on microglial migration. *Ann N Y Acad Sci* 2007; 1096: 179-83. (NKI)
693. Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. *Clin Cancer Res* 2007; 13: 4474-81. (NKI)
694. Radi M, Adema AD, Daft JR, Cho JH, Hoebe EK, Alexander LE, Peters GJ, Chu CK. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs. *J Med Chem* 2007; 50(9): 2249-2253. (VUmc)
695. Rassweiler J, Schulze M, Stock C, Teber D, de la Rosette J. Bipolar transurethral resection of the prostate - technical modifications and early clinical experience. *Minimally Invasive Therapy & Allied Technologies* 2007; 16(1): 11-21. (AMC)
696. Rayavarapu RG, Petersen W, Ungureanu C, Post JN, van Leeuwen TG, Manohar S. Synthesis and bioconjugation of gold nanoparticles as potential molecular probes for light-based imaging techniques. *International Journal of Biomedical Imaging* 2007; 29817-. (AMC)
697. Raymond K, Kreft M, Song JY, Janssen H, Sonnenberg A. Dual role of (alpha)6(beta)4 integrin in epidermal tumor growth: Tumor-suppressive versus tumor-promoting function. *Mol Biol Cell* 2007; 18: 4210-21. (NKI)
698. Reese TA, Liang HE, Tager AM, Luster AD, van Rooijen N, Voehringer D, Locksley RM. Chitin induces accumulation in tissue of innate immune cells associated with allergy. *Nature* 2007; 447(7140): 92-96. (VUmc)
699. Reijneveld JC, Ponten SC, Berendse HW, Stam CJ. The application of graph theoretical analysis to complex networks in the brain. *Clin Neurophysiol* 2007; 118(11): 2317-2331. (VUmc)
700. Reinartz SM, Schot LJ, Riedl RG, Oldenburger F, Van Den Brekel MWM. Presentation of two cases of nasal type NK/T-cell lymphoma. *Eur Arch Otorhinolaryngol* 2007; 264: 39-43. (NKI)
701. Repanas K, Zingler N, Layer LE, Schumann GG, Perrakis A, Weichenrieder O. Determinants for DNA target structure selectivity of the human LINE-1 retrotransposon endonuclease. *Nucleic Acids Res* 2007; 35: 4914-26. (NKI)
702. Rezk BM, van der Vijgh WJ, Bast A, Haenen GR. Alpha-tocopheryl phosphate is a novel apoptotic agent. *Front Biosci* 2007; 12: 2013-2019. (VUmc)
703. Rijkeboer A, Voskuyl AE, van Agtmael MA. Fatal *Salmonella enteritidis* septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist. *Scand J Infect Dis* 2007; 39(1): 80-83. (VUmc)
704. Rijkhorst EJ, van Herk M, Lebesque JV, Sonke JJ. Strategy for Online Correction of Rotational Organ Motion for Intensity-Modulated Radiotherapy of Prostate Cancer. *Int J Radiat Oncol Biol Phys* 2007; 69: 1608-17. (NKI)
705. Rijnsburger MC, Delwel S, Boutaga K, van Steenberghe TJ, Savelkoul PHM, van Winkelhoff AJ. Comparison of restriction enzyme analysis and amplified fragment length polymorphism typing of *Porphyromonas gingivalis* isolated from spouses. *Oral Microbiol Immunol* 2007; 22(6): 369-373. (VUmc)
706. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. *J Hepatol* 2007; 47(4): 571-579. (VUmc)
707. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, van Rooijen N, Husseinzadeh N, Farland-Mancini MM, Drew AF. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. *Cancer Res* 2007; 67(12): 5708-5716. (VUmc)
708. Roenhorst AW, van den Bergh AC, van Putten JW, Smit EF. Iris metastasis in small-cell lung carcinoma. *J Thorac Oncol* 2007; 2(12): 1128-1129. (VUmc)
709. Rompp A, Dekker L, Taban I, Jenster G, Boogerd W, Bonfrer H, Spengler B, Heeren R, Smitt PS, Luider TM. Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS. *Proteomics* 2007; 7: 474-81. (NKI)
710. Roovers RC, van Dongen GAMS, en Henegouwen PM. Nanobodies in therapeutic applications. *Curr Opin Mol Ther* 2007; 9(4): 327-335. (VUmc)

711. Roozendaal R, Carroll MC. Complement receptors CD21 and CD35 in humoral immunity. *Immunol Rev* 2007; 219: 157-166. (VUmc)
712. Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, Van De Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. *Proc Natl Acad Sci U S A* 2007; 104: 12117-22. (NKI)
713. Rouwendal GJ, Wuhrer M, Florack DE, Koeleman CA, Deelder AM, Bakker H, Stoopen GM, van Die IM, Helsper JP, Hokke CH, Bosch D. Efficient introduction of a bisecting GlcNAc residue in tobacco N-glycans by expression of the gene encoding human N-acetylglucosaminyltransferase III. *Glycobiology* 2007; 17(3): 334-344. (VUmc)
714. Rowe M, Glaunsinger B, van Leeuwen D, Zuo J, Sweetman D, Ganem D, Middeldorp J, Wiertz EJ, Rensing ME. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. *Proc Natl Acad Sci U S A* 2007; 104(9): 3366-3371. (VUmc)
715. Rozkiewicz DI, Brugman W, Kerkhoven RM, Ravoo BJ, Reinhoudt DN. Dendrimer-mediated transfer printing of DNA and RNA microarrays. *J Am Chem Soc* 2007; 129: 11593-9. (NKI)
716. Ruijs MWG, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, van't Veer LJ. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. *Eur J Hum Genet* 2007; 15: 110-4. (NKI)
717. Ruzniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, Pauwels S, Kwekkeboom DJ, Rindi G, Bechstein WO, Caplin M, Christ E, Couvelard A, De Herder WW, Eriksson B, Falchetti A, Falconi M, Ferone D, Goretzki P, Gross D, Hyrdel R, Jensen R, Kaltsas G, timur F, Knapp W, Knigge UP, rner M, Kvols L, Lewington V, Lopes JM, Manfredi R, McNicol AM, Mitry E, Niederle B, Nikou G, Nilsson O, berg K, O'Connor J, O'Toole D, Pape UF, Pavel M, Perren A, ckinge U, Ramage J, Ricke J, Salazar R, Sauvanet A, Scarpa A, Scoazec JY, Sevilla Garcia MI, Iler T, Sundin A, Taal B, Van Cutsem E, Vullierme MP, Wiedenmann B, Wildi S, Yao JC, Zgliczynski S. Well-differentiated gastric tumors/carcinomas. *Neuroendocrinology* 2007; 84: 158-64. (NKI)
718. Rygiel AM, van Baal JWPM, Milano F, Wang KK, ten Kate FJ, Fockens P, Rosmolen WD, Bergman JJGHM, Peppelenbosch MR, Krishnadath KK. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. *Cancer* 2007; 109(10): 1980-1988. (AMC)
719. Saeland E, van Vliet SJ, Backstrom M, van den Berg V, Geijtenbeek TBH, Meijer GA, van Kooyk Y. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. *Cancer Immunol Immunother* 2007; 56(8): 1225-1236. (VUmc)
720. Sagiv Y, Bai L, Wei DG, Agami R, Savage PB, Teyton L, Bendelac A. A distal effect of microsomal triglyceride transfer protein deficiency on the lysosomal recycling of CD1d. *J Exp Med* 2007; 204: 921-8. (NKI)
721. Samsom JN, van der Marel AP, van Berkel LA, van Helvoort JM, Simons-Oosterhuis Y, Jansen W, Greuter M, Nelissen RL, Meeuwisse CM, Nieuwenhuis EE, Mebius RE, Kraal G. Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance. *J Immunol* 2007; 179(10): 6588-6595. (VUmc)
722. Santegoets SJAM, Schreurs MW, Reurs AW, Lindenberg JJ, Kueter EW, van den Eertwegh AJM, Hooijberg E, Brandwijk RJ, Hufton SE, Hoogenboom HR, Scheper RJ, Somers VA, de Gruijl TD. Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapy. *J Immunol* 2007; 179(3): 2005-2012. (VUmc)
723. Savaskan NE, Borchert A, Brauer AU, Kuhn H. Role for glutathione peroxidase-4 in brain development and neuronal apoptosis: Specific induction of enzyme expression in reactive astrocytes following brain injury. *Free Radic Biol Med* 2007; 43: 191-201. (NKI)
724. Savaskan NE, Rocha L, Kotter MR, Baer A, Lubec G, Van Meeteren LA, Kishi Y, Aoki J, Moolenaar WH, Nitsch R, Brauer AU. Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma. *Cell Mol Life Sci* 2007; 64: 230-43. (NKI)
725. Savaskan NE, Ufer C, Kuhn H, Borchert A. Molecular biology of glutathione peroxidase 4: From genomic structure to developmental expression and neural function. *Biol Chem* 2007; 388: 1007-17. (NKI)
726. Savelkoul PHM, Melles DC, Buffing N, Gorkink R, Simons G, van Belkum A. High density whole genome fingerprinting of methicillin-resistant and -susceptible strains of *Staphylococcus aureus* in search of phenotype-specific molecular determinants. *J Microbiol Methods* 2007; 71(1): 44-54. (VUmc)
727. Scarpa M, van Koperen PJ, Ubbink DT, Hommes DW, ten Kate FJW, Bemelman WA. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. *British Journal of Surgery* 2007; 94(5): 534-545. (AMC)
728. Schabussova I, Amer H, van Die IM, Kosma P, Maizels RM. O-methylated glycans from *Toxocara* are specific targets for antibody binding in human and animal infections. *Int J Parasitol* 2007; 37(1): 97-109. (VUmc)
729. Schellens JH. Capecitabine. *Oncologist* 2007; 12: 152-5. (NKI)

730. Schilder CM, Schagen SB. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. *Minerva Ginecol* 2007; 59: 387-401. (NKI)
731. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, van't Veer LJ. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. *Cancer Res* 2007; 67: 9584-90. (NKI)
732. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, van 't Veer LJ. Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation. *J Clin Oncol* 2007; 25: 64-9. (NKI)
733. Schmidt MK, van Leeuwen FE, Broeks A, Krol-Warmerdam EM, Peterse JL, 't Veer LJ, Tollenaar RAEM. The CHEK2 1100delC germline variant predicts worse breast cancer outcome: A case study. *Am J Hematol Oncol* 2007; 6: 285-8. (NKI)
734. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W, Vellenga E. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. *Blood* 2007; 109(2): 486-491. (VUmc)
735. Schreibelt G, Kooij G, Reijkerker A, van Doorn R, Gringhuis SI, van der Pol S, Weksler BB, Romero IA, Couraud PO, Piontek J, Blasig IE, Dijkstra CD, Ronken E, de Vries HE. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. *FASEB J* 2007; 21(13): 3666-3676. (VUmc)
736. Schreinemachers MCJM, Doorschodt BM, van Gulik TM. Machine perfusion preservation of the liver: a worthwhile clinical activity? *Current Opinion in Organ Transplantation* 2007; 12(3): 224-230. (AMC)
737. Schultsz C, Vien IM, Campbell JI, Chau NV, Diep TS, Hoang NV, Nga TT, Savelkoul PHM, Stepniewska K, Parry C, Hien TT, Farrar JJ. Changes in the nasal carriage of drug-resistant *Streptococcus pneumoniae* in urban and rural Vietnamese schoolchildren. *Trans R Soc Trop Med Hyg* 2007; 101(5): 484-492. (VUmc)
738. Scott NW, Fayers PM, Aaronson NK, Bottomley A, De Graeff A, Groenvold M, Koller M, Petersen MA, Sprangers MAG. The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30. *Qual Life Res* 2007; 16: 115-29. (NKI)
739. Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, Magagnin MG, Rouschop KM, Krishnan S, Rao RB, Evelo CT, Begg AC, Wouters BG, Lambin P. Impact of supervised gene signatures of early hypoxia on patient survival. *Radiother Oncol* 2007; 83: 374-82. (NKI)
740. Sekine H, Ferreira RC, Pan H, Graham RR, Ziemba B, De Vries SS, Liu J, Hippen K, Koeuth T, Ortmann W, Iwahori A, Elliott MK, Offer S, Skon C, Du L, Novitzke J, Lee AT, Zhao N, Tompkins JD, Altshuler D, Gregersen PK, Cunningham-Rundles C, Harris RS, Her C, Nelson DL, Hammarstrom L, Gilkeson GS, Behrens TW. Role for Msh5 in the regulation of Ig class switch recombination. *Proc Natl Acad Sci U S A* 2007; 104: 7193-8. (NKI)
741. Senan S, Haasbeek NJ, Smit EF, Lagerwaard FJ. Stereotactic radiotherapy for centrally located early-stage lung tumors. *J Clin Oncol* 2007; 25(4): 464. (VUmc)
742. Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. *Oncologist* 2007; 12(4): 465-477. (VUmc)
743. Senan S. Staging nodal disease in non-small cell lung cancer: implications for radiation therapy. *J Thorac Oncol* 2007; 2(7): 585-587. (VUmc)
744. Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJLM, Willemze R. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. *J Clin Oncol* 2007; 25(12): 1581-1587. (VUmc)
745. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RDM, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q. The major 8p22 tumor suppressor *DLC1* is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. *Oncogene* 2007; 26(6): 934-944. (VUmc)
746. Sharp JT, Angwin J, Boers M, Duryea J, von Ingersleben G, Hall JR, Kauffman JA, Landewe R, Langs G, Lukas C, Maillefert JF, Bernelot Moens HJ, Peloschek P, Strand V, van der Heijde D. Computer based methods for measurement of joint space width: update of an ongoing OMERACT project. *J Rheumatol* 2007; 34(4): 874-883. (VUmc)
747. Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *J Thorac Oncol* 2007; 2(12): 1067-1077. (VUmc)
748. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF. Application of a methylation gene panel by quantitative PCR for

- lung cancers. *Cancer Lett* 2007; 247(1): 56-71. (VUmc)
749. Siegel-Lakhai WS, Beijnen JH, Vervenne WL, Boot H, Keessen M, Versola M, Koch KM, Smith DA, Pandite L, Richel DJ, Schellens JHM. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. *Clinical Cancer Research* 2007; 13(15 Part 1): 4495-4502. (AMC/NKI)
750. Sigmond J, Kamphuis JA, Laan AC, Hoebe EK, Bergman AM, Peters GJ. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent. *Biochem Pharmacol* 2007; 73(10): 1548-1557. (VUmc)
751. Sigurdson AJ, Bhatti P, Doody MM, Hauptmann M, Bowen L, Simon SL, Weinstock RM, Linet MS, Rosenstein M, Stovall M, Alexander BH, Preston DL, Struwing JP, Rajaraman P. Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. radiologic technologists. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 2000-7. (NKI)
752. Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, DeNunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, Livingston DM. Further Evidence for BRCA1 Communication with the Inactive X Chromosome. *Cell* 2007; 128: 991-1002. (NKI)
753. Sixma TK. Nicotinic receptor structure emerging slowly. *Nat Neurosci* 2007; 10: 937-8. (NKI)
754. Skolarikos A, Alivizatos G, Laguna P, de la Rosette J. A review on follow-up strategies for renal cell carcinoma after nephrectomy. *European Urology* 2007; 51(6): 1490-500; discussion 1501. (AMC)
755. Slofstra SH, Bijlsma MF, Groot AP, Reitsma PH, Lindhout T, ten Cate H, Spek CA. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. *Blood* 2007; 110(9): 3176-3182. (AMC)
756. Slofstra SH, Groot AP, Obdeijn MHP, Reitsma PH, ten Cate H, Spek CA. Gene expression profiling identifies C/EBP delta as a candidate regulator of endotoxin-induced disseminated intravascular coagulation. *American Journal of Respiratory and Critical Care Medicine* 2007; 176(6): 602-609. (AMC)
757. Slotman BJ, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus PE, Collette L, Musat E, Senan S. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N Engl J Med* 2007; 357(7): 664-672. (VUmc)
758. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg* 2007; 245: 104-9. (NKI)
759. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Progression of Pseudomyxoma Peritonei after Combined Modality Treatment: Management and Outcome. *Ann Surg Oncol* 2007; 14: 493-9. (NKI)
760. Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. *Br J Surg* 2007; 94: 1408-14. (NKI)
761. Smeenk RM, Verwaal VJ, Zoetmulder FAN. Pseudomyxoma peritonei. *Cancer Treat Rev* 2007; 33: 138-45. (NKI)
762. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJF, Pawlita M, Meijer CJLM, Braakhuis BJM, Leemans CR, Brakenhoff RH. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. *Int J Cancer* 2007; 121(11): 2465-2472. (VUmc)
763. Smit EF, Hoekstra OS. New imaging techniques (PET, PET-CT, MRI, E9B)US) for lung cancer staging and response assessment. *J Thorac Oncol* 2007; 2: 144-145. (VUmc)
764. Smit LA, Hallaert DYH, Spijker R, de Goeij B, Jaspers A, Kater AP, van Oers MHJ, van Noesel CJM, Eldering E. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. *Blood* 2007; 109(4): 1660-1668. (AMC)
765. Smith JS, Moses S, Hudgens MG, Agot K, Franceschi S, Maclean IW, Ndinya-Achola JO, Parker CB, Pugh N, Meijer CJLM, Snijders PJF, Bailey RC. Human papillomavirus detection by penile site in young men from Kenya. *Sex Transm Dis* 2007; 34(11): 928-934. (VUmc)
766. Smith P, Mangan NE, Walsh CM, Fallon RE, McKenzie AN, van Rooijen N, Fallon PG. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. *J Immunol* 2007; 178(7): 4557-4566. (VUmc)
767. Smorenburg CH, van Groeningen CJ, Meijer OW, Visser M, Boven E. Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands. *Neth J Med* 2007; 65(4): 132-136. (VUmc)
768. Smulders SA, Gundy CM, van Lingen A, Comans EFI, Smeenk FW, Hoekstra OS. Observer variation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in mediastinal staging of non-small cell lung cancer as a function of experience, and its potential clinical impact. *Mol Imaging Biol* 2007; 9(5): 318-322. (VUmc)
769. Sonke GS, Chang S, Strom SS, Sweeney AM, Annegers JF, Sigurdson AJ. Prenatal and perinatal risk factors and testicular cancer: A hospital-based case-control study. *Oncol Res* 2007; 16: 383-7. (NKI)

770. Sonnenberg A, Liem RK. Plakins in development and disease. *Exp Cell Res* 2007; 313: 2189-203. (NKI)
771. Sonnenberg A, Rojas AM, de Pereda JM. The structure of a tandem pair of spectrin repeats of plectin reveals a modular organization of the plakin domain. *J Mol Biol* 2007; 368: 1379-91. (NKI)
772. Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GEG, Cornelissen JJ, Schaafsma MR, van Oers MHJ, Wijermans PW, Westveer PHM, Lokhorst HM. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. *Haematologica-the Hmatology Journal* 2007; 92(7): 928-935. (AMC)
773. Soolsma J, Van Den Brekel MWM, Ackerstaff AH, Balm AJM, Tan B, Hilgers FJM. Long-term results of Provox ActiValve, solving the problem of frequent candida- and "underpressure"-related voice prosthesis replacements. *Laryngoscope* 2007; 117: (NKI)
774. Sosef MN, de Bondt RBJ, Bosma A, de Bruijn C, van Gulik TM. The fate of autologous hepatocytes transplanted into spleen, pancreas, mesentery, stomach, and small bowel wall in pigs. *HPB: The Official Journal of the International Hepato Pancreato Biliary Association* 2007; 9(3): 216-218. (AMC)
775. Sparidans RW, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 855: 200-10. (NKI)
776. Sparidans RW, Prins JM, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. *Biomed Chromatogr* 2007; 21: 621-7. (NKI)
777. Spek CA, ten Kate FJW, te Velde Anie A. Factor V Leiden and the etiology of inflammatory bowel disease. *Thrombosis and Haemostasis* 2007; 98(3): 670-673. (AMC)
778. Spiekstra SW, Breetveld M, Rustemeyer T, Scheper RJ, Gibbs S. Wound-healing factors secreted by epidermal keratinocytes and dermal fibroblasts in skin substitutes. *Wound Repair Regen* 2007; 15(5): 708-717. (VUmc)
779. Spiewak R, Moed H, von Blomberg BME, Bruynzeel DP, Scheper RJ, Gibbs S, Rustemeyer T. Allergic contact dermatitis to nickel: modified in vitro test protocols for better detection of allergen-specific response. *Contact Dermatitis* 2007; 56(2): 63-69. (VUmc)
780. Stam CJ, Reijneveld JC. Graph theoretical analysis of complex networks in the brain. *Nonlinear Biomed Phys* 2007; 1(1): 3. (VUmc)
781. Stam FJ, MacGillavry HD, Armstrong NJ, de Gunst MC, Zhang Y, van Kesteren RE, Smit AB, Verhaagen J. Identification of candidate transcriptional modulators involved in successful regeneration after nerve injury. *Eur J Neurosci* 2007; 25: 3629-37. (NKI)
782. Steggerda MJ, Moonen LM, van der Poel HG, Schneider CJ. The influence of geometrical changes on the dose distribution after I-125 seed implantation of the prostate. *Radiother Oncol* 2007; 83: 11-7. (NKI)
783. Stern-Ginossar N, Nedvetzki S, Markel G, Gazit R, Betser-Cohen G, Achdout H, Aker M, Blumberg RS, Davis DM, Appelmelk BJ, Mandelboim O. Intercellular transfer of carcinoembryonic antigen from tumor cells to NK cells. *J Immunol* 2007; 179(7): 4424-4434. (VUmc)
784. Stevens SJC, Smits PH, Verkuijlen SA, Rockx DA, van Gorp EC, Mulder JW, Middeldorp JM. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription. *Aids* 2007; 21(16): 2141-2149. (VUmc)
785. Stone S, Sobeck A, van Kogelenberg M, de Graaf B, Joenje H, Christian J, Hoatlin ME. Identification, developmental expression and regulation of the Xenopus ortholog of human FANCG/XRCC9. *Genes Cells* 2007; 12(7): 841-851. (VUmc)
786. Strik MCM, de Koning PJA, Kleijmeer Monique J, Bladergroen BA, Wolbink AM, Griffith JM, Wouters D, Fukuoka Y, Schwartz L, Hack CE, van Ham SM, Kummer JA. Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. *Molecular Immunology* 2007; 44(14): 3462-3472. (AMC)
787. Stroom J, Blaauwgeers H, van Baardwijk A, Boersma L, Lebesque J, Theuws J, van Suylen RJ, Klomp H, Liesker K, van Pel R, Siedschlag C, Gilhuijs K. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. *Int J Radiat Oncol Biol Phys* 2007; 69: 267-75. (NKI)
788. Stucki G, Boonen A, Tugwell P, Cieza A, Boers M. The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. *J Rheumatol* 2007; 34(3): 600-606. (VUmc)
789. Sutherland KD, Lindeman GJ, Visvader JE. Knocking off SOCS genes in the mammary gland. *Cell Cycle* 2007; 6: 799-803. (NKI)
790. Szojda MM, Cuesta MA, Mulder CM, Felt-Bersma RJ. Review article: Management of diverticulitis. *Aliment Pharmacol Ther* 2007; 26 Suppl: 267-276. (VUmc)
791. Szojda MM, Mulder CJ, Felt-Bersma RJ. Differences in taste between two polyethylene

- glycol preparations. *J Gastrointest Liver Dis* 2007; 16(4): 379-381. (VUmc)
792. Taal BG, Van Der Velden AWG, Schouten M, Korse CM, Bonfrer JMG, Visser O. The prognosis of carcinoid tumours has improved. *Salud (i) Ciencia* 2007; 15: 716-20. (NKI)
793. Tack JW, Rakhorst G, van der Houwen EB, Mahieu HF, Verkerke GJ. In vitro evaluation of a double-membrane-based voice-producing element for laryngectomized patients. *Head Neck* 2007; 29(7): 665-674. (VUmc)
794. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. *J Clin Invest* 2007; 117(1): 185-194. (VUmc)
795. Tait SW, de Vries E, Maas C, Keller AM, D'Santos CS, Borst J. Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment. *J Cell Biol* 2007; 179: 1453-66. (NKI)
796. Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KFK, Hrycyna CA, Schuetz JD. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. *Cancer Res* 2007; 67: 6965-72. (NKI/VUmc)
797. Talbot DC, Von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, Huitema ADR, Norbury CJ, Ellis P, Bosquee L, Reck M. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulamas second-line therapy in patients with advanced non-small cell lung cancer. *Clin Cancer Res* 2007; 13: 1816-22. (NKI)
798. Te Poele EM, de Bont ES, Marike BH, Revesz T, Bokkerink JP, Beishuizen A, Nijhuis IJ, Oude Nijhuis CS, Veerman AJP, Kamps WA. Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high?. *Eur J Cancer* 2007; 43(17): 2532-2536. (VUmc)
799. Te Riele H. Retinoblastoma teaches a new lesson. *Cell* 2007; 131: 227-9. (NKI)
800. Temmink OH, de Bruin M, Turksma AW, Cricca S, Laan AC, Peters GJ. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. *Int J Biochem Cell Biol* 2007; 39: 565-75. (NKI/VUmc)
801. Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. *Cancer Sci* 2007; 98(6): 779-789. (VUmc)
802. Temmink OH, Hoebe EK, Fukushima M, Peters GJ. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. *Eur J Cancer* 2007; 43(1): 175-183. (VUmc)
803. Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. *Br J Cancer* 2007; 96(2): 231-240. (VUmc)
804. Temmink OH, Prins HJ, van Gelderop E, Peters GJ. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. *Br J Cancer* 2007; 96(1): 61-66. (VUmc)
805. ten Brinke A, Karsten ML, Dieker MC, Zwaginga JJ, van Ham SM. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. *Vaccine* 2007; 25(41): 7145-7152. (AMC)
806. ten Kate GL, Kleibeuker JH, Nagengast FM, Craanen M, Cats A, Menko FH, Vasen HF. Is surveillance of the small bowel indicated for Lynch syndrome families? *Gut* 2007; 56: 1198-201. (NKI/VUmc)
807. ter Heine R, Alderden-Los CG, Rosing H, Hillebrand MJ, van Gorp EC, Huitema AD, Beijnen JH. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007; 21: 2505-14. (NKI)
808. Terhaard C, Lubsen H, Tan B, Merckx T, van der Laan B, Baatenburg-de Jong R, Manni H, Knegt P. Corrigendum to "Facial nerve function in carcinoma of the parotid gland" [*European Journal of Cancer*, 42 (2006) 2744-2750] (DOI:10.1016/j.ejca.2006.06.010). *Eur J Cancer* 2007; 43: 1883. (NKI)
809. Terheggen F, Troost D, Majolie CB, Leenstra S, Richel DJ. Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide. *Journal of Neuro-Oncology* 2007; 82(1): 113-116. (AMC)
810. Theodorou V, Kimm MA, Boer M, Wessels L, Theelen W, Jonkers J, Hilken J. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. *Nat Genet* 2007; 39: 759-69. (NKI)
811. Timmer TGC, Baltus B, Vondenhoff M, Huizinga TW, Tak PP, Verweij CL, Mebius RE, van der Pouw-Kraan TCM. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology:

- identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. *Arthritis Rheum* 2007; 56(8): 2492-2502. (VUmc)
812. Timmers GJ, Simoons-Smit AM, Leidekker ME, Janssen JJWM, Vandenbroucke-Grauls CMJE, Huijgens PC. Levofloxacin vs ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. *Clin Microbiol Infect* 2007; 13(5): 497-503. (VUmc)
813. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD. Analysis of PALB2/FANCN-associated breast cancer families. *Proc Natl Acad Sci U S A* 2007; 104: 6788-93. (NKI)
814. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell Stem Cell* 2007; 1(4): 389-402. (AMC)
815. Top J, Willems R, Blok H, de Regt M, Jalink K, Troelstra A, Goorhuis B, Bonten M. Ecological replacement of *Enterococcus faecalis* by multiresistant clonal complex 17 *Enterococcus faecium*. *Clin Microbiol Infect* 2007; 13: 316-9. (NKI)
816. Touma M, Sun ZYJ, Clayton LK, Marissen WE, Kruisbeek AM, Wagner G, Reinherz EL. Importance of the CD3 ϵ ectodomain terminal η -strand and membrane proximal stalk in thymic development and receptor assembly. *J Immunol* 2007; 178: 3668-79. (NKI)
817. Triesscheijn M, Ruevekamp M, Out R, van Berkel TJC, Schellens J, Baas P, Stewart FA. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men. *Cancer Chemother Pharmacol* 2007; 60: 113-22. (NKI)
818. Tsakiris P, de la Rosette J.: Imaging in genitourinary cancer from the urologists' perspective. *Cancer imaging* 2007; 7: 84-92. (AMC)
819. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, van der Heijde D, Wells G, Dougados M. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. *J Rheumatol* 2007; 34(5): 1188-1193. (VUmc)
820. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. *Trials* 2007; 8: 38. (VUmc)
821. Uitterhoeve ALJ, Koolen MGJ, van Os RM, Koedooder K, van de Kar M, Pieters BR, Koning CCE. Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer. *Radiation oncology* (London, England) 2007; 2: 27. (AMC)
822. Vainchtein L, Rosing H, Mirejovsky D, Lenaz L, Schellens J, Beijnen J. Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer. *J Pharm Biomed Anal* 2007; 43: 285-92. (NKI)
823. Vainchtein LD, Rosing H, Maier A, Fiebig HH, Schellens JH, Beijnen JH. Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 856: 261-6. (NKI)
824. Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2007; 21: 2312-22. (NKI)
825. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht AA, Ogata K, Orfao A, Pfeilstocker M, Ruter B, Sperr WR, Stauder R, Wells DA. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. *Leuk Res* 2007; 31(6): 727-736. (VUmc)
826. van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. *Am J Pathol* 2007; 170(3): 818-829. (VUmc)
827. van Berlo RJ, Wessels LFA, de Ridder D, Reinders MJT. Protein complex prediction using an integrative bioinformatics approach. *J Bioinform Comput Biol* 2007; 5: 839-64. (NKI)
828. van Dalen EC, Caron HN, Kremer LCM. Prevention of anthracycline-induced cardiotoxicity in children: the evidence. *European Journal of Cancer* 2007; 43(7): 1134-1140. (AMC)
829. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, van der Meer JT, de Vries HJ, Mulder JW, van Agtmael MA, Jurriaans S, Wolthers KC, Coutinho RA. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. *J Infect Dis* 2007; 196(2): 230-238. (VUmc)
830. van de Lande J, Torrenza B, Raijmakers PG, Hoekstra OS, van Baal MW, Broilman HA, Verheijen RHM. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. *Gynecol Oncol* 2007; 106(3): 604-613. (VUmc)
831. van de Vijver MJ, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Ruschoff J. Chromogenic in situ hybridisation for the

- assessment of HER2 status in breast cancer: an international validation ring study. *Breast Cancer Res* 2007; 9: R68. (NKI)
832. van de Vijver MJ. Pathology of uncommon ovarian cancers. *EJC Suppl* 2007; 5(5): 239-42. (NKI)
833. van de Vosse E, van Agtmael MA. Targets of anticytokine therapy and the risk of infections in humans and mice. *Curr Opin Rheumatol* 2007; 19(6): 626-635. (VUmc)
834. Van De Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming ML, Schinkel AH, Beijnen JH, Borst P. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. *Mol Pharmacol* 2007; 72: 387-94. (NKI)
835. van de Wetering MD, Weggelaar N, Offringa M, Caron HN, Kuijpers TW. Granulocyte transfusions in neutropaenic children: a systematic review of the literature. *European Journal of Cancer* 2007; 43(14): 2082-2092. (AMC)
836. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, Ylstra B. CGHcall: calling aberrations for array CGH tumor profiles. *Bioinformatics* 2007; 23(7): 892-894. (VUmc)
837. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol* 2007; 25: 4370-8. (NKI)
838. van den Berg H, Caron HN. Paratesticular neuroblastoma: a case against metastatic disease? *Journal of pediatric hematology oncology* 2007; 29(3): 187-189. (AMC)
839. van den Berg RM, Van Tinteren H, Van Zandwijk N, Visser C, Pasic A, Kooi C, Sutedja TG, Baas P, Grunberg K, Mooi WJ, Snijders PJ, Postmus PE, Smit EF. The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. *Am J Respir Crit Care Med* 2007; 175: 1061-5. (NKI/VUmc)
840. van den Bout I, Truong HH, Huvneers S, Kuikman I, Danen EHJ, Sonnenberg A. The regulation of MacMARCKS expression by integrin (beta)3. *Exp Cell Res* 2007; 313: 1260-9. (NKI)
841. van den Broek GB, Wreesmann VB, van den Brekel MW, Rasch CR, Balm AJ, Rao PH. Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. *Clin Cancer Res* 2007; 13: 4386-91. (NKI)
842. van den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 2007; 854: 245-59. (NKI)
843. van den Broek PJ, Kluytmans JA, Ummels LC, Voss A, Vandenbroucke-Grauls CMJE. How many infection control staff do we need in hospitals?. *J Hosp Infect* 2007; 65(2): 108-111. (VUmc)
844. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, Vellenga E, Ossenkoppele GJ, Lowenberg B, Sonneveld P. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. *Ann Hematol* 2007; 86(5): 329-337. (VUmc)
845. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, ten Wolde S, Han KH, van Krugten MV, Allaart CF, Breedveld FC, Dijkmans BAC. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. *Arthritis Rheum* 2007; 56(7): 2129-2134. (VUmc)
846. van der Deen M, Timens W, Timmer-Bosscha H, van der Strate BW, Scheper RJ, Postma DS, de Vries EG, Kerstjens HA. Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice. *Respir Res* 2007; 8: 49. (VUmc)
847. van der Esch M, Steultjens M, Harlaar J, Knol D, Lems WF, Dekker J. Joint proprioception, muscle strength, and functional ability in patients with osteoarthritis of the knee. *Arthritis Rheum* 2007; 57(5): 787-793. (VUmc)
848. van der Esch M, Steultjens MP, Lems WF, Dekker J. Gender difference in varus-valgus laxity in osteoarthritis of the knee. *Scand J Rheumatol* 2007; 36(2): 157-159. (VUmc)
849. van der Gaag NA, de Castro SMM, Rauws EAJ, Bruno MJ, van Eijck CHJ, Kuipers EJ, Gerritsen JJGM, Rutten JP, Greve JW, Hesselink EJ, Klinkenbijl JHG, Rinkes IHM, Borel, Boerma D, Bonsing BA, van Laarhoven CJ, Kubben FJGM, van der Harst E, Sosef MN, Bosscha Koop, de Hingh IHJT, de Wit L, van Delden OM, Busch ORC, van Gulik TM, Bossuyt PMM, Gouma DJ.: Preoperative biliary drainage for periampullary tumors causing obstructive jaundice; DRainage vs. (direct) OPeration (DROP-trial). *BMC Surgery* 2007; 7: 3. (AMC)
850. van der Gaag NA, Gouma DJ, van Gulik TM, Busch ORC, Boermeester MA. Review article: Surgical management of chronic pancreatitis. *Alimentary Pharmacology & Therapeutics* 2007; 26 Suppl 2(Suppl. 2): 221-232. (AMC)
851. van der Geld YG, Senan S, van Sornsen de Koste JR, Verbakel WF, Slotman BJ, Lagerwaard FJ. A four-dimensional CT-based evaluation of techniques for gastric irradiation. *Int J Radiat Oncol Biol Phys* 2007; 69(3): 903-909. (VUmc)
852. van der Hage JJ, Mieog SJ, van de Vijver MJ, van de Velde CC, cooperating investigators of the European Organization for Research and Treatment

- of Cancer. Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. *Breast Cancer Res* 2007; 9: R70. (NKI)
853. van der Heijde D, Landewe R, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Lukas C, Jurik AG, Boers M, Baraliakos X, Braun J. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?. *J Rheumatol* 2007; 34(4): 871-873. (VUmc)
854. van der Heijden JW, Dijkmans BAC, Scheper RJ, Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside. *Nat Clin Pract Rheumatol* 2007; 3(1): 26-34. (VUmc)
855. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, van Groenendael JH, Hazes JM, Breedveld FC, Allaart CF, Dijkmans BAC. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Ann Rheum Dis* 2007; 66(10): 1356-1362. (VUmc)
856. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van WM, de Groot ER, Wolbink G, Dijkmans BAC, Aarden LA. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. *Ann Rheum Dis* 2007; 66(2): 253-256. (VUmc)
857. van der Lee JH, Mokkink LB, Grootenhuis MA, Heymans HS, Offringa M. Definitions and measurement of chronic health conditions in childhood: a systematic review. *JAMA-Journal of the American Medical Association* 2007; 297(24): 2741-2751. (AMC)
858. van der Luit AH, Budde M, Zerp S, Caan W, Klarenbeek JB, Verheij M, Van Blitterswijk WJ. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. *Biochem J* 2007; 401: 541-9. (NKI)
859. van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, Van Blitterswijk WJ. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. *Mol Cancer Ther* 2007; 6: 2337-45. (NKI)
860. van der Marel AP, Samsom JN, Greuter M, van Berkel LA, O'Toole T, Kraal G, Mebius RE. Blockade of IDO inhibits nasal tolerance induction. *J Immunol* 2007; 179(2): 894-900. (VUmc)
861. van der Meij EH, Mast H, van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. *Oral Oncol* 2007; 43(8): 742-748. (VUmc)
862. van der Ploeg HP, Streppel KR, van der Beek AJ, van der Woude LH, Vollenbroek-Hutten MM, Van Harten WH, Van Mechelen W. Successfully improving physical activity behavior after rehabilitation. *Am J Health Promot* 2007; 21: 153-9. (NKI)
863. van der Ploeg IM, Valdes Olmos RA, Nieweg OE, Rutgers EJ, Kroon BB, Hoefnagel CA. The Additional Value of SPECT/CT in Lymphatic Mapping in Breast Cancer and Melanoma. *J Nucl Med* 2007; 48: 1768-0. (NKI)
864. van der Poel H, Beetsma D, van Boven H, Horenblas S. Perineal Salvage Prostatectomy for Radiation Resistant Prostate Cancer. *Eur Urol* 2007; 51: 1565-72. (NKI)
865. van der Poel HG. Cytoskeleton fragments unveiling bladder cancer. *Eur Urol* 2007; 51: 1162-3. (NKI)
866. van der Poel HG. Molecular markers in the diagnosis of prostate cancer. *Crit Rev Oncol Hematol* 2007; 61: 104-39. (NKI)
867. van der Poel HG. Radionuclide Treatment in Metastasized Prostate Cancer{A figure is presented}. *EAU-EBU Update Series* 2007; 5: 113-25. (NKI)
868. van der Pouw-Kraan TCM, van Baarsen LGM, Rustenburg F, Baltus B, Fero M, Verweij CL. Gene expression profiling in rheumatology. *Methods Mol Med* 2007; 136: 305-327. (VUmc)
869. van der Pouw-Kraan TCM, Wijbrandts CA, van Baarsen LGM, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BAC, Tak PP, Verweij CL. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. *Ann Rheum Dis* 2007; 66(8): 1008-1014. (VUmc)
870. Van Der Schoot SC, Nuijen B, Flesch FM, Gore A, Mirejovsky D, Lenaz L, Beijnen JH. Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. *AAPS PharmSciTech* 2007; 8: E61. (NKI)
871. Van Der Schoot SC, Nuijen B, Huitema AD, Beijnen JH. Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis. *Pharm Res* 2007; 24: 605-12. (NKI)
872. Van Der Schoot SC, Vainchtein LD, Beijnen JH, Gore A, Mirejovsky D, Lenaz L, Nuijen B. EO-9 bladder instillations: Formulation selection based on stability characteristics and in vitro simulation studies. *Int J Pharm* 2007; 329: 135-41. (NKI)
873. van der Stoep N, Quinten E, Alblas G, Plancke A, van Eggermond MC, Holling TM, van den Elsen PJ. Constitutive and IFN γ -induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream

- regulatory region. *Mol Immunol* 2007; 44(8): 2036-2046. (VUmc)
874. van der Veen FJC, Strackee SD, Karim RB, Hage JJ. Poor results after interpositional arthroplasty with fascia lata allograft for arthritis of the trapezio-metacarpal joint. *Eur J Plast Surg* 2007; 29: 257-62. (NKI)
875. van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. *Histopathology* 2007; 51: 322-35. (NKI)
876. van der Veldt AAM, van den Eertwegh AJM, Hoekman K, Barkhof F, Boven E. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. *Ann Oncol* 2007; 18(10): 1747-1750. (VUmc)
877. van der Waal R, van der Waal I. Oral non-squamous malignant tumors; diagnosis and treatment. *Med Oral Patol Oral Cir Bucal* 2007; 12(7): E486-E491. (VUmc)
878. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner M, Peters PJ. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. *Cell* 2007; 129: 1287-98. (NKI)
879. van Dijk J, Huisman J, Moll AC, Schouten-van Meeteren AY, Bezemer PD, Ringens PJ, Cohen-Kettenis PT, Imhof SM. Health-related quality of life of child and adolescent retinoblastoma survivors in the Netherlands. *Health Qual Life Outcomes* 2007; 5(1): 65. (VUmc)
880. van Dijk J, Imhof SM, Moll AC, Ringens PJ, Cohen-Kettenis PT, Rijmen F, Huisman J. Quality of life of adult retinoblastoma survivors in the Netherlands. *Health Qual Life Outcomes* 2007; 5: 30. (VUmc)
881. van Dijk M, Benninga MA, Grootenhuis MA, Onland-van Nietwenhuizen AM, Last BF. Chronic childhood constipation: a review of the literature and the introduction of a protocolized behavioral intervention program. *Patient Education and Counseling* 2007; 67(1-2): 63-77. (AMC)
882. van Dongen GAMS, Visser GWM, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications. *Oncologist* 2007; 12(12): 1379-1389. (VUmc)
883. van Eeden S, Offerhaus GJ, Hart AAM, Boerrigter L, Nederlof PM, Porter E, van Velthuysen MLF. Goblet cell carcinoid of the appendix: a specific type of carcinoma. *Histopathology* 2007; 51: 763-73. (NKI)
884. van Elmpt WJ, Nijsten SM, Dekker AL, Mijnheer BJ, Lambin P. Treatment verification in the presence of inhomogeneities using EPID-based three-dimensional dose reconstruction. *Med Phys* 2007; 34: 2816-26. (NKI)
885. van Erp EJM, Heintz APM, Helmerhorst TJM, Koster META, van Leeuwen FE. [Settlement effected for damages for victims of diethylstilbestrol (DES). Regeling voor schadevergoeding aan slachtoffers van diethylstilbestrol (des) een feit. *Ned Tijdschr Geneesk* 2007; 151: 1197-200. (NKI)
886. Van Erp NPH, Oostendorp RL, Guchelaar HJ, Schellens JHM, Gelderblom H. Is rectal administration an alternative route for imatinib? *Cancer Chemother Pharmacol* 2007; 60: 623-4. (NKI)
887. van Geel AN, den Bakker MA, Kirkels W, Horenblas S, Kroon BB, de Wilt JH, Eggermont AM, Mooi WJ, van der Aa MN. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. *Urology* 2007; 70: 143-7. (NKI/VUmc)
888. van Gerven MA, Diez FJ, Taal BG, Lucas PJ. Selecting treatment strategies with dynamic limited-memory influence diagrams. *Artif Intell Med* 2007; 40: 171-86. (NKI)
889. van Gerven MA, Jurgelenaite R, Taal BG, Heskes T, Lucas PJ. Predicting carcinoid heart disease with the noisy-threshold classifier. *Artif Intell Med* 2007; 40: 45-55. (NKI)
890. van Gogh CDL, Mahieu HF, Kuik DJ, Rinkel RN, Langendijk JA, Verdonck-de Leeuw IM. Voice in early glottic cancer compared to benign voice pathology. *Eur Arch Otorhinolaryngol* 2007; 264(9): 1033-1038. (VUmc)
891. van Goor AT, Kroger R, Klomp HM, de Jong MA, van den Brekel MW, Balm AJ. Introduction of lymphangiography and percutaneous embolization of the thoracic duct in a stepwise approach to the management of chylous fistulas. *Head Neck* 2007; 29: 1017-23. (NKI)
892. van Gulik TM, de Graaf W, Dinant S, Busch ORC, Gouma DJ. Vascular occlusion techniques during liver resection. *Digestive Surgery* 2007; 24(4): 274-281. (AMC)
893. van Gulik TM, Dervenis C. Bloodless liver resection. *Digestive Surgery* 2007; 24(4): 249. (AMC)
894. van Gulik TM, Dinant S, Busch ORC, Rauws EAJ, Obertop H, Gouma DJ. Original article: New surgical approaches to the Klatskin tumour. *Alimentary Pharmacology & Therapeutics* 2007; 26 Suppl 2(Suppl. 2): 127-132. (AMC)
895. van Gulik TM, Gouma DJ. Changing perspectives in the assessment of resectability of hilar cholangiocarcinoma. *Annals of Surgical Oncology* 2007; 14(7): 1969-1971. (AMC)
896. van Gulik TM, Marsman HA. Advances of surgical resection of liver metastasis with the integration of new biologic agents. *Digestive Oncology* 2007; 7: 88-90. (AMC)
897. van Gulik TM, Vetelainen R. Steatosis as a risk factor in liver surgery - Reply. *Annals of Surgery* 2007; 246(2): 341. (AMC)

898. van Gulik TM. Diagnostiek en behandeling van het leverceladenoom in Nederland: landelijke overeenstemming gewenst. *Nederlands Tijdschrift voor Geneeskunde* 2007; 151(24): 1325-1326. (AMC)
899. van Haaren PMA, Kok HP, van den Berg CAT, Zum Vorde Sive Vording PJ, Oldenburg S, Stalpers LJA, Schilthuis MS, de Leeuw AAC, Crezee J.: On verification of hyperthermia treatment planning for cervical carcinoma patients. *International Journal of Hyperthermia* 2007; 23(3): 303-314. (AMC)
900. van Halm V, Nielen MMJ, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, Twisk JW, van de Stadt RJ, de Koning MH, Habibuw MR, van der Horst-Bruinsma IE, Dijkmans BAC. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. *Ann Rheum Dis* 2007; 66(2): 184-188. (VUmc)
901. Van Harten WH, Veldhuis MJ, Hoeksma BH, Krabbendam KJ. Strategic behaviour of institutional providers in mental handicapped care in the Netherlands. *J Health Organ Manag* 2007; 21: 184-93. (NKI)
902. van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, Wapenaar MC, Barnardo MC, Bethel G, Holmes GK, Feighery C, Jewell D, Kelleher D, Kumar P, Travis S, Walters JR, Sanders DS, Howdle P, Swift J, Playford RJ, McLaren WM, Mearin ML, Mulder C. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. *Nat Genet* 2007; 39(7): 827-829. (VUmc)
903. van Herk M. 4D Radiotherapy. *Clin Oncol (R Coll Radiol)* 2007; 19: S10. (NKI)
904. van Herk M. Different styles of image-guided radiotherapy. *Semin Radiat Oncol* 2007; 17: 258-67. (NKI)
905. van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, Schinkel AH. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. *Mol Cell Biol* 2007; 27: 1247-53. (NKI)
906. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. *J Clin Invest* 2007; 117: 3583-92. (NKI)
907. Van Hest LP, Ruijs MWG, Wagner A, Van Der Meer CA, Verhoef S, van't Veer LJ, Meijers-Heijboer H. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. *Fam Cancer* 2007; 6: 311-6. (NKI)
908. van Hooft JE, Bemelman WA, Breumelhof R, Siersema PD, Kruyt PM, van der Linde K, Veenendaal RA, Verhulst M-L, Marinelli AW, Gerritsen JJGM, van Berkel A-M, Timmer R, Grubben MJAL, Scholten P, Geraedts AAM, Oldenburg B, Sprangers MAG, Bossuyt PMM, Fockens P. Colonic stenting as bridge to surgery versus emergency surgery for management of acute left-sided malignant colonic obstruction: a multicenter randomized trial (Stent-in 2 study). *BMC Surgery* 2007; 7: 12. (AMC)
909. van Hooft JE, Bemelman WA, Fockens P. Onderzoek naar de waarde van colonstentplaatsing als overbrugging tot electieve operatie bij de behandeling van een acute maligne linkszijdige colonobstructie: de STENT-IN 2-studie. *Nederlands Tijdschrift voor Geneeskunde* 2007; 151(22): 1249-1251. (AMC)
910. van Houdt I, Muris JJ, Hesselink AT, Kramer D, Cillessen SA, Moesbergen LM, Vos W, Hooijberg E, Meijer CJLM, Kummer JA, Oudejans JJ. Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation. *Histopathology* 2007; 51(6): 778-784. (VUmc)
911. van Koperen PJ, D'Hoore A, Wolthuis AM, Bemelman WA, Slors JFM. Anal fistula plug for closure of difficult anorectal fistula: a prospective study. *Diseases of the Colon & Rectum* 2007; 50(12): 2168-2172. (AMC)
912. van Kuilenburg ABP, Klumpen H-J, Westermann AM, Zoetekouw L, van Lenthe H, Bakker PJM, Richel DJ, Guchelaar HJ. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. *European Journal of Cancer* 2007; 43(2): 459-465. (AMC)
913. van la Parra RF, Kon M, Schellekens PP, Braunius WW, Pameijer FA. The prognostic value of abnormal findings on radiographic swallowing studies after total laryngectomy. *Cancer Imaging* 2007; 7: 119-25. (NKI)
914. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJLM, Raaphorst FM. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. *Eur Urol* 2007; 52(2): 455-463. (VUmc)
915. van Liempt E, van Vliet SJ, Engering A, Garcia Vallejo JJ, Bank CM, Sanchez-Hernandez M, van Kooyk Y, van Die IM. *Schistosoma mansoni* soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic cell activation. *Mol Immunol* 2007; 44(10): 2605-2615. (VUmc)
916. van Loo I, Diederens BM, Savelkoul PHM, Woudenberg JHC, Roosendaal R, van Belkum A, Lemmens-den Toom N, Verhulst C, van Keulen PH, Kluytmans JA. Methicillin-resistant *Staphylococcus aureus* in meat products, the Netherlands. *Emerg Infect Dis* 2007; 13: 1753-1755. (VUmc)
917. van Loo I, Huijsdens X, Tiemersma E, de Neeling A, van de Sande-Bruinsma N, Beaujean D, Voss A, Kluytmans JA. Emergence of Methicillin-resistant *Staphylococcus aureus* of animal origin in

- humans. *Emerg Infect Dis* 2007; 12: 1834-1839. (VUmc)
918. van Luijn HEM, Musschenga AW, Aaronson NK. Evaluating the risks and benefits of phase II and III cancer clinical trials: a look at Institutional Review Board Members in the Netherlands. *IRB* 2007; 29: 13-8. (NKI)
919. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, Van Zandwijk N, Splinter TAW, Giaccone G. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. *J Natl Cancer Inst* 2007; 99: 442-50. (NKI/VUmc)
920. Van Meeteren LA, Moolenaar WH. Regulation and biological activities of the autotaxin-LPA axis. *Prog Lipid Res* 2007; 46: 145-60. (NKI)
921. van Meurs T, van Doorn R, Kirtschig G. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. *Dermatol Surg* 2007; 33(5): 623-626. (VUmc)
922. van Montfort T, Nabatov AA, Geijtenbeek TBH, Pollakis G, Paxton WA. Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes. *J Immunol* 2007; 178(5): 3177-3185. (VUmc)
923. van Nieuwenhuizen D, Klein M, Stalpers LJ, Leenstra S, Heimans JJ, Reijneveld JC. Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. *J Neurooncol* 2007; 84(3): 271-278. (VUmc)
924. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MVM, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. *Int J Radiat Oncol Biol Phys* 2007; 69(4): 1246-1253. (AMC/VUmc)
925. van Oers Marinus HJ. Rituximab maintenance therapy: a step forward in follicular lymphoma. *Haematologica - The Hematology Journal* 92(6), 2007, 826-833. (AMC)
926. van Oers MHJ. Rituximab maintenance in indolent lymphoma: indications and controversies. *Current Oncology Reports* 2007; 9(5): 378-383. (AMC)
927. van Oosterwijk MF, Juwana H, Arens R, Tesselaar K, van Oers MHJ, Eldering E, van Lier RAW. CD27-CD70 interactions sensitise naive CD4(+) T cells for IL-12-induced T(h)1 cell development. *International Immunology* 2007; 19(6): 713-718. (AMC)
928. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Aberrant marker expression patterns on the CD34+. *Leukemia* 2007; 21(8): 1700-1707. (VUmc)
929. van Rhenen A, Moshaver B, Ossenkoppele GJ, Schuurhuis GJ. New approaches for the detection of minimal residual disease in acute myeloid leukemia. *Malignancy Reports* 2007; 2: 111-118. (VUmc)
930. van Rhenen A, van Dongen GAMS, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van WM, Zweegman S, Ossenkoppele GJ, Jan SG. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. *Blood* 2007; 110(7): 2659-2666. (VUmc)
931. Van Rijk MC, Tanis PJ, Nieweg OE, Loo CE, Olmos RAV, Oldenburg HSA, Rutgers EJT, Hoefnagel CA, Kroon BBR. Sentinel node biopsy and concomitant probe-guided tumor excision of nonpalpable breast cancer. *Ann Surg Oncol* 2007; 14: 627-32. (NKI)
932. van Rijn RS, Simonetti ER, Hagenbeek A, Bonyhadi M, Storm G, Martens ACM, Ebeling SB. Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality. *Experimental Hematology* 2007; 35(1): 117-127. (AMC)
933. van Rossum MAJ, van Soesbergen RM, Boers M, Zwiderman AH, Fiselier TJ, Franssen MJ, ten Cate R, van Suijlekom-Smit LW, Wulffraat NM, van Luijk WH, Oostveen JC, Kuis W, Dijkmans BAC. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. *Ann Rheum Dis* 2007; 66(11): 1518-1524. (VUmc)
934. van Schaardenburg D, Wolbink G, Nurmohamed MT, Dijkmans BAC. Do C-reactive protein levels help predict onset of rheumatoid arthritis in women?. *Nat Clin Pract Rheumatol* 2007; 3(6): 318-319. (VUmc)
935. Van Seters M, Ten Kate FJW, van Beurden M, Verheijen RHM, Meijer CJLM, Burger MPM, Helmerhorst TJM. In the absence of (early) invasive carcinoma, vulvar intraepithelial neoplasia associated with lichen sclerosis is mainly of undifferentiated type: New insights in histology and aetiology. *J Clin Pathol* 2007; 60: 504-9. (NKI/VUmc)
936. van Sornsen de Koste JR, Cuijpers JP, de Geest FG, Lagerwaard FJ, Slotman BJ, Senan S. Verifying 4D gated radiotherapy using time-integrated electronic portal imaging: a phantom and clinical study. *Radiat Oncol* 2007; 2: 32. (VUmc)
937. van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Dijkmans BAC, Boers M. Why are Dutch rheumatologists reluctant to use the COBRA treatment strategy in early rheumatoid arthritis?. *Ann Rheum Dis* 2007; 66(7): 974-976. (VUmc)
938. van Veen SQ, Meijers JCM, Levi M, van Gulik TM, Boermeester MA. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental

- polymicrobial peritonitis. *Shock* 2007; 27(5): 534-541. (AMC)
939. van Velthoven MEJ, Faber DJ, Verbraak FD, van Leeuwen TG, de Smet MD. Recent developments in optical coherence tomography for imaging the retina. *Progress in Retinal and Eye Research* 2007; 26(1): 57-77. (AMC)
940. van Vliet MH, Klijn CN, Wessels LFA, Reinders MJT. Module-based outcome prediction using breast cancer compendia. *PLoS ONE* 2007; 2: e1047. (NKI)
941. van Vliet SJ, Aarnoudse CA, Broks-van den Berg VC, Boks M, Geijtenbeek TBH, van Kooyk Y. MGL-mediated internalization and antigen presentation by dendritic cells: a role for tyrosine-5. *Eur J Immunol* 2007; 37(8): 2075-2081. (VUmc)
942. van Vliet SJ, den Dunnen JT, Gringhuis SI, Geijtenbeek TBH, van Kooyk Y. Innate signaling and regulation of Dendritic cell immunity. *Curr Opin Immunol* 2007; 19(4): 435-440. (VUmc)
943. van Well GT, van der Mark LB, Vermeulen RJ, van Royen BJ, Wuisman PI, van Furth AM. Spinal tuberculosis in a 14-year-old immigrant in the Netherlands. *Eur J Pediatr* 2007; 166(10): 1071-1073. (VUmc)
944. van Well GT, Wieland CW, Florquin S, Roord JJ, van der Poll T, van Furth AM. A new murine model to study the pathogenesis of tuberculous meningitis. *J Infect Dis* 2007; 195(5): 694-697. (VUmc)
945. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van Hinsbergh V, Lowik CW. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. *Eur J Cancer* 2007; 43(2): 433-442. (VUmc)
946. Van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P, Burgers S, Nederlof P. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. *Ann Oncol* 2007; 18: 99-103. (NKI)
947. Van Zandwijk N, van de Vijver MJ. Clairvoyance or reliable prediction of the future? *Ann Oncol* 2007; 18: 407-8. (NKI)
948. van Zeijl L, Ponsioen B, Giepmans BN, Ariaens A, Postma FR, Varnai P, Balla T, Divecha N, Jalink K, Moolenaar WH. Regulation of connexin43 gap junctional communication by phosphatidylinositol 4,5-bisphosphate. *J Cell Biol* 2007; 177: 881-91. (NKI)
949. Varghese B, Rajan V, van Leeuwen TG, Steenbergen W. Discrimination between Doppler-shifted and non-shifted light in coherence domain path length resolved measurements of multiply scattered light. *Optics Express* 2007; 15(20): 13340-13350. (AMC)
950. Varghese B, Rajan V, van Leeuwen TG, Steenbergen W. Evaluation of a multimode fiber optic low coherence interferometer for path length resolved Doppler measurements of diffuse light. *Review of Scientific Instruments* 2007; 78(12): 126103. (AMC)
951. Varghese B, Rajan V, van Leeuwen TG, Steenbergen W. Path-length-resolved measurements of multiple scattered photons in static and dynamic turbid media using phase-modulated low-coherence interferometry. *Journal of Biomedical Optics* 2007; 12(2): 024020. (AMC)
952. Varghese B, Rajan V, van Leeuwen TG, Steenbergen W. Path-length-resolved optical Doppler perfusion monitoring. *Journal of Biomedical Optics* 2007; 12(6): 060508. (AMC)
953. Varghese B, Rajan V, van Leeuwen TG, Steenbergen W. Quantification of optical Doppler broadening and optical path lengths of multiply scattered light by phase modulated low coherence interferometry. *Optics Express* 2007; 15(15): 9157-9165. (AMC)
954. Varma MJO, Breuls RGM, Schouten TE, Jurgens WJFM, Bontkes HJ, Schuurhuis GJ, van Ham SM, van Milligen FJ. Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells. *Stem cells and development* 2007; 16(1): 91-104. (AMC/VUmc)
955. Veenhof AA, Kropman RH, Engel AF, Craanen ME, Meijer S, Meijer OW, van der Peet DL, Cuesta MA. Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery. *Int J Colorectal Dis* 2007; 22(5): 507-513. (VUmc)
956. Vekony H, Ylstra B, Wilting SM, Meijer GA, van de Wiel MA, Leemans CR, van der Waal I, Bloemena E. DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. *Clin Cancer Res* 2007; 13(11): 3133-3139. (VUmc)
957. Veldt BJ, van der Vliet HJ, von Blomberg BME, van Vlierberghe H, Gerken G, Nishi N, Hayashi K, Scheper RJ, de Knecht RJ, van den Eertwegh AJM, Janssen HL, van Nieuwkerk CM. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. *J Hepatol* 2007; 47(3): 356-365. (VUmc)
958. Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JHM. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. *Cancer Chemother Pharmacol* 2007; 59: 43-50. (NKI)
959. Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JHM, Rodenhuis S. Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. *Invest New Drugs* 2007; 25: 279-81. (NKI)

960. Veltkamp SA, Rosing H, Huitema ADR, Fetell MR, Nol A, Beijnen JH, Schellens JHM. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. *Cancer Chemother Pharmacol* 2007; 60: 635-42. (NKI)
961. Vens C, Hofland I, Begg AC. Involvement of DNA polymerase beta in repair of ionizing radiation damage as measured by in vitro plasmid assays. *Radiat Res* 2007; 168: 281-91. (NKI)
962. Verbruggen MB, Zweemer RP, Piek JM, van Unnik GA, van Diest PJ, Gilje JJ, Menko FH, Dorsman JC, Verheijen RHM. A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature. *Int J Gynecol Cancer* 2007; 17(5): 1143-1147. (VUmc)
963. Verdonck LF, Notenboom A, De Jong DD, MacKenzie MA, Verhoef GEG, Kramer MHH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, Van Imhoff GW. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin Lymphoma: A phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). *Blood* 2007; 109: 2759-66. (NKI/VUmc)
964. Verdonck-de Leeuw IM, Eerenstein SE, van der Linden MH, Kuik DJ, de Bree R, Leemans CR. Distress in spouses and patients after treatment for head and neck cancer. *Laryngoscope* 2007; 117(2): 238-241. (VUmc)
965. Verhagen AP, Bierma-Zeinstra SM, Boers M, Cardoso JR, Lambeck J, de Bie RA, de Vet HC. Balneotherapy for osteoarthritis. *Cochrane Database Syst Rev* 2007; (4): CD006864. (VUmc)
966. Verhagen MM, van Aifen N, Pillen S, Weemaes CM, Yntema JL, Hiel JA, Ter Laak H, van Deuren M, Broeks A, Willemssen MA. Neuromuscular abnormalities in ataxia telangiectasia: a clinical, electrophysiological and muscle ultrasound study. *Neuropediatrics* 2007; 38: 117-21. (NKI)
967. Verhoeff JJ, Stalpers LJ, Coumou AW, Koedooder K, Lavini C, van Noorden CJ, Haveman J, Vandertop WP, van Furth WR. Experimental iodine-125 seed irradiation of intracerebral brain tumors in nude mice. *Radiat Oncol* 2007; 2: 38. (VUmc)
968. Vermeulen C, Bertocci B, Begg AC, Vens C. Ionizing radiation sensitivity of DNA polymerase lambda-deficient cells. *Radiat Res* 2007; 168: 683-8. (NKI)
969. Vermeulen C, Verwijs-Janssen M, Cramers P, Begg A, Vens C. Role for DNA polymerase beta in response to ionizing radiation. *DNA Repair* 2007; 6: 202-12. (NKI)
970. Vermeulen M, van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. *Journal of Neurology Neurosurgery and Psychiatry* 2007; 78(10): 1154. (AMC)
971. Verwaal VJ. Detection and treatment of recurrent disease after cytoreduction and HIPEC. *Cancer Treat Res* 2007; 134: 419-24. (NKI)
972. Verwaal VJ. Results of cytoreduction followed by HIPEC in carcinomatosis of colorectal origin. *Cancer Treat Res* 2007; 134: 291-301. (NKI)
973. Veteläinen R, Bennink RJ, van Vliet AK, van Gulik TM. Mild steatosis impairs functional recovery after liver resection in an experimental model. *British Journal of Surgery* 2007; 94(8): 1002-1008. (AMC)
974. Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. *Annals of Surgery* 2007; 245(1): 20-30. (AMC)
975. Veteläinen R, van Vliet A, van Gulik TM. Essential pathogenic and metabolic differences in steatosis induced by choline or methionine-choline deficient diets in a rat model. *Journal of Gastroenterology and Hepatology* 2007; 22(9): 1526-1533. (AMC)
976. Veteläinen R, van Vliet AK, van GTM. Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. *Annals of Surgery* 2007; 245(1): 44-50. (AMC)
977. Vink SR, Van Blitterswijk WJ, Schellens JH, Verheij M. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. *Cancer Treat Rev* 2007; 33: 191-202. (NKI)
978. Vink SR, van der Luit AH, Klarenbeek JB, Verheij M, Van Blitterswijk WJ. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. *Biochem Pharmacol* 2007; 74: 1456-65. (NKI)
979. Vischioni B, Oudejans JJ, Kruyt FAE, Giaccone G, Rodriguez JA. Immunohistochemical detection of nuclear survivin in NSCLC: a comparison of commercial antibodies. *Histopathology* 2007; 50(5): 671-675. (VUmc)
980. Visser DH, van den Berg YL, van Furth AM, Oomen MW, Schouten-van Meeteren AY, Pajkrt D, van den Bos C, van Well GT. Diagnosis and treatment of cutaneous zygomycosis. *Pediatr Infect Dis J* 2007; 26(12): 1165-1166. (VUmc)
981. Visser O, Bakx R, Zoetmulder FAN, Levering CC, Meijer S, Slors JFM, Van Lanschot JJB. The influence of total mesorectal excision on local recurrence and survival in rectal cancer patients: A population-based study in greater Amsterdam. *J Surg Oncol* 2007; 95: 447-54. (NKI/VUmc)
982. Visser O, van Leeuwen FE. Cancer risk in first generation migrants in North-Holland/Flevoland, The Netherlands, 1995-2004. *Eur J Cancer* 2007; 43: 901-8. (NKI)
983. Voehringer D, van Rooijen N, Locksley RM. Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively

- activated macrophages. *J Leukoc Biol* 2007; 81(6): 1434-1444. (VUmc)
984. Vogel MJ, Peric-Hupkes D, van Steensel B. Detection of in vivo protein-DNA interactions using DamID in mammalian cells. *Nat Protoc* 2007; 2: 1467-78. (NKI)
985. von Meyenfeldt EM, Mantel SF, Gouma DJ, van Gulik TM. Tumoren in de galblaas; een moeilijke differentiatie tussen maligniteit en goedaardige tumor. *Nederlands Tijdschrift voor Geneeskunde* 2007; 151(19): 1049-1054. (AMC)
986. Vondenhoff MF, Kraal G, Mebius RE. Lymphoid organogenesis in brief. *Eur J Immunol* 2007; 37 Suppl 1S46-S52: S46-S52. (VUmc)
987. Voorhoeve PM, Agami R. Classifying microRNAs in cancer: The good, the bad and the ugly. *Biochim Biophys Acta (CR)* 2007; 1775: 274-82. (NKI)
988. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. *Adv Exp Med Biol* 2007; 604: 17-46. (NKI)
989. Voortman J, Checinska A, Giaccone G, Rodriguez JA, Kruyt FAE. Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. *Mol Cancer Ther* 2007; 6(3): 1046-1053. (VUmc)
990. Voortman J, Checinska A, Giaccone G. The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. *Mol Cancer* 2007; 6: 73. (VUmc)
991. Voortman J, Resende TP, bou El Hassan MA, Giaccone G, Kruyt FAE. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. *Mol Cancer Ther* 2007; 6(7): 2103-2112. (VUmc)
992. Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde CJ, Giaccone G. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. *Clin Cancer Res* 2007; 13(12): 3642-3651. (VUmc)
993. Vos MJ, Tony BN, Hoekstra OS, Postma TJ, Heimans JJ, Hooft L. Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in the detection of recurrent glioma. *Nucl Med Commun* 2007; 28(6): 431-439. (VUmc)
994. Voskuil DW, Monnikhof EM, Elias SG, Vlems FA, van Leeuwen FE. Physical activity and endometrial cancer risk, a systematic review of current evidence. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 639-48. (NKI)
995. Vrieling A, Rookus MA, Kampman E, Bonfrer JM, Korse CM, van Doorn J, Lampe JW, Cats A, Witteman BJ, van Leeuwen FE, van't Veer LJ, Voskuil DW. Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk. *J Nutr* 2007; 137: 379-83. (NKI)
996. Vrieling A, Voskuil DW, Bonfrer JM, Korse CM, van Doorn J, Cats A, Depla AC, Timmer R, Witteman BJ, van Leeuwen FE, van't Veer LJ, Rookus MA, Kampman E. Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer. *Am J Clin Nutr* 2007; 86: 1456-62. (NKI)
997. Vrolijk L, Yuana Y, Schuurhuis GJ, van Hinsbergh V, Gundy C, de Haas R, van Crujssen H, Boven E, Hoekman K, Broxterman HJ. VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. *Thromb Haemost* 2007; 98(2): 440-450. (VUmc)
998. Wang H, Madariaga ML, Wang S, van Rooijen N, Oldenborg PA, Yang YG. Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells. *Proc Natl Acad Sci U S A* 2007; 104(34): 13744-13749. (VUmc)
999. Wapenaar MC, Monsuur AJ, Poell J, van 't Slot R, Meijer JW, Meijer GA, Mulder CJ, Mearin ML, Wijmenga C. The SPINK gene family and celiac disease susceptibility. *Immunogenetics* 2007; 59(5): 349-357. (VUmc)
1000. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. *J Oral Pathol Med* 2007; 36(10): 575-580. (VUmc)
1001. Welm AL, Sneddon JB, Taylor C, Nuyten DSA, van de Vijver MJ, Hasegawa BH, Bishop JM. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. *Proc Natl Acad Sci U S A* 2007; 104: 7570-5. (NKI)
1002. Wendling M, Zijp LJ, McDermott LN, Smit EJ, Sonke JJ, Mijnheer BJ, van Herk M. A fast algorithm for gamma evaluation in 3D. *Med Phys* 2007; 34: 1647-54. (NKI)
1003. Westerman BA, Breuer RHJ, Poutsma A, Chhatta A, Noorduy LA, Koolen MGJ, Postmus PE, Blankenstein MA, Oudejans CBM. Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors. *Int J Biol Markers* 2007; 22: 114-23. (NKI/VUmc)
1004. Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia. *Biomed Pharmacother* 2007; 61(6): 306-314. (VUmc)
1005. Westerterp M, Pruijm J, Oyen W, Hoekstra OS, Paans A, Visser E, van Lanschot J, Sloof G,

- Boellaard R. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. *Eur J Nucl Med Mol Imaging* 2007; 34(3): 392-404. (VUmc)
1006. Wieland CW, Koppel EA, den Dunnen JT, Florquin S, McKenzie AN, van Kooyk Y, van der Poll T, Geijtenbeek TBH. Mice lacking SIGIRR have stronger T helper 1 responses to Mycobacterium tuberculosis. *Microbes Infect* 2007; 9(2): 134-141. (VUmc)
1007. Wiersma J, van Wieringen N, Crezee H, van Dijk JDP. Delineation of potential hot spots for hyperthermia treatment planning optimisation. *International Journal of Hyperthermia* 2007; 23(3): 287-301. (AMC)
1008. Wijnhoven SWP, Speksnijder EN, Liu X, Zwart E, VanOostrom CT, Beems RB, Hoogervorst EM, Schaap MM, Attardi LD, Jacks T, Van Steeg H, Jonkers J, de Vries A. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. *Cancer Res* 2007; 67: 4648-56. (NKI)
1009. Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A, Extermann M, Girre V, Brain E, Audisio RA, Bartelink H, Barton M, Giordano SH, Muss H, Aapro M. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. *Lancet Oncol* 2007; 8: 1101-15. (NKI)
1010. Wilhelmsen K, Litjens SHM, Kuikman I, Margadant C, van Rheenen J, Sonnenberg A. Serine phosphorylation of the integrin (beta)4 subunit is necessary for epidermal growth factor receptor-induced hemidesmosome disruption. *Mol Biol Cell* 2007; 18: 3512-22. (NKI)
1011. Williams ES, Stap J, Essers J, Ponnaiya B, Luijsterburg MS, Krawczyk PM, Ullrich RL, Aten JA, Bailey SM. DNA double-strand breaks are not sufficient to initiate recruitment of TRF2. *Nature Genetics* 2007; 39(6): 696-8; author reply 698-9. (AMC)
1012. Williams SK, de la Rosette JJMCH, Landman J, Keeley FX. Cryoablation of small renal tumors. *EAU-EBU Update Series* 2007; 5: 206-218. (AMC)
1013. Wind J, Bemelman WA. Re: tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma. *Diseases of the Colon & Rectum* 2007; 50(9): 1484; author reply 1484-1484; author reply 1485. (AMC)
1014. Wind J, Bemelman WA. Systematic review of enhanced recovery programmes in colonic surgery (*Br J Surg* 2006; 93 : 800-809) - Reply. *British Journal of Surgery* 2007; 94(2): 248. (AMC)
1015. Wind J, Cremers JEL, Henegouwen MI van Berge, Gouma Dirk J, Jansen FW, Bemelman WA. Medical liability insurance claims on entry-related complications in laparoscopy. *Surgical Endoscopy and Other Interventional Techniques* 2007; 21(11): 2094-2099. (AMC)
1016. Wind J, Koopman AG, Henegouwen MI, van Berge, Slors JFM, Gouma DJ, Bemelman WA. Laparoscopic reintervention for anastomotic leakage after primary laparoscopic colorectal surgery. *British Journal of Surgery* 2007; 94(12): 1562-1566. (AMC)
1017. Wind J, Lagarde SM, ten Kate FJW, Ubbink DT, Bemelman WA, van Lanschot JJB. A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. *EJSO : European Journal of Surgical Oncology* 2007; 33(4): 401-408. (AMC)
1018. Wind J, Smit EJ, Senan S, Eerenberg JP. Residual disease at the bronchial stump after curative resection for lung cancer. *Eur J Cardiothorac Surg* 2007; 32(1): 29-34. (VUmc)
1019. Wink MH, de la Rosette JJMCH, Grimbergen CA, Wijkstra H. Transrectal contrast enhanced ultrasound for diagnosis of prostate cancer. *World Journal of Urology* 2007; 25(4): 367-373. (AMC)
1020. Wink MH, de La Rosette JJMCH, Laguna P, Lagerveld BW, Wijkstra H. Ultrasonography of renal masses using contrast pulse sequence imaging: a pilot study. *Journal of Endourology* 2007; 21(5): 466-472. (AMC)
1021. Wink MH, Laguna MP, Lagerveld BW, de La Rosette JJMCH, Wijkstra H. Contrast-enhanced ultrasonography in the follow-up of cryoablation of renal tumours: a feasibility study. *BJU International* 2007; 99(6): 1371-1375. (AMC)
1022. Witlox MA, Lamfers MLM, Wuisman PI, Curiel DT, Siegal GP. Evolving gene therapy approaches for osteosarcoma using viral vectors: review. *Bone* 2007; 40(4): 797-812. (VUmc)
1023. Witte MG, van der Geer J, Schneider C, Lebesque JV, Alber M, van Herk M. IMRT optimization including random and systematic geometric errors based on the expectation of TCP and NTCP. *Med Phys* 2007; 34: 3544-55. (NKI)
1024. Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Peters GJ, Postmus PE. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. *Clin Cancer Res* 2007; 13(8): 2414-2421. (VUmc)
1025. Woerdeman LAE, Hage JJ, Hofland MMI, Rutgers EJT. A prospective assessment of surgical risk factors in 400 cases of skin-sparing mastectomy and immediate breast reconstruction with implants to establish selection criteria. *Plast Reconstr Surg* 2007; 119: 455-63. (NKI)
1026. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. *Arthritis Rheum* 2007; 57(6): 935-942. (VUmc)
1027. Wolters VM, Verbeek WHM, Zhernakova A, Onland-Moret C, Schreurs MW, Monsuur AJ, Verduijn W, Wijmenga C, Mulder CJ. The MYO9B gene is a strong risk factor for developing

- refractory celiac disease. *Clin Gastroenterol Hepatol* 2007; 5(12): 1399-405, 1405. (VUmc)
1028. Wondergem N, de la Rosette JJMCH. HIFU and cryoablation - non or minimal touch techniques for the treatment of prostate cancer. Is there a role for contrast enhanced ultrasound? *Minimally Invasive Therapy & Allied Technologies* 2007; 16(1): 22-30. (AMC)
1029. Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJF, Meijer CJLM, Franceschi S. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. *Int J Cancer* 2007; 121(6): 1306-1311. (VUmc)
1030. Wu W, Sigmond J, Peters GJ, Borch RF. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. *J Med Chem* 2007; 50(15): 3743-3746. (VUmc)
1031. Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. *Nat Genet* 2007; 39(2): 159-161. (VUmc)
1032. Yu L, Andrews N, Zhao Q, McKean D, Williams J, Connor L, Gerasimenko O, Hilkens J, Hirabayashi J, Kasai K, Rhodes J. Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion. *J Biol Chem* 2007; 282: 773-81. (NKI)
1033. Yu Z, Genest PA, Ter Riet B, Sweeney K, DiPaolo C, Kieft R, Christodoulou E, Perrakis A, Simmons JM, Hausinger RP, van Luenen HGAM, Rigden DJ, Sabatini R, Borst P. The protein that binds to DNA base J in trypanosomatids has features of a thymidine hydroxylase. *Nucleic Acids Res* 2007; 35: 2107-15. (NKI)
1034. Zandvliet AS, Huitema ADR, Copalu W, Yamada Y, Tamura T, Beijnen JH, Schellens JHM. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. *Clin Cancer Res* 2007; 13: 2970-6. (NKI)
1035. Zencak D, Crippa SV, Tekaya M, Tanger E, Schorderet DE, Munier FL, van Lohuizen M, Arsenijevic Y. BMI1 loss delays photoreceptor degeneration in Rd1 mice. Bmi1 loss and neuroprotection in Rd1 mice. *Adv Exp Med Biol* 2006; 572: 209-15. (NKI)
1036. Zhang P, Weis RM, Peters PJ, Subramaniam S. Electron tomography of bacterial chemotaxis receptor assemblies. *Methods Cell Biol* 2007; 79: 373-84. (NKI)
1037. Zijlstra JM, Comans EFI, van Lingen A, Hoekstra OS, Gundy CM, Coebergh WJ, Bongers V. FDG PET in lymphoma: the need for standardization of interpretation An observer variation study. *Nucl Med Commun* 2007; 28(10): 798-803. (VUmc)
1038. Zinner R, Teller K, Versteeg R, Cremer T, Cremer M. Biochemistry meets nuclear architecture: multicolor immuno-FISH for co-localization analysis of chromosome segments and differentially expressed gene loci with various histone methylations. *Advances in Enzyme Regulation* 2007; 47: 223-241. (AMC)
1039. Zoetmulder FAN, Verwaal VJ. Lessons learnt from clinical trials in peritoneal surface oncology: colorectal carcinomatosis. *Recent Results Cancer Res* 2007; 169: 99-103. (NKI)
1040. Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, Dreschler WA, Balm AJ. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. *Int J Radiat Oncol Biol Phys* 2007; 68: 1320-5. (NKI)
1041. Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. *J Clin Oncol* 2007; 25: 3759-65. (NKI)
1042. Zuur JK, Muller SH, de Jongh FH, van der Horst MJ, Shehata M, van Leeuwen J, Sinaasappel M, Hilgers FJM. A newly developed tool for intra-tracheal temperature and humidity assessment in laryngectomized individuals: the Airway Climate Explorer (ACE). *Med Biol Eng Comput* 2007; 45: 737-45. (NKI)
1043. Zuur JK, Muller SH, Sinaasappel M, Hart GA, Van Zandwijk N, Hilgers FJM. Influence of heat and moisture exchanger respiratory load on transcutaneous oxygenation in laryngectomized individuals: A randomized crossover study. *Head Neck* 2007; 29: 1102-10. (NKI)
1044. Zwart W, Griekspoor A, Berno V, Lakeman K, Jalink K, Mancini M, Neeffjes J, Michalides R. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. *EMBO J* 2007; 26: 3534-44. (NKI)
1045. Zwart W, Griekspoor A, Rondaij M, Verwoerd D, Neeffjes J, Michalides R. Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor alpha. *Mol Cancer Ther* 2007; 6: 1526-33. (NKI)
1046. Zweegman S, Kessler FL, Kerkhoven RM, Heimerikx M, Celie JW, Janssen JJ, Huijgens PC, Drager AM, van den Born J. Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile. *Matrix Biol* 2007; 26: 561-71. (NKI/VUmc)
1047. Zwijnenburg PJ, van der Poll T, Florquin S, Polfliet MM, van den Berg TK, Dijkstra CD, Roord JJ, Hack CE, van Furth AM. C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice. *J Infect Dis* 2007; 196(1): 115-123. (VUmc)

